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This dissertation uses three types of routinely collected data from HIV care and 
treatment facilities in sub-Saharan Africa to investigate the association between the 
availability of adherence support and active outreach services on patient non-retention, 
loss to follow-up, and measured death after ART initiation.  Following a literature review 
summarizing the state of knowledge concerning the influence of programmatic services 
on patient retention in care and survival, these relationships are first examined in an 
aggregate analysis of over 232,000 patients at 349 HIV care and treatment facilities 
initiating ART between January 2004 and December 2008.  Key findings are that 
several adherence support and outreach services are associated with reduced rates of 
non-retention, loss to follow-up, and death.  Specifically, facilities offering three or more 
adherence support services, written educational materials promoting ART adherence, 
one-on-one or group adherence counseling sessions, reminder tools, and food rations 





follow-up, while facilities offering on-site support groups for HIV+ patients, peer 
educators, provision of reminder tools, and food rations to promote ART adherence 
were associated with reduced death rates.  In sub-analyses investigating six- and 12-
month retention after ART initiation, facilities offering three or more separate adherence 
support services, routine review of medication pickup and/or dedicated ART 
pharmacists, and active patient outreach to trace patients missing visits had lower non-
retention.  Taken together, this analysis provides evidence that program-level services 
found efficacious in experimental settings are also effective in operational settings. 
 
Next, a sub-analysis is conducted among facilities also providing electronic patient-level 
data to investigate similarities and differences in the association between adherence 
support and outreach services and patient non-retention, loss to follow-up, and 
measured death using aggregate vs. patient-level estimates of these outcomes, and to 
assess whether adjustment for patient-level differences between facilities change these 
measures of association.  In multivariate analyses, clinics offering active patient 
outreach had lower rates of non-retention in both the ART cohort analysis and the 
patient-level analysis, and clinics offering food rations to promote ART adherence were 
associated with a lower risk of ascertained death in both the facility-level and patient-
level analyses, but this association was diminished after adjustment for patient-level 
covariates.  In contrast, various adherence counseling or support services were 
associated with lower non-retention in the ART cohort analyses but not in the patient-
level data analyses.  When compared with the results in the first paper, fewer 





databases are not representative of the entire range of HIV care and treatment facilities 
assessed in the first paper, and/or the specific facilities with electronic databases are 
more similar to each other than they are to facilities without electronic databases. 
 
Finally, the dissertation concludes with an investigation into the relationship between 
loss to follow-up and measured death.  For this analysis, estimates of the death 
probability among patients lost to follow-up are created under varying assumptions 
(either assuming that the death probability among those lost to follow-up is equivalent to 
the death probability within various strata of covariates, or assuming that the probability 
of death is greater among patients lost to follow-up).  Key findings from this analysis are 
that ratio comparisons of death rates between facilities offering different services are 
robust to changes in the death probability if patients lost to follow-up are assumed to 
have a similar probability of death, conditioned on covariates, as those not lost to follow-
up, but that associations between facility services and death rates are masked under 
the scenario where the facility service is associated with loss to follow-up and the death 
probability is assumed to be higher, conditioned on covariates, then the death 
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Introduction  
The ultimate goal of HIV care and treatment programs is improving patient survival.  In 
sub-Saharan Africa and other settings where resources are limited and future 
international funding cannot be counted on to expand, identifying specific program 
services that improve patient survival can inform programmatic decision-making on 
program design and resource allocation.  However, this identification is complicated by 
a lack of complete patient- and program-level information across these facilities.  
Information on the cumulative number of patients initiating ART, and the cumulative 
numbers who have died or become lost to follow-up is routinely available for HIV care 
and treatment centers supported under the U.S. President’s Emergency Plan for AIDS 
Relief (PEPFAR), and overall rates of non-retention, loss to follow-up, and death can be 
constructed from this information.  In addition, HIV care and treatment centers 
supported under PEPFAR report on the number of patients initiating ART each quarter, 
and the number of these patients remaining on ART 6 and 12 months after ART 
initiation.  Finally, a subset of facilities also collect electronic patient-level data that can 
be used to estimate rates of non-retention, loss to follow-up, and death at different time 
intervals after ART initiation.  Combining these outcomes with program-level surveys 
assessing the availability of adherence support and retention-promoting services can be 
used to assess whether these services improve patient survival and retention, and 
whether different estimates of survival and retention result in differing associations 
between program service availability and patient outcomes. 
 
In any analysis investigating the influence of program service availability on patient 
survival, loss to follow-up complicates analysis because it causes incomplete 
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ascertainment of vital status.  Additionally, loss to follow-up is both caused by death (if 
that death is unascertained) and a cause of death (if patients lost to follow-up do not 
access ART treatment elsewhere).  Overall death rates are underestimated when loss 
to follow-up exists because of this incomplete ascertainment, and relative measures 
comparing death rates between facilities offering different program services may be 
biased if the relationship between loss to follow-up and death differs between these 
facilities. 
 
The purposes of this dissertation are (1)to identify program-level services designed to 
influence patient adherence to ART and retention in care are associated with improved 
rates of non-retention, loss to follow-up, and death, (2) to assess whether any observed 
associations between program-level service availability and estimates of non-retention, 
loss to follow-up, and death differ by the source of the outcome estimate (overall 
aggregate, cohort, and patient-level), and (3) to investigate how different estimates of 
the survival distribution among patients lost to follow-up influence measures of 
association comparing death rates between facilities offering different services. 
 
The first paper in this dissertation presents an ecologic analysis of over 232,000 
patients at 349 HIV care and treatment facilities initiating ART between January 2004 
and December 2008.  Key findings are that several adherence support and outreach 
services are associated with reduced rates of non-retention, loss to follow-up, and 
death.  Specifically, facilities offering three or more adherence support services, written 
educational materials promoting ART adherence, one-on-one or group adherence 
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counseling sessions, reminder tools, and food rations to promote ART adherence were 
associated with reduced non-retention and loss to follow-up, while facilities offering on-
site support groups for HIV+ patients, peer educators, provision of reminder tools, and 
food rations to promote ART adherence were associated with reduced death rates.  In 
sub-analyses investigating six- and 12-month retention after ART initiation, facilities 
offering three or more separate adherence support services, routine review of 
medication pickup and/or dedicated ART pharmacists, and active patient outreach to 
trace patients missing visits had lower non-retention.  Taken together, this analysis 
provides evidence that program-level services found efficacious in experimental settings 
are also effective in operational settings. 
 
The second paper refines the non-retention, loss to follow-up, and death rate estimates 
by (1) comparing estimates obtained from aggregate vs. patient-level databases and (3) 
additionally allowing for adjustment for patient-level predictors of loss to follow-up and 
death.  This analysis focuses on a subset of HIV care and treatment facilities in 5 
countries that also have electronic patient-level databases.  92,561 patients initiating 
ART before July 1, 2009 at 92 care and treatment facilities were included in this 
analysis.  A key finding, examined in more detail in Appendix 3, is that estimates of 
death rates were similar in the aggregate and patient-level analyses, while loss to 
follow-up rates were higher in analyses using the patient level database.  In multivariate 
analyses, clinics offering active patient outreach had lower rates of non-retention in both 
the ART cohort analysis and the patient-level analysis, and clinics offering food rations 
to promote ART adherence were associated with a lower risk of ascertained death in 
4 
 
Dissertation Introduction     
 
both the facility-level and patient-level analyses, but this association was diminished 
after adjustment for patient-level covariates.  In contrast, various adherence counseling 
or support services were associated with lower non-retention in the ART cohort 
analyses but not in the patient-level data analyses.  When compared with the results in 
the first paper, fewer associations were observed, suggesting either that the countries 
with patient-level databases are not representative of the entire range of HIV care and 
treatment facilities assessed in the first paper, and/or the specific facilities with 
electronic databases are more similar to each other than they are to facilities without 
electronic databases.  The discussion in Paper 2 expands on these conclusions in more 
detail. 
 
Finally, the third paper focuses on the problem of loss to follow-up in biasing estimates 
of death rates, and in biasing relative comparisons of death rates between facilities.  For 
this analysis, estimates of the death probability among patients lost to follow-up are 
created under varying assumptions (either assuming that the death probability among 
those lost to follow-up is equivalent to the death probability within various strata of 
covariates, or assuming that the probability of death is greater among patients lost to 
follow-up).  Key findings from this analysis are that ratio comparisons of death rates 
between facilities offering different services are robust to changes in the death 
probability if patients lost to follow-up are assumed to have a similar probability of death, 
conditioned on covariates, as those not lost to follow-up, but that associations between 
facility services and death rates are masked under the scenario where the facility 
service is associated with loss to follow-up and the death probability is assumed to be 
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higher, conditioned on covariates, then the death probability among patients not lost to 
follow-up. 
 
This dissertation contains six chapters and several appendices.  Following this 
introductory chapter, Chapter 2 presents a literature review on adherence to ART, and 
retention and survival in care, with a specific focus on the influence of program services 
on patient non-retention, loss to follow-up, and survival.  Chapter three begins the 
analytic work with an ecologic analysis investigating the relationship between 
adherence support and outreach services and facility-level rates on non-retention, loss 
to follow-up, and death.  Chapter 4 compares ecologic and patient-level analyses 
assessing the same research question motivating Chapter 3.  Chapter 5 investigates 
the relationship between loss to follow-up and ascertained death in more detail with a 
sensitivity analysis investigating the influence of different assumptions of the death 
likelihood among patients lost  to follow-up on the observed relationship between 
adherence support and outreach services and rates of death.  Finally, Chapter 6 
summarizes the findings of this dissertation, reviews the process taken to achieve these 
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Chapter 2: Background and literature review 
Overview of the HIV epidemic in Sub-Saharan Africa 
HIV/AIDS continues to be a catastrophic health problem in much of the world, most 
acutely in the countries of Sub-Saharan Africa. The introduction of highly active 
antiretroviral therapy (HAART) in 1995-6 drastically reduced the mortality rates, 
incidence, and overall numbers of deaths from AIDS in low-burden, resource-rich 
settings [1-3].  However, access to HAART is far from universal, and until recently care 
and treatment programs in the areas of the world most affected by HIV were rare.  
Approximately 22.5 million of the 33.2 million individuals living with HIV/AIDS worldwide, 
1.7 million of the 2.5 million new cases of HIV, and 1.6 million of the 2.1 million deaths 
from AIDS were in Sub-Saharan Africa in 2007 [4].   
 
Initiatives aimed at providing care and treatment to HIV-positive individuals in Sub-
Saharan Africa have been established through a variety of organizations, both 
governmental and non-governmental.  In contrast to more patient-centered approaches 
offered in resource-rich areas, sub-Saharan governments have established public 
health-centered approaches to HIV care and treatment based on WHO guidelines [5].  
International and non-governmental initiatives work with each country to interpret these 
guidelines to meet the needs and constraints of each country.  Three of the largest 
initiatives which have provided funding and/or technical assistance to support the 
development and maintenance of HIV care and treatment facilities in resource-poor 
environments are the President’s Emergency Plan for AIDS relief (PEPFAR), the Global 
Fund for AIDS, Tuberculosis, and Malaria, and the World Health Organization’s 3x5 
initiative [6].  These umbrella initiatives work by developing partnerships with local and 
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international governmental, non-governmental, and private sector actors to develop 
infrastructure, recruit and train health care personnel, and provide steady access to 
HAART medication.  While these initiatives all work from the same framework of WHO 
guidelines for scaling up HIV care and treatment, the implementation of these guidelines 
differs markedly by country, and by facility, resulting in a heterogeneous mixture of care 
and treatment programs.  
 
These, and other, treatment initiatives have dramatically increased the number of 
individuals in care and on ART in developing countries.  According to the World Health 
Organization, there were over 500,000 persons receiving treatment in Sub-Saharan 
Africa through June 2005 [7].  A more recent WHO report [5] estimates that in sub-
Saharan Africa, about 1.3 million (28%) of 1those needing HAART treatment are 
receiving it.  Although this proportion is still low, it is clear that some progress is being 
made.  
Antiretroviral Treatment Adherence 
Definition and overview 
 
Consistent and continual adherence to ART medication drastically improves treatment 
outcomes for patients living with HIV/AIDS.  Adherence is defined as the consistent and 
regular taking of prescribed ART medication, with ‘good adherence’ generally classified 
as correctly taking the prescribed dosage >95% of the time [8].  Maintaining a 
suppressed viral load and delaying progression to AIDS or death depends on 
                                                
1
 ‘treatment failure’ is defined here based on CD4 counts.  According to the WHO, guidelines for treatment failure are (1) CD4 
count below 100 cells/mm3 after six months of therapy; (2) a return to, or a fall below, the pre-therapy CD4 baseline after six 
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individuals maintaining high and consistent adherence to ART treatment.  Studies both 
in resource-rich and resource-poor environments have found non-adherence to be 
associated with lack of viral suppression, accelerated progression to AIDS, and 
treatment failure* [9-16].  Lack of adherence to HAART has also been associated with 
increased likelihood of developing drug-resistant mutations [17-19], posing a potential 
treatment difficulty both to the individual and to any individuals a person with drug-
resistant HIV may infect.  Modeling studies by Paterson et al [14] and Low-Beer et al 
[20] suggest that adherence of >95% is optimal for adequate viral suppression and 
minimizing the development of drug resistant strains of HIV. 
 
What is unknown is how best to optimize consistent and continual adherence in the 
context of scale-up of HIV care and treatment service delivery in resource-limited 
settings.  Optimal adherence requires two inter-related components: day-to-day 
adherence and long-term adherence.  At the onset of the scale-up of antiretroviral 
programs in sub-Saharan Africa there was apprehension among researchers and public 
health practitioners in resource-rich countries about the ability to support and ensure 
adequate adherence in resource-poor settings [21, 22].  However, early reports on 
treatment adherence in sub-Saharan Africa were promising, with several suggesting 
that antiretroviral adherence in the region was higher than was observed in developed 
countries [13, 23].  More recent reports [9, 10, 13, 16-19, 23-27], including a 2006 meta-
analysis comparing reported results of adherence in US and sub-Saharan Africa [28], 
supported these findings.   However, most of these studies were performed on 
populations participating in trials or research studies with fairly strict inclusion criteria, 
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such as prior demonstration of adherence to tuberculosis regimens [25], completion of 
at least 30 days of ART with full adherence [13], or consistent attendance at an HIV 
clinic [10, 24, 26], all of which may select for higher adherence levels than would be 
expected in more general populations.  Until now there has also been insufficient time to 
evaluate longer-term adherence, and it is consequently unknown whether the levels of 
adherence demonstrated in these early studies has been sustained.  It is not 
unexpected, then, that a more thorough investigation of adherence levels indicates a 
high degree of heterogeneity in reported levels of adherence in resource-poor countries.  
In the past 5 years, there have been several studies reported in meeting abstracts and 
journals assessing adherence to antiretroviral medication, with reported adherence 
levels ranging from 30% “completely adherent” in Burkina Faso [29] to 100% adherent 
at 3 months in the Democratic Republic of Congo [30] (reviewed in [21]).  This suggests 
that the earliest reports of high adherence in sub-Saharan Africa may not representative 
of the overall ART adherence picture in the region. 
Adherence barriers and enablers 
There is little information on the reasons for non-adherence to antiretroviral medication 
in developing countries, and much of the investigation of barriers to adherence in 
resource-rich countries have focused on individual-level reasons for non-adherence.  A 
2000 review of published literature on reasons for nonadherence to ART in developed 
countries found mostly patient-level factors, such as illicit drug use, forgetfulness, 
change in one’s daily routine, perceived or real side effects, and lack of belief in benefit 
of treatment [31, 32], with little published information available on group-level factors.  
Reasons for non-adherence to antiretroviral medication in developed countries do not 
seem to be markedly different from reasons for non-adherence to other medications in 
10 
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the published literature [33].  However, there is reason to expect that barriers to 
adherence in developing countries differ from those in developed counties.  A 2006 
qualitative review of barriers to adherence in both resource-rich and resource-poor 
countries found important differences in reported reasons for non-adherence [34].  
Reasons for non-adherence in developing settings were more likely to include issues of 
consistent access to medication and financial constraints.  An extensive literature 
search has revealed only three published studies formally investigating reasons for non-
adherence to antiretroviral medication in developing countries: one in Brazil [35], one in 
Botswana [19], and one in Botswana, Tanzania and Uganda [36].  In the study 
conducted in Brazil, which has a nationalized health care system and guaranteed free 
access to antiretroviral medication, reasons for non-adherence were similar to those 
found in more developed countries, including forgetfulness and concern over side 
effects [35].  In contrast, the study in Botswana, where treatment was not free and the 
health care system is much less developed than it is in Brazil, the most common 
reasons given for nonadherence were related to inability to pay for treatment, 
forgetfulness, inconsistent availability of antiretroviral medication, long travel to obtain 
antiretrovirals, and being ‘too busy.’ [19]  They also estimated that, had medication been 
given free of charge, the levels of adherence would have risen from 54% to 74% [19].  A 
2007 qualitative study in three sub-Saharan African countries focused on reasons for 
non-adherence to antiretroviral medication in settings where the medicines are offered 
free of charge to the patients, and found such reasons as high transport costs, long 
waiting times at the clinic (resulting in lost wages), issues related to hunger (either 
inability to take drugs more than  once a day because they only have food once a day, 
11 
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or inability to procure sufficient food to combat increased hunger in initial stages of 
treatment), stigma, and side effects [36]. 
 
The qualitative studies on lack of adherence to antiretroviral medications provide an 
important, if incomplete, starting point for the more central question: how can we 
improve adherence?  As reviewed above, qualitative studies have suggested a plethora 
of reasons for non-adherence, both in developed and developing settings.  However, 
there have been few studies looking at whether interventions aimed at improving 
adherence actually do so, with almost all studies being conducted in developed 
countries.  One study in a California population evaluated the impact of an adherence 
intervention program, combining written information, a verbal discussion with the health 
care provider on the importance of adherence and suggestions of tools, such as pill 
boxes and reminder calendars to improve adherence, on adherence.  This study found 
that 91% of individuals who additionally received the adherence intervention reported 
>95% adherence to medication, compared with 75% of individuals only receiving 
information on the importance of safer sex [37].  A small randomized trial investigating 
the impact of an adherence program including an informational component and the 
availability of various reminder tools found an increase in self-reported adherence 
during the prior week, but not the prior month, when compared to a control group 
receiving no additional information on adherence [38].  Similarly, a randomized trial in 
France found that an intensive informational adherence program improved self-reported 
adherence levels at 6 months and 12 months, but not at 24 months, when compared 
with a control arm receiving no intervention [39].  Another French trial found a small but 
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significant improvement in adherence 6 months after a nurse-provided adherence 
intervention compared with a control arm (75% vs. 61% adherent) [40].  A randomized 
trial comparing individual-based cognitive behavioral therapy to standard of care 
improved adherence at 12 months (70% in intervention arm obtaining >95% adherence 
measured via electronic monitoring vs 50% in control arm) [41]. Conversely, a study in 
Texas found no difference in adherence levels or change in viral load between a group 
receiving an educational adherence intervention and those receiving standard of care 
[42], and a randomized trial in New York City comparing adherence and HIV viral load 
suppression between individuals in a peer-support intervention arm to those in a 
standard of care arm found no effect of the intervention on these outcomes [43]. 
 
There have been very few studies attempting to investigate how a facility-level 
intervention could improve adherence in the context of ART scale-up in resource-poor 
settings.  The study by Weiser et al [19] suggested that, if treatment were offered free of 
charge in their study population in Botswana, adherence levels would increase from 
54% to 74%.  A study presented at the 2004 International AIDS conference, in which 
only 30% of patients reported complete adherence, found that counseling on the 
importance of adherence helped 75% of those not completely adherent at baseline 
improve their adherence, although this abstract did not specify how much the 
improvement was [29].  In a 2005 letter to the editor describing adherence to an 
antiretroviral treatment program in Rwanda, Demeester et al. reported that counseling 
and family support were ‘essential’ to their high levels of adherence (87% reporting no 
missed doses during previous month) [44].   
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Directly Observed Therapy (DOT), in which patients take their medication in the 
presence of a health administer, has been shown to effectively improve adherence to 
antiretroviral medication in Haiti [45, 46].  This method has also shown effectiveness in 
the treatment of tuberculosis [47], another infectious disease requiring a fairly long 
treatment regimen.  However, the intensive resources needed to scale-up this type of 
program, the projected numbers of patients, and the fact that ART adherence is 
required for a lifetime, are likely to limit the applicability of such an intervention on a 
large scale.  Other, less resource-intensive interventions are increasingly available as 
part of the HIV care and treatment programs in resource-limited countries.  However, an 
extensive literature search has found no evidence of studies which have looked at 
whether adherence interventions actually improve adherence in resource-poor settings. 
 
Given the heterogeneous nature of the services offered at HIV care and treatment 
programs in sub-Saharan Africa, the rapid scale up of these programs, and the 
importance of adherence to improving treatment outcomes, research is urgently needed 
on how best to optimize adherence in these settings. 
 
Long-term adherence and retention in care and treatment programs 
Overview 
Optimal HIV care and treatment requires long-term patient follow-up, both to ensure 
adherence and to provide routine monitoring and treatment of comorbidities.  
Successful treatment for HIV is a lifelong activity.  In the context of Sub-Saharan Africa, 
patients who are not retained in HIV care and treatment will not receive ART, 
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dramatically increasing morbidity and mortality risk.  Demonstrating this, a study by 
Mocroft et al. came to the succinct conclusion that individuals with clinical AIDS who 
discontinue treatment will likely die within a short time [48].   
   
Long-term retention in care in the context of HIV treatment in sub-Saharan African has 
often been seen as a ‘side issue,’ with the focus on treatment and outcome evaluation 
of patients remaining in care [49] and those not retained deemed “lost to follow-up” and 
treated as a source of potential bias in analysis.  This is in part because scale-up of HIV 
care and treatment centers in sub-Saharan Africa only began in 2004, giving insufficient 
time for any long-term analysis of retention in care until recently [49].  Published 
proportions of patients lost to follow-up in clinical settings in Sub-Saharan Africa range 
from less than 5% [50-52] to over 50% [26].  A recent review [49] gives estimates of 
patient retention from 33 scale-up programs in sub-Saharan Africa, finding extreme 
heterogeneity in the amounts of loss to follow-up, with 24-month retention rates ranging 
from 46% at a fee-for-service facility in Uganda [53] to 85% at a community-based clinic 
in South Africa [50].  This review was limited by the varying definitions of loss to follow-
up across the facilities included in the analysis.  A recent study [54] from the ART-LINC 
collaboration on predictors of loss to follow-up in resource-poor settings in Africa, Asia 
and Latin America found large variation in follow-up across sites, with facilities serving 
larger numbers of patients more likely to have higher rates of loss to follow-up.  The 
study found rates of loss to follow-up ranging from no loss in a variety of sites with 
active follow-up of patients to 45% of patients in a Malawi care and treatment center 
with no active follow-up [54].  Similarly, a community-based HIV care and treatment 
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program in South Africa, with active tracing of patients missing scheduled visits, had low 
rates (2.3%) of loss to follow-up through 4 months of treatment [55]. 
There have studies investigating the baseline characteristics of patients lost to follow-up 
in these settings.  The ART-LINC collaboration [54] found that, across a range of care 
and treatment facilities in Africa, Asia, and Latin America, compared to individuals with 
baseline CD4 counts >50 cells/µL, individuals with baseline CD4 counts < 25 cells/µL 
had a higher probability of no follow-up (OR 2.5, 95% CI 1.4-4.3) or loss to follow-up 
within 4 months (HR = 1.5, 95% CI 1.2-1.8).  Since low CD4 count is a strong predictor 
of mortality, this suggests that individuals with low CD4 counts who are lost to follow-up 
may actually be unascertained deaths.  Facility characteristics associated with loss to 
follow-up were being a fee-for-service program (OR for no follow-up = 3.7, 95% CI 1.0-
16.1).  The study also found that loss to follow-up increased substantially from earlier 
calendar periods (before or during 2000) to more recent periods (2003-2004).  The 
Odds Ratio of no follow-up  (OR = 5.1, 95% CI 1.3-20.0) and the Hazard Ratio of loss to 
follow-up (HR 7.6, 95% CI 4.6-12.8) was significantly higher for the later follow-up 
period compared with earlier periods, suggesting that sites with increasing numbers of 
patients, and thus diminishing resources to devote to aspects other than direct patient 
care, are finding it harder to continue retention.  Only one published study in sub-
Saharan Africa (Malawi) attempted to identify patients initially lost to follow-up.  This 
study traced patients who had not attended the facility for 3 or more months and found 
that 50% of the patients classified as lost to follow-up had died [56].  This study 
highlights the fact that loss to follow-up is an important program outcome in itself, since 
those lost are at higher risk for treatment failure and death than those retained in 
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treatment.  Taken together, these studies highlight the heterogeneous nature of 
individuals classified as ‘lost to follow-up,’ comprising both those individuals whose 
death prevented them from returning to clinic (a group who would see a benefit in more 
complete ascertainment, but not reduced risk of death, if exposed to an outreach 
program) and individuals who, had they been identified through and outreach program 
may have been re-entered into care.   
 
Methods for improving program retention 
It is clear that maximizing patient retention is essential for optimal treatment outcomes.  
However, there has been little investigation into identifying and evaluating what 
methods of optimizing retention work best.  Methods for improving long-term retention 
are varied in the context of care and treatment in Sub-Saharan Africa, and the impact of 
these methods has not been sufficiently assessed.  Active outreach programs attempt 
to locate individuals missing scheduled visitations through mail, telephone, or home 
visitation.  In contrast, facilities describing their outreach programs as ‘passive’ do not 
attempt to locate missing individuals, and rely on medical records and death certificates 
to classify individuals no longer attending the facility as dead, transferred, or unknown.  
It has been documented that HIV care and treatment centers offering some type of 
active outreach are likely better able to retain patients in care than are sites offering no 
outreach [57].  Active outreach programs focused on ART patients have been shown to 
improve adherence [58] and reduce attrition [57] both in resource-rich and resource-
poor environments.  However, whether targeting patients for active outreach before they 
are on ART, in addition to those on ART, improves retention has not been investigated.  
Active outreach of patients in HIV care, but who do not yet meet ART eligibility criteria, 
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can provide an indoctrination into the HIV care and treatment process, establish a 
routine for maintaining contact with medical staff, provide information about the 
importance of adherence to ARV medications and prompt initiation of treatment when 
they become clinically eligible.  Pre-ART individuals maintaining regular scheduling with 
their care and treatment facility also have access to a variety of non-ART treatment 
options, such as opportunistic infection prophylaxis.   In addition, the existence of active 
outreach of pre-ART patients is likely to be indicative of a more comprehensive and/or 
well-resourced care and treatment program since resources are usually first allocated 
toward those patients already initiated onto ARV treatment.  Interestingly, there has 
been no systematic evaluation of whether this prioritization of resources is optimal.  
Thus, comparing treatment outcomes between patients on ART medication attending 
sites which have active follow-up for both pre-ART and ART patients to those attending 
sites without such a comprehensive outreach program is thus a useful way to measure 
the impact of such follow-up, and of comprehensiveness of care in general, on patient 
outcomes.  However, the complication that improved ascertainment of deaths increases 
a facility’s death rate makes assessment of the impact of such outreach programs on 
actual survival difficult.  An approach that can disentangle these effects would thus be 
beneficial. 
Rationale for investigating treatment adherence and retention at the 
facility/program level. 
 
As discussed above, there are many reasons that an individual patient may fail to 
adhere on a day-to-day basis to their antiretroviral medication.  There are also many 
reasons why a patient may fail to maintain regular contact with their care and treatment 
facility.  Using a public health approach to treatment scale-up, we are most concerned 
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with where to potentially intervene in order to best to improve adherence and retention.  
Thus, even though the act of adherence and retention occurs at the individual-level, the 
best intervention to improve adherence and retention may occur at the facility/program-
level. 
 
As evidenced by the studies of adherence in resource-rich environments, non-
adherence to medication is a common problem across all chronic diseases, and we 
must expect that regardless of the amount of education, adherence reminder tools, and 
structural interventions, certain individuals will simply not adhere to their medication.  
There also exist important differences between the reasons for non-adherence given by 
patients in resource-rich and resource-poor environments, with non-adherence more 
intimately linked to structural issues of drug availability, cost, and lack of education on 
the importance of adherence in resource-poor environments [34].  Improving adherence 
to medication also requires behavioral change, which in turn is intimately tied to 
questions involving the ability to sustain change and the relationship between this 
change and social norms surrounding the behavior.  In the context of improving 
adherence to HIV treatment in sub-Saharan Africa, this suggests that programs that 
have strong adherence support, and active follow-up of patients in care and treatment, 
may also have better adherence both for individuals participating in the adherence 
support activities and those not participating, due to information sharing and the overall 
changing of social norms concerning adherence.    This type of ‘spillover effect’ may be 
important in evaluating the overall impact of adherence and follow-up programs on 
treatment outcomes and would be missed in an individual-only assessment.  
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Conversely, if adherence support activities are found to only benefit those attending, but 
the proportion of eligible individuals attending such programs is low, there would not be 
a strong facility and program-level benefit to such an intervention.  Finally, from a 
service delivery perspective, focusing on facility and program-level factors improving 
treatment adherence and retention is desirable because this level offers the easiest 
point of intervention, since HIV care and treatment is organized around these facilities.   
 
As highlighted by the findings of studies in resource-poor environments documenting 
that issues surrounding transportation, cost and drug availability are important 
determinants of adherence to antiretroviral medication, it follows that interventions 
targeting more structural issues may have the most impact on improving adherence.  
Evaluating adherence and retention at the facility/program level offers an opportunity to 
investigate these more structural interventions on individual-level outcomes.  Further, 
since the number of care and treatment facilities for HIV is exponentially increasing in 
sub-Saharan Africa, the identification of facility/program-level interventions which 
improve adherence, or reduce attrition, could potentially be incorporated into new and 
existing care and treatment facilities.  Using an evidence-based approach to 
investigating which characteristics of care and treatment programs best improve 
adherence, reduce attrition, and improve treatment outcomes is thus important. 
 
Complexities in assessing program/facility-level factors associated with 
treatment adherence and patient retention 
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We must recognize that differences in the characteristics of individuals attending 
different HIV care and treatment facilities may partially explain observed differences in 
treatment outcomes between sites.  If these individual-level differences are not caused 
by the programs themselves (such as if patient-level differences in CD4 counts at 
treatment initiation are caused by differing facility policies on when to initiate treatment), 
they can provide an alternate explanation for an observed difference in patient 
outcomes between sites.  This potential for individual-level confounding is a threat to the 
internal validity of any study investigating the causal effect of a facility/program-level 
intervention.  Multilevel methods, which can assess the impact of a facility/program-level 
characteristic while adjusting for known individual-level differences between sites, have 
the potential to reduce this limitation, but requires sufficient information to be gathered 
at the individual level.  When individual-level information is not available, it may be 
possible to adjust for aggregate-level differences in patient populations between 
facilities using such factors as average CD4 count at treatment initiation and sex and 
age distribution [59].  This type of analysis, which does not directly evaluate the 
potential for individual-level differences to drive observed facility-level differences, has 
not been evaluated for its potential to reduce the threat from individual-level 
confounding. 
Loss to follow-up as a hindrance to evaluation of the impact of facility and 
program-level services on mortality  
 
A methodological complexity arises when attempting to evaluate the effectiveness of 
facility/program characteristics on patient mortality rates in settings where there exist 
non-trivial amounts of censoring.  As discussed above, one way in which 
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facility/program characteristics targeting treatment adherence and patient retention 
attempt to reduce patient mortality rates is by improving retention in the programs.  That 
is, retention in programs is hypothesized to be in the causal pathway between the 
exposures of interest (treatment adherence support programs and active outreach 
programs) and the outcome (death).  If we had complete ascertainment of the outcome 
status of all patients, we would be able to directly measure the relationship between the 
exposures of interest and patient survival, conceptualizing patient retention as a 
mediator on this causal pathway.  However, in the context of HIV care and treatment 
facilities in resource-poor environments, there is often a substantial proportion of 
patients whose outcome status is unknown.  These patients may be at higher risk of 
death than those retained in the program, since program retention is hypothesized as a 
mediator of the relationship between the facility/program-level characteristics and death.  
Thus we are left with a situation in which we want to reduce the information bias caused 
by incomplete outcome ascertainment without adjusting for the causal intermediate of 
patient retention.   
 
Conventional statistical modeling, such as Cox Proportional Hazards modeling, requires 
an assumption that, conditioned on the covariates in the model, individuals who are lost 
to follow-up are missing at random, meaning that they have no greater risk for having 
the outcome of interest than do individuals retained in the analysis.  However, this 
assumption is clearly untenable since those individuals lost to follow-up are not exposed 
to the proposed intermediate (patient retention in the care and treatment facility) on the 
causal pathway between exposure and outcome.  More sophisticated statistical 
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methods, such as marginal structural models [60] and g-estimation techniques, are also 
ill-suited to adjust for a variable that is both a source of information bias and an 
intermediate variable.  Both of these techniques require that censored observations are 
‘non-informative’ conditioned on measured past exposure and covariate history [61], 
which does not hold if those censored are at increased risk of death due to their lack of 
exposure to an intermediate variable.   
 
Methods to separate the effects of an outreach program on (1) death ascertainment and 
(2) actual death risk are particularly important when evaluating the impact of program-
level interventions on survival when the amount of censoring is on the order of, or 
greater than, the measured death rate.  Situations such as this create counterintuitive 
results that programs having an active outreach service have higher measured death 
rates than programs not having such services [49, 57].  Patient non-retention and loss 
to follow-up are often used synonymously in the literature discussed above, but there is 
an important conceptual distinction between the two concepts.  Patients who are not 
retained in a care and treatment facility may have died, transferred to a different 
program, or opted out of treatment.  These endpoints exist regardless of whether the 
facility has the information to classify their patients’ outcomes.  In contrast, patients who 
are lost to follow-up are those patients whose eventual outcome status is unknown.  
Thus, loss to follow-up is a source of measurement error that would disappear if we 
were able to ascertain each individual’s outcome status correctly.  The distinction 
between patient non-retention and loss to follow-up is often blurred in studies 
investigating patient retention, since much of the literature investigating patient retention 
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in care and treatment facilities defines those individuals whose outcome status is 
unknown as the pool of patients who have not been retained in the facility.  This creates 
a difficulty in estimating the impact of interventions to improve patient treatment 
outcomes because the impact of reducing censoring on the measured death rate works 
in the opposite direction of the hypothesized impact on the actual death rate.  This 
creates seemingly counterintuitive findings in several studies looking at patient survival 
rates that facilities with active patient outreach programs report substantially higher 
death rates than facilities without such programs [49, 57]. 
 
Conclusion and specific aims 
The specific aims investigated in this dissertation stem from gaps in the literature 
surrounding predictors of non-retention, loss to follow-up, and ascertained death among 
ART patients in resource-limited settings.  Specifically the purposes of this dissertation 
are (1)to identify whether program-level services designed to influence patient 
adherence to ART and retention in care are associated with improved rates of non-
retention, loss to follow-up, and death, (2) to assess whether any observed associations 
between program-level service availability and estimates of non-retention, loss to follow-
up, and death differ by the source of the outcome estimate (overall aggregate, cohort, 
and patient-level), and (3) to investigate how different estimates of the survival 
distribution among patients lost to follow-up influence measures of association 
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High rates of loss to follow-up (LTF) and death remain common in HIV care and 
treatment clinics in sub-Saharan Africa. Few studies have examined the impact of 
different treatment adherence support strategies and active outreach for patients who 
miss clinic visits on program retention.   
Methods: 
Using routinely collected aggregate PEPFAR indicators from 349 HIV care and 
treatment clinics in 10 sub-Saharan African countries, we investigated the relationship 
between adherence support and outreach services on patient non-retention in care, 
LTF, and death among 232,389 patients initiating ART during 2004-2008, and on a 
subset of ART patients (n=83,389) with 6-month and 12-month follow-up information.  
Data on adherence support and outreach services were obtained from annual 
structured site assessments. Multivariate Poisson regression using generalized 
estimating equations was used to examine differences in mean rates of non-retention, 
loss to follow-up, and death between clinics with and without adherence support and 
outreach services. 
Results:  Among the 232,389 patients included in this analysis, the overall non-
retention, LTF, and death rates following ART initiation were 14.1, 9.2, and 4.9 per 100 
person-years on ART, respectively.  In multivariate analyses lower non-retention rates 
were observed among sites offering more than two adherence support services (RRadj = 
0.59, 95% CI = 0.35-1.0), written educational materials on ART adherence (RRadj = 
0.73, 95% CI = 0.63-0.85), one-on-one or group adherence counseling services (RRadj = 
0.62, 95% CI = 0.42-0.92), reminder tools (RRadj = 0.79, 95% CI = 0.64-0.97), and food 
rations to promote ART adherence (RRadj = 0.72, 95%CI = 0.58-0.90) compared with 
those sites that did not offer such services.  Variables associated with non-retention 
were similarly associated with loss to follow-up.  Lower rates of ascertained death were 
associated with the availability of on-site support groups (RRadj = 0.81, 95% CI = 0.71-
0.93) and peer educator programs (RRadj=0.84, 95% CI = 0.74-0.96), along with the 
provision of reminder tools (RRadj = 0.81, 95% CI = 0.66-0.98) and food support to 
promote ART adherence (RRadj = 0.83, 95% CI = 0.69-1.0).  Six-month non-retention 
after ART initiation was lower among clinics with more than two adherence support 
services (RRadj= 0.84, 95% CI = 0.73-0.96), dedicated pharmacists or routine review of 
medication pickup (RRadj= 0.78, 95% CI = 0.69-0.90), and active patient outreach 
(RRadj=0.85, 95% CI = 0.73-0.99). 
 Conclusions: Targeted adherence support services, coupled with active patient 
outreach, may substantially improve retention and possibly survival among patients 
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Introduction  
The efficacy of antiretroviral therapy (ART) in treating patients with HIV is well-
established.  However, ART provides optimal outcomes only if patients consistently and 
continually adhere to their medication, thus requiring both day-to-day adherence to ART 
medication and retention in care.  Although estimates of ART medication adherence 
among those retained in care in resource-limited settings are thought to be comparable 
to or better than those in resource rich countries [1-3], little is known about whether 
services designed to improve retention have an impact on patient outcomes in 
resource-limited settings.  Even less is known about the combined effects of efforts 
aimed to improve retention in care as well as ART adherence.  Identifying factors 
associated with patient retention in care and survival is a pre-requisite to rolling out and 
targeting best-practice interventions. 
 
Loss to follow-up results in underestimated survival rates, and is most pronounced 
where loss to follow-up is substantial.  Loss to follow-up is a heterogeneous mixture of 
undocumented deaths, unascertained transfers, and disengagement from care.  
However, the distribution of loss to follow-up into these categories is unknown.  As a 
consequence, even though survival is the ultimate outcome of interest, non-retention in 
care (which combines ascertained deaths and loss to follow-up, but excludes known 
transfers) has often been used to measure program performance where loss to follow-
up is high, implicitly treating death and loss to follow-up as undesirable outcomes when 
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A 2007 review of 33 scale-up clinics in sub-Saharan Africa reported high non-retention 
at 6 (12%-45%) and 12 (10%-51%) months after ART initiation with substantial 
variability across clinics  [4], and a more recent review provided a pooled estimate of 
12-month retention from 39 ART cohorts in resource-limited settings of 20% (range 
across sites: 7%-45%) [5].  A systematic review of studies where patients lost to follow-
up (LTF) were actively traced found high levels of unascertained deaths (nearly 50%) 
[6], while more recent, smaller studies reported much higher levels of unascertained 
transfers (up to 50%) [7, 8], together suggesting that undocumented deaths and 
unascertained transfers both contribute substantially to the LTF population. 
 
Determinants of ART adherence in sub-Saharan Africa likely operate at multiple levels 
(individual, clinic, structural, societal, etc.).  Adherence support services provided by 
clinics aim to promote ART medication adherence and ideally focus on commonly 
identified barriers to adherence identified in qualitative studies, including forgetfulness 
[2, 9-12], lack of knowledge about the importance of adherence [2, 9-14], fear of an 
increased appetite coupled with food insecurity [12, 14, 15], and issues of stigma [12-
15].  Studies in resource-rich settings investigating the impact of adherence support 
services on improving treatment adherence have reported small, but generally 
consistent, positive effects on individual patient adherence to medication [16-20], with a 
few studies showing no effect [21].  The few studies conducted in resource-limited 
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Services aiming to improve ART adherence may also improve longer-term retention in 
care by increasing survival and reducing loss to follow-up through influencing a patient’s 
belief in the importance of long-term adherence, or by offering incentives to regularly 
return to clinic.  
Efforts to improve retention in care in resource-limited settings aim to reduce attrition in 
the first place by reducing travel time or offering non-medical incentives to stay in care 
(scale-up of clinics in more remote regions, travel reimbursement, food support, etc.) 
[26], or aim to identify patients missing scheduled visits so that they can be contacted 
and returned to care (“active patient outreach”) [27, 28].  While strategies to improve 
patient retention in care are understudied in comparison to strategies focusing on 
adherence, active outreach appears to be associated with lower rates of loss to follow-
up and more complete ascertainment of vital status [28, 29].  
 
Two distinct estimates of patient retention after ART initiation are routinely available 
from HIV care and treatment clinics supported by international governmental initiatives 
such as the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).  Both are 
aggregate measures and have distinct strengths and weaknesses.  First, cumulative 
measures of non-retention, loss to follow-up, and measured survival are available on a 
quarterly basis, but are limited to tracking changes in cumulative estimates over time at 
the facility-level, because information on the time each individual is followed is 
unknown.  Because these estimates are cumulative, they are less sensitive to changes 
in retention rate trajectories over time than estimates from cohorts of individuals 
initiating ART in a given time period.  Second, cohort estimates of the percentage of 
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patients initiating ART within a given 3-month period that are retained on ART at 6 and 
12 months after ART initiation are routinely available, and are more sensitive to 
identifying changes in retention for a given clinic over time.  However, the routinely-
collected cohort information does not separate non-retention into loss to follow-up and 
death. 
This paper uses both types of routinely-collected aggregate data, each with strengths 
and limitations, to investigate whether program-level services designed to improve 
adherence to ART medication and retention in care are associated with better survival 
and retention and lower rates of loss to follow-up after ART initiation in HIV care and 




The study population included all patients initiating ART at HIV care and treatment 
clinics directly supported by Columbia University’s International Center for AIDS Care 
and Treatment Programs (ICAP; www.columbia.icap.org) in 10 sub-Saharan African 
countries (Cote d’Ivoire, Ethiopia, Kenya, Lesotho, Mozambique, Nigeria, Rwanda, 
South Africa, Tanzania, Zambia).  Each care and treatment clinic is governed by 
national guidelines, and all patients attending these clinics are provided free 
antiretroviral treatment.  Care and treatment sites were considered for the analysis if: (1) 
they reported quarterly care and treatment results for at least 3 consecutive quarters, 
(2) they completed a survey assessing clinic and facility-level services offered at the 
site, and (3) they initiated patients on ART medication during the period of observation 
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(January 2004 through December 2008).  Collectively, the 349 (89%) of the 392 clinics 
supported by ICAP during this time period were included in the analyses, and over 
232,000 patients initiated ART at these clinics during the study period. 
 
Data Sources 
This analysis uses two aggregate sources of data, each with different strengths and 
weaknesses.  Figure 1 highlights key differences between these two study populations.  
To obtain estimates of overall non-retention in care, as well as to estimate the 
proportion of those non-retained that are either lost to follow-up or ascertained deaths, 
quarterly estimates of person-time were calculated and summed to obtain overall rates 
of non-retention, loss to follow-up, and death (methodology described below).  To 
examine non-retention in the six- and 12-month period after ART initiation within defined 
cohorts of patients, non-retention proportions were estimated from cohorts of patients 
initiating ART within the same quarter (referred to as the “ART cohort population” 
below).   
 
Cumulative population 
ICAP is required to provide aggregate quarterly reports summarizing the patient 
population at sites it supports under PEPFAR’s Track 1.0 agreement [30].  These data 
are gathered by site staff with technical assistance and oversight by ICAP and focus on 
key “indicators of care” at each clinic, including the number of patients enrolled in care 
and initiating ART, disaggregated by sex and age, as well as information on cohorts of 
patients initiating ART.  These data are collected into a web-based database system. A 
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standard operating procedure on indicator definitions and quality assurance is in place 
to help ensure consistency of reported indicators across sites and settings. 
 
ART cohort population 
A subset of the 232,000 patients in the overall analysis were also included in 
retrospective cohorts of patients initiating ART within the same quarter.  Information on 
cohorts includes the number of new ART patients in the cohort (cohort size), the 
number retained at 6 and 12 months after ART initiation, and the number of retained 
patients who received ART for 6 out of 6 and 12 out of 12 months, respectively.  Each 
quarter, facilities are asked about the number of patients age 6 years and older who 
initiated ART six and twelve months ago, and the number of these patients remaining in 
care through the end of the current quarter.  This gives two estimates of the baseline 
population (one at 6 months after ART initiation, and one at 12 months after ART 
initiation) for each 12-month cohort.  For this study, cohorts were excluded if (a) they did 
not report both 6- and 12-month retention estimates and (b) estimates of the number 
initiating ART in each cohort from 6- and 12-month follow-up differed by more than 20%.  
1,227 cohorts had both 6-month and 12-month follow-up, and 1,097 of these, across 
221 clinics, had baseline estimates of the number of patients initiating ART reported at 6 
and 12 months of follow-up within 20%.  The average of the two reports on the number 
of patients in the baseline cohort was used in this analysis as the denominator for each 
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Overall rates (overall non-retention, Loss to follow-up (LTF), death) 
Overall rates of non-retention, loss to follow-up (LTF.), and ascertained death per 100 
person-years on ART were estimated from information reported quarterly from each 
clinic on (1) the cumulative number of patients in care and on ART, (2) the cumulative 
number of patients lost to program through death, transfer, withdrawal, or loss to follow-
up, and (3) the number of patients newly enrolled in care and on ART during each 
quarter.  For rate denominators, the total person-time in care and on ART as of the end 
of each quarter was calculated, assuming care discontinuations (due to death, transfer, 
withdrawal, or loss to follow-up) occurred at the midpoint of the quarter.  Total person-
time on ART for patients at a given clinic was calculated by summing up the estimated 
person-time from each quarter since the site began reporting on HIV care and ART 
services.  Overall death, loss to follow-up, and non-retention rates were computed for 
each clinic by dividing the cumulative number reported dead, LTF, or non-retained 
(dead, stopped ART, or LTF), respectively, by the total person-time. Rates are 
expressed per 100 person-years on ART, and are through December 2008.  It is 
important to note that the rates calculated in this manner are not cohort-specific, since 
information on the amount of time a given individual contributes to the denominator is 
unknown.  Appendix 3 to this dissertation provides a description of the methodology 
used to calculate these rate estimates, and compares these estimates with those 
obtained in a more traditional manner using patient-level data. 
 
Retention at 6 and 12 months following ART initiation 
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For the subset of patients in the ART cohorts, retention at 6 and 12 months was 
calculated as the proportion of patients in each cohort initiating ART during 2004-2008 
who remained alive and in care 6 and 12 months after ART initiation.  
Probability of receiving all ART regimens for 6 and 12 months after ART initiation 
To test whether adherence support services improve patient retention in part by 
improving adherence to ART medication, a secondary analysis used the proportion of 
patients receiving ART medication for 6 out of 6, or 12 out of 12 months, as the 
outcome of interest.  This outcome combines retention and ART adherence.  Analyses 
follow the same structure outlined for the 6 and 12 month ART cohorts. 
 
Exposure measures  
Clinic-level data, capturing information on clinic characteristics and service 
availability came from routinely conducted structured site assessments 
completed by ICAP field staff.  This survey focuses on program context (type of 
clinic, location, size, etc) and the services available to HIV+ patients at the clinic.  
Rounds of site assessment were conducted in June 2007, December 2007, and 
July 2008.  Test-retest agreement was recently assessed for a subset of survey 
items at 58 ICAP-supported clinics in seven of the nine countries included in this 
analysis.  For the 31 questions that were assessed, agreement was 83% overall, 
79% for the adherence support questions, and 74% for the outreach questions. 
 
Adherence support and related services 
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Adherence support services offered at HIV clinics can be categorized according to the 
level of interaction between the patient and staff, and according to the barrier to ART 
adherence they target.  Services are considered to be “directed support services” if they 
require interaction with site staff and focus on improving adherence to medication.  
These “directed support services” include the availability of one-on-one or group 
adherence counseling, on-site support groups for HIV+ patients, and peer educator 
programs.  Services are defined as “informational” if they provide materials to promote 
ART adherence but do not require interaction with clinic staff, and include the provision 
of written educational tools providing information on the importance of adherence or 
reminder tools (such as pill boxes or calendars).  “Pharmacy services” include those 
services intended to make it easier for patients to regularly obtain prescribed ART 
regimens and to track pharmacy pickups, and include the availability of a dedicated on-
site ART pharmacist or routine review of medication pickup.  The availability of food 
rations for adults and/or children to promote ART adherence is in a separate category, 
as it targets a structural barrier to ART adherence by offering a tangible incentive to 
consistently return to clinic.  Each measured adherence support service (Table 2) was 
dichotomized according to its reported availability at the time of the survey.  In addition, 
three additional variables were created to examine breadth and scope of adherence 
support services.  First, the total number of adherence support services at a given clinic 
were summed (range: 0-7), and a dichotomous variable was created comparing clinics 
offering 3 or more services with those offering two or fewer services to compare clinics 
in the lowest quintile of the number of services offered with those in the upper four 
quintiles. Second, the number of “directed ART support services” (defined here as: one-
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on-one or group counseling, peer educator programs, and on-site HIV+ support groups) 
at a clinic were summed to compare clinics offering two or all three directed services to 
those offering only one service.  Third, the frequency with which one-on-one or group 
adherence counseling services were offered (at least every 3 months vs. less often) 
was examined based on the cutpoints established in the site assessment. 
 
Active Outreach 
Clinics were considered as offering active patient outreach if they reported actively 
tracing patients who miss visits through telephone calls, letters, or home visits.  Clinics 
reporting active outreach were further classified as to whether outreach activities 
targeted ART patients only or both pre-ART and ART patients. 
 
Covariates 
Factors routinely collected (either from the quarterly form or the semiannual structured 
site assessment) thought to be plausibly associated with patient outcomes and the 
exposures of interest examined as potential confounders included clinic size 
(cumulative number of patients in care), clinic location (urban/rural), facility type 
(primary, secondary, tertiary), provider-to-patient ratio, year of program start, and 
calendar time of ART initiation (aggregate cohort population). 
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Overall rates of non-retention, loss to follow-up, and death, along with 6/12 month non-
retention proportions for ART cohorts, were combined with contemporaneous program-
level exposure data from the site assessments for analysis and analyzed as follows:  
Overall rates of non-retention, LTF, and death 
Multivariate Poisson regression using generalized estimating equations was used to 
estimate non-retention, LTF, and death rate ratios comparing clinics offering a given 
adherence support or outreach service to those not offering such a service.  Both 
unadjusted and adjusted models were fit, with adjusted models controlling for factors 
considered a priori as potential confounders that appreciably changed the estimate 
between the exposure and outcome of interest (program location (urban/rural), facility 
type (primary, secondary, tertiary), and total number of patients enrolled at the site).   
Next, a “full” model was constructed to assess the joint influence of each treatment 
adherence and active outreach service found to be associated with the outcome of 
interest at alpha level of 0.1 or below.  Finally, to assess whether the association of 
adherence support services with non-retention differed depending on whether an 
outreach program was also present, analyses were repeated, both stratifying by the 
presence or absence of an active patient outreach program and testing for additive-
scale interaction by computing the Interaction Contrast Ratio (ICR) introduced by 
Rothman [31] and 95% confidence intervals according to methodology outlined by 
Hosmer and Lemeshow [32]. 
  
Retention at 6 and 12 months following ART initiation 
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To assess whether patients at clinics offering various adherence support or outreach 
services experienced lower non-retention at 6 and 12 months after ART initiation, 
information on availability of these services from repeated site assessments was 
matched to cohorts according to the quarter of ART initiation for each cohort. The mean 
proportion not retained in ART initiation cohorts within a given clinic at 6 and 12 months 
were modeled using Poisson regression with repeated measures generalized estimating 
equations [33], to account for within-site similarity in the retention proportions of cohorts.  
A secondary model used the proportion of patients not receiving ART medication for 6 
out of 6, or 12 out of 12 months, as the outcome of interest.  Assessment of potential 
additive-scale interaction between active outreach and adherence support services was 
conducted in a manner parallel to that of the overall analysis.  
 
Results 
Facility and patient characteristics 
There were 349 care and treatment clinics in 10 countries comprising over 232,000 
patients who initiated ART, contributing 300,700 person-years of observation on ART.  
The majority of clinics were housed in primary (47%) or secondary (48%) health 
facilities, and 57% were located in semi-urban or urban areas (Table 1).  Kenya 
contributed the most clinics to the analysis (71 or 20%), while Mozambique contributed 
the most patients (53,000, or 23%).   
Adherence support and outreach characteristics 
Table 2 describes the variation in adherence support and active outreach services 
across the clinics and cohorts comprising the study population.  Almost all clinics (93%) 
42 
 
Dissertation Paper #1    
 
reported at least one adherence support service, while 53% of the clinics reported that 
active patient outreach was available.  Clinics reported an average of 4 adherence 
support services, and there was variability in the specific types of adherence support 
services offered, ranging from 17% offering food rations to adults and/or children for 
ART adherence to 88% reporting one-on-one or group counseling services.   
Outcome characteristics 
Of the 232,389 patients comprising the study population, 42,208 (18%) were classified 
as non-retained (14,678 known to have died; 27,602 lost to follow-up) as of December 
2008, for an overall rate of 14.1 per 100 person-years (4.9 deaths per 100 person-
years; 9.2 LTF per 100 person-years).  Comparing across clinics, the median non-
retention rate was 15.1 per 100 person-years (IQR: 6.8-23.6), the median loss to follow-
up rate was 5.5 per 100 person-years (IQR: 0.3-12.9), and the median death rate was 
6.4 per 100 person-years (IQR: 3.3-10.7). 
 
Among the 1,097 12-month ART cohorts included in this analysis, 82,981 patients had 
initiated ART, with 80% retained at 6 months and 73% at 12 months.  Comparing across 
cohorts, the median (IQR) proportion retained at 6 and 12 months was 93% (IQR: 80%-
98%) and 90% (IQR: 73%-97%), respectively.   
 
Association of adherence support and outreach with overall rates of overall non-
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Table 3 provides the results of the analyses examining whether various adherence 
support and outreach services are associated with reduced non-retention, loss to follow-
up, or measured death.  In the unadjusted analyses, clinics offering more than 2 
adherence support services had lower non-retention and loss to follow-up than clinics 
offering fewer services. After adjusting for facility type (primary, secondary, tertiary), 
location (urban/rural), the year each clinic began offering ART services, and size of 
program (cumulative number of patients enrolled in care), clinics offering three or more 
services had significantly lower non-retention rates than those offering 2 or fewer 
services (RRadj = 0.59, 95% CI: 0.35-1.0).  For specific services, the availability of 
educational materials (RRadj = 0.73, 95% CI = 0.63-0.85), one-on-one or group 
counseling (RRadj = 0.62, 95% CI = 0.42-0.92), food rations to support ART adherence 
(RRadj = 0.72, 95% CI = 0.58-0.90) and reminder tools  (RRadj = 0.79, 95% CI = 0.64-
0.97) were associated with lower non-retention rates. 
Loss to follow-up 
In both crude and adjusted analyses, a protective effect was observed for clinics 
offering three or more adherence support services (RRadj  = 0.48, 95% CI = 0.25-0.92).  
For specific adherence services, the availability of educational materials (RRadj = 0.63, 
95% CI = 0.52-0.77), directed counseling or support services (RRadj = 0.36, 95%CI = 
0.16-0.83), one-on-one or group adherence counseling services (RRadj = 0.55, 95%CI = 
0.33-0.89), the availability of a dedicated pharmacist or routine review of medication 
pickup (RRadj = 0.60, 95%CI = 0.36-1.0), and food support (RRadj = 0.65, 95% CI = 0.47-
0.88) were associated with lower LTF compared to clinics that did not offer such 
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services.  Similar associations were observed when using non-retention or loss to 
follow-up as the outcome of interest for all of the exposures of interest.  
Ascertained deaths 
Rates of ascertained death were not associated with the total number of adherence 
support services in this analysis.  However, clinics with specific adherence support 
services were associated with lower death rates.  Clinics offering more than one 
directed counseling or support service were associated with lower measured death 
rates (RRadj,2vs1 = 0.77, 95% CI = 0.63-0.93; RRadj,3vs1 = 0.75, 95% CI = 0.64-0.87) than 
those clinics offering fewer such services.  Among the directed adherence services, 
clinics with on-site support group for HIV+ patients (RRadj= 0.81, 95% CI = 0.70-0.93), 
peer educators ( RRadj = 0.84, 95% CI = 0.74-0.96) had lower ascertained death rates 
than clinics without such services.  Among the informational services, clinics that 
provided reminder tools (RRadj = 0.81, 95% CI = 0.66-0.98) were associated with lower 
ascertained death rates compared to those without such tools.  Clinics offering food 
rations to support ART adherence had lower measured death rates (RRadj = 0.69-1.0) 
compared with those that did not offer food rations. Finally, clinics offering active patient 
outreach had marginally lower measured death rates than clinics not offering active 
patient outreach (RRadj = 0.91, 95% CI = 0.79-1.06), with a similar association among 
clinics offering outreach to all patients, compared with clinics offering to only ART 
patients (RRadj = 0.86, 95% CI = 0.70-1.06).  
 
In the model including all adherence support or outreach services significant at an alpha 
level of 0.1 in addition to clinic-level confounders (Table 5a), the provision of 
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educational materials and food support remained associated with lower non-retention 
and LTF rates, while all services except for active patient outreach remained associated 
with lower ascertained death rates. 
 
Association of adherence support and outreach with non-retention at 6 and 12 
months after ART initiation 
Table 4 presents the results of the analysis investigating whether adherence support 
and outreach services were associated with lower 6- and 12-month non-retention after 
ART initiation among cohorts of ART patients.  In both the crude and adjusted analyses, 
clinics offering more than two adherence support services had lower non-retention at 6 
months (RRadj = 0.84, 95% CI = 0.73-0.96), though this was not statistically significant at 
12 months (RRadj = 0.89, 95% CI = 0.75-1.05).  Specifically, clinics offering a dedicated 
pharmacist or routine review of ART medication pickup had lower non-retention at 6 and 
12 months (RRadj,6m = 0.78, 95% CI = 0.69-0.90; RRadj,12m = 0.85, 95% CI = 0.73-1.00).  
Clinics offering active patient outreach were also associated with lower non-retention at 
6 and 12 months (RRadj,6m = 0.86, 95% CI = 0.73-0.99; RRadj,12m = 0.84, 95% CI = 0.74-
0.96).   In the model including all adherence support or outreach services significant at 
an alpha level of 0.1 (Table 5b), both services remained significantly associated with 
lower non-retention.  
 
The percentage of patients retained in each 12-month cohort who received ART 
medication for 6 out of 6, or 12 out of 12 months was used in a secondary analysis as a 
proxy for cohort medication adherence to assess whether adherence support services 
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were associated with this outcome (see Appendix 1.1).  In this analysis, cohorts 
initiating ART at sites with three or more adherence support services had higher 
proportions of retained patients receiving ART 6 out of 6 months (RRadj = 1.23, 95% CI 
= 1.05-1.45), with a similar-magnitude but non-significant association with retained 
patients receiving ART 12 out of 12 months (RRadj = 1.15, 95% CI = 0.87-1.52).  Among 
specific adherence support services, cohorts of patients attending clinics offering a 
dedicated pharmacist or routine review of medication pickup had higher proportions of 
retained patients receiving ART 6 out of 6 months (RRadj = 1.25, 95% CI = 1.06-1.47), 
with marginally significant associations observed for the provision of educational 
pamphlets, food support to promote ART adherence, and active patient outreach.  
 
Interaction analyses 
To investigate whether associations between specific adherence support services and 
patient outcome measures differed according to whether a given facility also offered 
active patient outreach services, we (1) stratified associations on the presence/absence 
of an active outreach program and (2) tested for additive-scale interaction in each 
adjusted analysis (Figure 2 and Appendix 1.2). 
 
Overall non-retention, LTF, and death rates.  The potential for additive-scale interaction 
was assessed for those adherence support services independently associated with 
overall rates of non-retention, loss to follow-up, or death in the previous analyses.  For 
non-retention and loss to follow-up as the outcomes of interest, these services were: 
more than two adherence support services, availability of educational materials 
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promoting ART adherence, one-on-one or group adherence counseling, availability of 
reminder tools, the availability of pharmacy services (routine review of ART medication 
pickup and/or on-site ART pharmacist availability), and food rations to promote ART 
adherence.  For death as the outcome of interest, the services tested for interaction 
were: more than one directed support or counseling service, on-site support groups for 
HIV+ patients, peer educators, reminder tool provision, and food rations to promote ART 
adherence. 
In the analyses of potential additive-scale interaction presented in Figure 2a, there was 
evidence of sub-additive interaction between active outreach and one-on-one or group 
adherence counseling services in their association with cumulative measures of non-
retention and loss to follow-up.  The rate ratios comparing rates of non-retention and 
loss to follow-up between clinics offering both counseling services and active outreach 
to those offering neither (RRnon-retention = 0.58, 95% CI = 0.39-0.86; RRltf = 0.50, 95% CI 
= 0.31-0.82) were closer to the null value than would be expected if the risks of non-
retention according to the availability of counseling and outreach services were perfectly 
additive (RRnon-retention expected if perfectly additive = 0.28; RRltf expected if perfectly 
additive = 0.11; Interaction Contrast Ratio (ICR) = 0.67, 95% CI = 0.06-1.28 for non-
retention, ICR = 0.94, 95% CI = 0.49-1.38 for loss to follow-up). 
With death as the outcome of interest (Figure 2b), there was evidence of super-
additivity between having at least three adherence support services and active 
outreach.  Clinics offering at least three adherence support services but not active 
outreach, and clinics offering both three or more adherence support services and active 
outreach, had lower cumulative rates of death than did clinics offering neither service, 
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while clinics offering active outreach but not at least three adherence support services 
had higher rates of death.  The rate ratio for having both at least three adherence 
support services and active outreach compared to having neither service (RRdeath = 
0.84, 95% CI = 0.70-1.00) was more protective than the expected association if these 
factors were perfectly additive (RRdeath expected if perfectly additive = 1.34; ICR = 0.58, 
95% CI = 0.13-1.02).   
Retention at 6 and 12-months after ART initiation. The potential for additive-scale effect 
modification was assessed for those adherence support services found to be 
independently associated with non-retention at 6 or 12 months in the previous analyses.  
These factors were: three or more adherence support services, on-site support groups 
for HIV+ patients, and the availability of a dedicated ART pharmacist and/or routine ART 
medication pickup review. 
 
Evidence of sub-additive interaction was found at both 6 and 12 months between active 
outreach and the availability of on-site support groups for HIV+ patients (Figure 2c).  
The risk ratio of non-retention comparing clinics offering both active outreach and on-
site support groups to clinics offering neither (RR6m= 0.78, 95% CI = 0.64-0.95; RR12m = 
0.78, 95% CI = 0.61-0.95) was less pronounced than would be expected had on-site 
support groups and active outreach been perfectly additive (RR6m expected if perfectly 
additive = 0.50, ICR = 0.43, 95% CI = 0.23-0.58; RR12m expected if perfectly additive = 
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These analyses suggest that clinic services designed to support patient adherence to 
medication and retention in care in HIV care and treatment clinics are associated with 
lower non-retention, loss to follow-up, and death in resource-limited settings.  These 
beneficial effects are consistent with those observed in previous trials examining the 
effect of adherence support services on patient medication adherence and retention in 
care [16-20, 22-25].  Our observations, within a programmatic service delivery context, 
that adherence support and outreach programs may beneficially influence retention, 
loss to follow-up, and survival are encouraging, given widespread concerns about 
persistent high rates of non-retention in HIV scale-up [1-5, 34].  
 
Results from both the overall analysis and the 12-month ART cohorts suggest that 
clinics offering multiple adherence support services have better retention than clinics 
offering fewer such services.  This supports the theory that clinics offering a more 
comprehensive set of services are better equipped to track and retain ART patients, and 
may also suggest that overall strengthening and diversification of program services, at 
least as they pertain to ART adherence, may influence patient outcomes.  However, the 
finding that number of adherence support services was not associated with ascertained 
death may be due to in part to the likelihood that clinics with lower LTF also have more 
complete ascertainment of deaths, which would result in an association between clinics 
with low LTF and increased ascertained death even if the actual death rate (comprised 
of known and unknown deaths) is not different. 
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Directed adherence counseling and support groups, including on-site support groups for 
HIV+ patients and peer educator programs, were associated with lower death rates but 
not lower loss to follow-up.  Crude rates of loss to follow-up were actually higher at 
clinics offering one or both of these services.  It is possible, but unverifiable, that the 
observed association between these services and lower death rates is due to artifact: 
namely, that clinics with high loss to follow-up have worse death ascertainment.  It is 
also possible that these directed counseling and support services have an impact on 
adherence (which we cannot measure) and, subsequently, survival, but do not impact 
retention.  Investigation into the likely outcomes of patients lost to follow-up through 
sampling or imputation techniques would be necessary to investigate this further. 
 
In contrast, the provision of educational materials promoting ART adherence, provision 
of one or more directed counseling or support (one-on-one or group counseling, on-site 
support groups for HIV+ patients, or peer educators), and the availability of a dedicated 
ART pharmacist or routine review of medication pickup were associated with lower LTF 
rates but not associated with lower rates of ascertained death in the overall analyses.  If 
these services worked to reduce actual death rates, situations where clinics with high 
loss to follow-up are differentially underascertaining deaths would mask this relationship 
by artificially deflating the ascertained death rate among clinics with high loss to follow-
up.  
 
In the overall analyses, the provision of food rations to promote ART adherence was 
alone among those tested in being associated with both reduced loss to follow-up and 
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reduced ascertained death.  Food rations to promote ART adherence was also 
associated with a lower risk of death 6 months, but not 12 months, after ART initiation in 
the aggregate ART cohort analysis.  This was expected, since food rations target both a 
potential reason for non-adherence to ART (studies have shown that fear of hunger may 
be an important cause of non-adherence in resource-limited settings [15]) as well as a 
more structural barrier to retention in care (e.g., patients attending clinic may be forced 
to lose a day’s wages to attend clinic, and the offer of free food may incentivize their 
decision to continue in care). 
The 12 month ART cohort analyses tested similar hypotheses (namely, an effect of 
adherence support and outreach service availability on non-retention) as the overall 
analyses using an overlapping but distinct study population.  There were areas of 
agreement and disagreement when comparing these results to those from the 
aggregate cumulative analyses.  Similar to the aggregate cumulative analyses, we 
found an association between the availability of more than 2 adherence support 
services, the availability of a dedicated pharmacists and/or routine medication pickup 
review, and food rations to promote ART adherence on lower rates of non-retention.  In 
addition to those common factors identified through both study populations, there was 
an observed association between the presence of active patient outreach and lower 
rates of non-retention in the ART cohort analysis that was not observed in the overall 
analysis.  This lack of an association in the overall analysis is counterintuitive, since the 
service is intended to reduce loss to follow-up by improving death ascertainment and 
returning lapsed patients to care.  The finding of a weak protective effect of outreach 
programs on ascertained death in the overall analysis, without a similar effect on loss to 
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follow-up, is also counterintuitive since several recent articles have suggested that 
unascertained deaths represent a substantial proportion of ART patients who become 
LTF [29, 35].  One explanation is that clinics experiencing high loss to follow-up may be 
likely to institute active patient outreach.  Another explanation is that the rates estimated 
from the aggregate cumulative population represent the entire history of the clinic 
through a given quarter, and is less sensitive to the effect of a recent initiation of an 
outreach program.  Cohort analyses, focusing on specific periods of time to estimate 
retention, can correct for this potential bias, but the lack of death information among 
cohorts prohibits the partitioning of non-retention into loss to follow-up and death.   
 
Analyses of potential effect modification between adherence support services and 
active outreach (Figure 2) suggest that different adherence support services may 
interact with active outreach in different ways.  Clinics offering one-on-one or group 
adherence counseling services had similarly lower rates of non-retention and loss to 
follow-up regardless of whether they also offered active patient outreach, compared with 
clinics offering neither counseling nor outreach services, even though clinics offering 
active outreach but not counseling had the lowest rates of non-retention and death.  
This finding could be caused by unmeasured differences in patient characteristics 
between clinics offering both counseling and outreach and clinics offering only outreach.  
This theory would need patient-level information to test.  In addition, clinics offering 
more than one directed counseling or support service had lower ascertained death rates 
than clinics offering neither more than one directed counseling or support service nor 
outreach services only among those clinics also offering active outreach.  This finding is 
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consistent with the theory that directed counseling services improve survival only if 
steps are taken to reduce loss to follow-up through outreach.  However, the potential for 
differences between clinics due to unmeasured patient-level characteristics cannot be 
dismissed. 
In the ART cohort analysis, clinics offering on-site support groups for HIV positive 
patients had similarly lower non-retention regardless of whether they also offered 
outreach services, compared with clinics offering neither counseling nor outreach 
services, even though clinics offering active outreach but not support groups had the 
lowest non-retention.  This finding could be caused by unmeasured differences in 
patient characteristics between clinics offering both counseling and outreach and clinics 
offering only outreach.  This theory would need patient-level information to test.  
 
This analysis has a number of strengths.  First, it uses routinely collected data from a 
wide range of HIV care and treatment clinics covering 10 sub-Saharan African 
countries, allowing us to conduct an analysis with more than 232,000 ART patients.  
This represents roughly 8% of all patients initiating ART during the time period in sub-
Saharan Africa [36].  The use of routine aggregate data also allows us to incorporate 
clinics, particularly small health centers in rural areas, which do not have electronic 
patient-level database systems.  The large number of clinics and contexts enabled 
examination of a wide array of relevant program-level factors targeted at improving 
adherence and retention while also allowing control for potentially confounding 
variables.  Finally, the use of two different types of outcomes (non-retention rates and 
non-retention at 12 months), each measured somewhat independently, is a strength of 
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this study.  It allows the examination the findings in the context of the different 
limitations inherent in each approach.  
 
This study also has numerous important limitations.  First, the overall analysis suffers 
from potential misclassification of exposure, since exposure is assigned based on 
responses to the most recent site assessment.  Clinics that have changed their program 
availability over time will have their adherence support programs misclassified for a 
portion of the follow-up time contributing to the aggregate outcome rates.  It may be 
reasonable to assume that sites offering adherence support services are not likely to 
remove them later, but sites originally without such services may have introduced them 
at some point during program existence.  This would bias associations toward the null, 
since the “exposed” cumulative non-retention rates would include times when patients 
at a given site were not in fact exposed to the specific adherence support or active 
counseling service.  The cohort analysis corrects this bias by allowing for program 
availability to change with each followed cohort (i.e., time updated exposure 
information).  Our findings of an association between active outreach in the cohort, but 
not aggregate cumulative, analysis, are consistent with this logic. 
 
The data used in this analysis were not collected for research purposes.  Information on 
the availability of adherence support and outreach services was based on surveys filled 
out by clinic staff and may be subject to non-differential misclassification.  Further, the 
site assessment does not investigate the quality of a given service being offered or the 
proportion of patients taking part in such adherence services.  These limitations are 
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likely to be non-differential, resulting in misclassification of clinics as having a given 
adherence support or outreach service even if, in reality, the quality or 
comprehensiveness of the service is poor.  
 
Central limitations of both techniques are that ecologic analyses cannot adjust for 
between-site differences in patient-level characteristics also associated with risk of non-
retention, LTF, or death.  Further, the overall analysis cannot estimate the average 
amount of time a given individual is followed on ART.  A more complete analysis would 
combine patient-level information on program utilization and patient-specific outcomes 
to adjust for differences in program utilization across sites.  However, patient-level data 
are not widely available in all contexts, and conclusions may not be as generalizable as 
those using routinely collected aggregate data.  An analysis focusing on the subset of 
clinics also having patient-level information will be the subject of a separate manuscript. 
 
Conclusions 
This study based on routinely collected service delivery data provides evidence that 
adherence support services, and active patient outreach, are associated with lower non-
retention, LTF and death rates across a wide array of HIV care and treatment scale-up 
clinics in sub-Saharan Africa.  Additional studies, performed in service settings but using 
differing tools to measure service offerings, would help reduce the number of non-
causal alternate explanations for these findings.  However, results for the aggregate 
cohort analysis are consistent with previous studies suggesting that facilities with active 
patient outreach services have greater retention in care [29].  It also suggests that at 
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least some adherence support activities may be responsible for reduced measured 
death rates, and improved retention through 1 year.    
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Table 1.  Facility and cohort-level characteristics  of study population 
Facility-Level Characteristics   
 
12-month Cohort-level Characteristics 
N (%) Facilities  Cum N (%) patients on ART  
 N (%) facilities 
with cohorts N (%) cohorts 
N (%) patients in 
cohorts 
median (q1-
q3)  patients 
per cohort 
per facility 
     





136,999 (59%) Median CD4 count at ART initiation:  41 (21-96) 
18,696 (8%) 
General Facility Characteristics 
 
Cote d'Ivoire 9 (2.6%) 980 (0.4%) . . . . 
Ethiopia 44 (12.6%) 37,374 (16.1%) 38 (17.2%) 244 (22.2%) 20,212 (24.2%) 49 (24-116) 
Kenya 71 (20.3%) 26,001 (11.2%) 33 (14.9%) 113 (10.3%) 6,410 (7.7%) 44 (18-80) 
Lesotho 26 (7.4%) 18,117 (7.8%) 11 (5.0%) 36 (3.3%) 4,362 (5.2%) 103 (52-178) 
Mozambique 39 (11.2%) 53,315 (22.9%) 36 (16.3%) 196 (17.9%) 23,023 (27.6%) 72 (28-186) 
Nigeria 27 (7.7%) 19,478 (8.4%) 12 (5.4%) 36 (3.3%) 5,873 (7%) 124 (88-181) 
Rwanda 44 (12.6%) 19,755 (8.5%) 39 (17.7%) 240 (21.9%) 8,334 (10%) 27 (11-43) 
South Africa 43 (12.3%) 37,620 (16.2%) 31 (14.0%) 148 (13.5%) 8,961 (10.7%) 47 (21-84) 
Tanzania 45 (12.9%) 19,202 (8.3%) 21 (9.5%) 84 (7.7%) 6,217 (7.5%) 56 (32-91) 
Zambia 1 (0.3%) 547 (0.2%) . . . . . 
Facility Type Primary 163 (46.7%) 49,434 (21.3%) 85 (38.5%) 354 (32.3%) 14,829 (17.8%) 24 (13-50) 
Secondary 168 (48.1%) 160,020 (68.9%) 122 (55.2%) 646 (58.9%) 56,978 (68.3%) 60 (31-115) 
Tertiary 14 (4.0%) 22,848 (9.8%) 12 (5.4%) 88 (8%) 10,842 (13%) 113 (46-192) 
Facility Location Rural 149 (42.7%) 30,484 (13.1%) 79 (36.0%) 341 (31.1%) 9,850 (11.8%) 24 (15-36) 
Semi-urban 114 (32.7%) 90,409 (38.9%) 75 (34.0%) 333 (30.4%) 23,519 (28.2%) 52 (25-96) 
Urban 80 (22.9%) 111,427 (47.9%) 65 (29.0%) 410 (37.4%) 49,228 (59%) 84 (49-162) 
Year site initiated 
ART care (site-




2003 7 (2%) 14,583 (6.3%) -- -- -- 
2004 41 (11.7%) 76,924 (33.1%) -- -- -- 
2005 73 (20.9%) 72,391 (31.2%) n.a 6 (0.5%) 132 (0.2%) 25 (10-32) 
2006 74 (21.2%) 39,457 (17%) n.a 58 (5.3%) 4,747 (5.7%) 61 (31-100) 
2007 59 (16.9%) 20,042 (8.6%) n.a 333 (30.4%) 26,145 (31.4%) 48 (20-105) 








Table 2.  Facility and cohort-level exposure charac teristics 
Facility -Level Characteristics   Cohort -level Characteristics (N = 221 facilities with coho rts)  
N (%) of 
facilities 
 Cum N (%) patients 
on ART   
Number (%) of 
cohorts 
Number (%) of 
patients in cohorts 
median (q1-q3)  
patients per 
cohort per site     
Overall 349 (100%) 232,389 (100%) 1,097 (100%) 83,389 (100%) 48 (21-96) 
Adherence support and related services 
Any adherence support 
program 
no 15 (4.3%)                 
396  
(0.2%) 1 (0.1%) 10 (0%) 10 (10-10) 
yes 326 (93.4%)       
231,783  
(99.7%) 1082 (98.6%) 82611 (99.1%) 48 (22-96) 
Availability of educational 
pamphlets, etc 
no 150 (43%) 85,929 (37%) 315 (28.7%) 26,578 (31.9%) 49 (18-110) 
yes 199 (57%) 146,460 (63%) 773 (70.5%) 56,070 (67.2%) 47 (23-94) 
 
Number of directed 
counseling or support 
services 
0 24 (6.9%) 2,225 (1%) 153 (13.9%) 9,272 (11.1%) 40 (16-70) 
1 115 (33%) 53,909 (23.2%) 327 (29.8%) 19,477 (23.4%) 40 (20-81) 
2 97 (27.8%) 60,556 (26.1%) 311 (28.4%) 25,532 (30.6%) 53 (20-110) 
3 113 (32.4%) 115,699 (49.8%) 297 (27.1%) 28,369 (34%) 64 (27-121) 
 one-on-one or group 
adherence counseling 
services 
no 41 (11.7%) 7,532 (3.2%) 403 (36.7%) 30,947 (37.1%) 48 (21-99) 
yes 308 (88.3%) 224,857 (96.8%) 685 (62.4%) 51,701 (62%) 48 (21-94) 
 frequency of counseling 
services 
< every 3 
months 
32 (9.2%) 31,821 (13.7%) 73 (6.7%) 6,733 (8.1%) 58 (22-127) 
> every 3
months 
276 (79.1%) 193,036 (83.1%) 612 (55.8%) 44,969 (53.9%) 48 (21-90) 
 on-site support group for 
HIV+ patients 
no 159 (45.6%) 62,447 (26.9%) 409 (37.3%) 24,238 (29.1%) 38 (18-74) 
yes 190 (54.4%) 169,942 (73.1%) 679 (61.9%) 58,411 (70%) 59 (25-115) 
 
peer educator program no 199 (57%) 105,070 (45.2%) 612 (55.8%) 37,115 (44.5%) 39 (19-80) 
yes 150 (43%) 127,319 (54.8%) 476 (43.4%) 45,534 (54.6%) 61 (26-128) 
 Availability of reminder tools 
(e.g., clocks, calendars, pill 
boxes) 
no 104 (29.8%) 27,522 (11.8%) 110 (10%) 7,844 (9.4%) 33 (17-82) 
yes 245 (70.2%) 204,867 (88.2%) 978 (89.2%) 74,805 (89.7%) 49 (22-99) 
 Routine  medication pickup 
review, dedicated or team 
pharmacist 
no 71 (20.3%) 9,253 (4%) 61 (5.6%) 3,220 (3.9%) 24 (12-55) 
yes 278 (79.7%) 223,136 (96%) 1,027 (93.6%) 79,428 (95.3%) 49 (23-99) 
 Food rations provided to 
adults or children 
no 289 (82.8%) 198,231 (85.3%) 919 (83.8%) 76,078 (91.2%) 53 (23-109) 
yes 60 (17.2%) 34,158 (14.7%) 178 (16.2%) 7,311 (8.8%) 27 (17-57) 
Outreach Services 
Active patient outreach no 164 (47%) 63,969 (27.5%) 363 (33.1%) 25,037 (30%) 44 (21-83) 
yes 185 (53%) 168,420 (72.5%) 725 (66.1%) 57,611 (69.1%) 50 (22-105) 
 Target population among 
sites w/ active outreach 
ART patients 136 (39%) 108,136 (46.5%) 525 (47.9%) 38,401 (46.1%) 44 (21-90) 







Table 3.  Crude and Adjusted overall rate ratios fo r non-retention, loss to follow-up, and death 
Facility-Level Characteristics  Overall Non-retention
1 rate ratio Overall Loss to Follow-up 2 rate ratio  Overall Death
3 rate ratio 







(95% CI)  
Crude 
(95% CI) Adjusted4 (95% CI) 
Adherence support services  
  
Total number of 
adherence support 
services provided 
> 2 vs < 2 292/57  0.51 (0.31-0.85) 0.59 (0.35-1.0)  0.45 (0.24-0.84) 0.48 (0.25-0.92)  0.7 (0.38-1.28) 0.94 (0.55-1.61) 
Availability of educational 
pamphlets, etc 
yes vs. no 199/150  0.83 (0.72-0.96) 0.73 (0.63-0.85)  0.69 (0.57-0.83) 0.63 (0.52-0.77)  1.19 (1.02-1.4) 0.98 (0.85-1.13) 
Availability of directed 
Counseling or support 
yes vs. no 325/24  0.44 (0.23-0.86) 0.51 (0.26-1.03)  0.33 (0.16-0.71) 0.36 (0.16-0.83)  1.13 (0.38-3.35) 1.49 (0.57-3.88) 
Number of directed 
counseling or support 
services 
2 vs 1 97/115  0.92 (0.74-1.14) 0.91 (0.72-1.14)  1.04 (0.78-1.39) 1.01 (0.74-1.38)  0.75 (0.61-0.92) 0.77 (0.63-0.93) 
3 vs 1 113/115  1.08 (0.9-1.3) 0.98 (0.82-1.18)  1.27 (0.99-1.62) 1.16 (0.9-1.49)  0.82 (0.69-0.98) 0.75 (0.64-0.87) 
One-on-one or group 
adherence counseling 
services 
yes vs. no 308/41  0.58 (0.4-0.86) 0.62 (0.42-0.92)  0.52 (0.32-0.84) 0.55 (0.33-0.89)  0.75 (0.48-1.17) 0.82 (0.55-1.21) 
Frequency of counseling 
services among sites 
providing them 
> every 3 months 
vs < every 3 
months 
276/32  1.48 (1.17-1.87) 1.14 (0.88-1.49)  1.43 (1.06-1.94) 1.20 (0.84-1.7)  1.58 (1.24-2.02) 1.05 (0.82-1.33) 
On-site support group for 
HIV+ patients 
yes vs. no 190/159  1.06 (0.89-1.25) 1.03 (0.87-1.22)  1.24 (0.99-1.55) 1.20 (0.95-1.52)  0.80 (0.69-0.94) 0.81 (0.7-0.93) 
Peer educator program yes vs. no 150/199  1.10 (0.95-1.27) 0.99 (0.86-1.14)  1.16 (0.96-1.4) 1.08 (0.89-1.32)  0.98 (0.85-1.14) 0.84 (0.74-0.96) 
Availability of reminder 
tools (e.g., clocks, 
calendars, pill boxes) 
yes vs. no 245/104  0.79 (0.64-0.98) 0.79 (0.64-0.97)  0.79 (0.6-1.05) 0.77 (0.58-1.02)  0.79 (0.63-0.99) 0.81 (0.66-0.98) 
Routine  medication 
pickup review, dedicated 
or team pharmacist 
yes vs. no 278/71  0.61 (0.42-0.91) 0.71 (0.48-1.05)  0.59 (0.36-0.96) 0.60 (0.36-1)  0.68 (0.45-1.03) 0.95 (0.66-1.37) 
Food rations provided to 
adults or children 
yes vs. no 60/289  0.83 (0.66-1.03) 0.72 (0.58-0.9)  0.66 (0.49-0.9) 0.65 (0.47-0.88)  1.16 (0.95-1.41) 0.83 (0.69-1) 
Outreach Services                  
Active patient outreach yes vs. no 185/164  0.97 (0.82-1.14) 1.00 (0.85-1.18)  1.03 (0.83-1.28) 1.05 (0.84-1.32)  0.87 (0.74-1.02) 0.91 (0.79-1.06) 
Target population among 
sites w/ active outreach 
All patients vs. 
ART only 
136/45  1.04 (0.85-1.28) 1.01 (0.81-1.27)  1.09 (0.84-1.43) 1.10 (0.81-1.48)  0.95 (0.78-1.16) 0.86 (0.7-1.06) 
1.  Overall non-retention rates estimated as the cumulative number of patients at a site lost to follow-up, withdrawn, or reported dead, over the total person-
years observed on ART at that site 
2.  Overall loss to follow-up rates estimated as the cumulative number of patients not returning to clinic for > 6 months since last visit, with no known status, over the total 
person-years observed on ART at that site 
3.  Overall death rates estimated as the cumulative number of patients reported dead, over the total person-years observed on ART at that site 






Table 4.  Cohort analysis 4: Crude and Adjusted  risk ratios for non-retention  through 6 and 12 months  
   
Facility-Level Characteristics Non-retention Risk Ratio through 6 
months 1 
 Non-retention Risk Ratio through 12 
months 2 
    
  
N 
(yes/no) Crude   RR (95% CI) 
Adjusted3 RR (95% 
CI) 
Crude   RR (95% 
CI) 
Adjusted3 RR (95% 
CI) 
Adherence support services 
  
Total number of adherence support 
services provided > 2 vs < 2 1016/81 0.82 (0.71-0.95) 0.84 (0.73-0.96) 0.9 (0.76-1.07) 0.89 (0.75-1.05) 
Availability of educational pamphlets, 
etc yes vs. no 773/315 1.01 (0.84-1.21) 0.97 (0.81-1.17)  1.05 (0.91-1.21) 1.02 (0.87-1.19) 
Availability of directed Counseling or 
support yes vs. no 935/162 1.03 (0.81-1.31) 1.03 (0.84-1.26)  1.14 (0.92-1.4) 1.10 (0.93-1.3) 
Number of directed counseling or 
support services 
2 vs 1 311/327 0.96 (0.74-1.24) 0.97 (0.79-1.2)  0.93 (0.74-1.18) 0.90 (0.74-1.1) 
3 vs 1 297/327 0.93 (0.7-1.22) 0.91 (0.74-1.11)  0.99 (0.78-1.25) 0.95 (0.79-1.14) 
one-on-one or group adherence 
counseling services yes vs. no 685/403 1.13 (1.01-1.26) 1.07 (0.96-1.2)  1.28 (1.12-1.45) 1.22 (1.1-1.36) 
Frequency of counseling services 
among sites providing them 
> every 3 months vs < 
every 3 months 612/73 1.34 (0.82-2.17) 1.08 (0.77-1.54)  1.32 (0.89-1.96) 1.22 (0.89-1.67) 
on-site support group for HIV+ 
patients yes vs. no 679/409 0.91 (0.72-1.14) 0.90 (0.74-1.1)  0.92 (0.77-1.11) 0.89 (0.77-1.03) 
peer educator program yes vs. no 476/612 0.93 (0.74-1.17) 0.93 (0.77-1.12)  0.97 (0.8-1.17) 0.94 (0.81-1.1) 
Availability of reminder tools (e.g., 
clocks, calendars, pill boxes) yes vs. no 978/110 1.04 (0.67-1.61) 1.03 (0.7-1.51)  1.03 (0.79-1.36) 1.02 (0.8-1.29) 
Routine  medication pickup review, 
dedicated or team pharmacist yes vs. no 1027/61 0.80 (0.68-0.93) 0.78 (0.69-0.9)  0.89 (0.77-1.03) 0.85 (0.73-1) 
Food rations provided to adults or 
children yes vs. no 178/919 0.89 (0.7-1.13) 0.82 (0.64-1.05)  1.01 (0.81-1.25) 0.98 (0.78-1.21) 
Outreach Services 
           
Active patient outreach yes vs. no 725/363 0.83 (0.71-0.96) 0.85 (0.73-0.99)  0.81 (0.71-0.91) 0.84 (0.74-0.96) 
Target population among sites w/ 
active outreach 
All patients vs. ART 
only 525/178 1.18 (0.87-1.59) 1.09 (0.83-1.43)   1.01 (0.78-1.31) 0.94 (0.74-1.21) 
1.  Cohort non-retention % estimated as 100 - (number of patients on ART through 6 months/number starting cohort at baseline) 
2.  Cohort non-retention % estimated as 100 - (number of patients on ART through 12 months/number starting cohort at baseline) 
3.  Adjusted for facility type (primary, secondary, or tertiary), urban/rural, cohort start year, and cumulative number of patients seen in care  






Table 5a.  Cumulative analyses:  Adjusted 1 mean  non-retention, LTF, and death rate ratios as sociated with adherence support: adjusting for othe r 
adherence support activities 
Adherence support services   Non-retention Rate Ratio LTF Rate Ratio Death Rate Ratio 
Availability of educational pamphlets, etc yes vs. no 
0.76 (0.66-0.89) 0.67 (0.55-0.81) not in model 
one-on-one or group adherence counseling yes vs. no 
0.77 (0.52-1.14) 0.72 (0.44-1.19) not in model 
Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) yes vs. no 0.83 (0.67-1.03) 0.83 (0.63-1.11) 0.78 (0.64-0.94) 
Dedicated pharmacist, team pharmacist, or routine  
medication pickup review yes vs. no 0.92 (0.62-1.38) 0.85 (0.50-1.42) not in model 
Food Support for ART adherence yes vs. no 
0.74 (0.60-0.92) 0.67 (0.49-0.91) 0.86 (0.71-1.04) 
on-site support group for HIV+ patients  not in model not in model 0.82 (0.69-0.99) 
peer educator program yes vs. no 
not in model not in model 0.89 (0.76-1.05) 
Active patient outreach program yes vs. no 
not in model not in model 1.12 (0.93-1.34) 
1.  All models adjusted for year of ART initiation, facility type (primary, secondary, tertiary), facility location (urban/rural), and cumulative number of patients enrolled in care 
2. Rates presented additionally adjusted for other adherence support and active outreach services listed in the above table 
Table 5b.  ART cohort analyses: Adjusted 1 non-retention risk ratio at 6 and 12 months, adjus ting for other adherence support activities 
Adherence support services  
Non-retention % through 6 
months 
Non-retention % through 12 
months 
  RR2 RR2 
Dedicated pharmacist, team pharmacist, or routine  
medication pickup review yes vs. no 0.8 (0.7-0.93) 0.88 (0.73-1.05) 
Active patient outreach program yes vs. no 
0.86 (0.74-1) 0.84 (0.74-0.96) 
1.  All models adjusted for year of ART initiation, facility type (primary, secondary, tertiary), facility location (urban/rural), and cumulative number of patients enrolled in care 








Figure 1.  Comparison of strengths and weaknesses o f aggregate cumulative and cohort data 
  Overall (cumulative) 12-month ART cohort 
can estimate non-retention proportion x 
ability to separate out non-retention into LTF and death x 
includes all patients at clinics in study population x 
can estimate non-retention within 6 months or 1 year after 
ART initiation x 
sensitive to changes in non-retention rate over time at a 
given clinic x 
can adjust for clinic-level predictors of non-retention x x 
can adjust for patient-level predictors of non-retention     
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Investigating the relationship of adherence support and active outreach services with 
rates of patient non-retention, loss to follow-up, and ascertained death using aggregate 











High rates of loss to follow-up and death remain common in HIV care and treatment 
clinics in sub-Saharan Africa.  Examining whether services intended to improve 
adherence to ART and retention in care are impacting patient outcomes can help 
identify priority areas of potential intervention, but the ability of using widely available 
routinely-collected aggregate data to assess this has not been investigated. 
 Methods: 
We used three sources of routinely collected data from 92 HIV care and treatment 
clinics in 5 sub-Saharan African countries ( (1) cumulative facility-level data, (2 )12 
month ART cohort data, and (3) patient-level data) to investigate whether specific 
adherence support and active outreach services were associated with measures of non-
retention, loss to follow-up, and death among 93,000 patients initiating ART through 
June 2009.  Multivariate Poisson regression using generalized estimating equations 
was used for the facility-level and 12 month ART cohort analyses, and Proportional 
Hazards models, which controlled for differences in patient characteristics across 
clinics, were used for the patient-level analyses.  Data on adherence support and 
outreach services were obtained from annual structured site assessments.  We 
examined whether these three data sources provided similar estimates of the 
relationship between adherence support and active outreach services and patient non-
retention, loss to follow-up, and death. 
Results:  Overall estimated death rates were similar between the facility-level (4.0 per 
100 person-years on ART) and the patient-level (3.4 per 100 person-years on ART) 
estimations, while the measured rate of loss to follow-up was substantially lower in the 
facility-level analysis (9.8 per 100 person-years on ART vs. 12.6 per 100 person-years 
on ART).  In multivariate analyses, clinics offering active patient outreach had lower 
rates of non-retention in both the ART cohort analysis and the patient-level analysis, 
and clinics offering food rations to promote ART adherence were associated with a 
lower risk of ascertained death in both the facility-level and patient-level analyses, but 
this association was diminished after adjustment for patient-level covariates.  In 
contrast, various adherence counseling or support services were associated with lower 
non-retention in the ART cohort analyses but not in the patient-level data analyses.  
Conclusions: Active patient outreach and food rations remained associated with 
reduced non-retention and measured death, respectively, in both aggregate and patient-
level analyses, providing stronger evidence that these two services may influence 
patient outcomes.  However, attenuation of these associations after adjustment for 
patient-level covariates, and differences in association in the aggregate and patient-








As scale-up of HIV care and treatment services in sub-Saharan Africa reaches maturity, 
focus has shifted towards identifying factors associated with optimal patient outcomes.  
We are ultimately interested in identifying modifiable factors improving patient survival 
so that we can intervene with programs that address these factors. Program-level 
services within HIV care and treatment clinics, such as outreach and adherence support 
programs, are intended to maximize patient retention and adherence to ART 
medications, which in turn is expected to improve survival.   
The identification of whether and which types of these services actually have an impact 
on patient survival in resource-limited settings is complicated by a number of issues.  
First, high levels of patient loss to follow-up from HIV care and treatment clinics have 
been observed in these settings [1-9].  Loss to follow-up results in underestimation of 
death rates, and biases comparisons of death rates between facilities offering different 
support services if patients lost to follow-up are at higher risk of death than those 
retained in care [10-12].  Second, routinely-collected data from most HIV care and 
treatment clinics is usually of limited scope and available only in aggregate.  This latter 
issue creates two related problems.  First, routinely-collected cumulative data can be 
used to estimate overall facility-level rates of non-retention, loss to follow-up, and death, 
but cannot be used to estimate the average amount of time an individual is retained on 
ART before reaching one of these endpoints.  Second, several studies have found that 
patient characteristics (e.g., baseline CD4 count and WHO stage, age, and gender, 
among others) are important predictors of retention in care and survival [13-15], and 
these differ across sites.  This suggests that observed differences in patient retention 
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and survival across clinics and program types may in part be due to baseline 
differences in the patient population attending clinics offering different adherence 
support and retention services.  When using aggregate data, the lack of patient-level 
information on predictors of survival prevents us from assessing this possibility. 
However, since relatively few clinics have patient-level electronic data available, and 
since most HIV clinics routinely generate aggregate data, an examination of the 
situations under which aggregate information can validly be used to assess 
determinants of patient retention and survival in HIV care and treatment clinics in 
resource-limited settings is warranted. 
Published studies that have investigated the impact of adherence support services on 
patient survival and retention in care have generally found small but positive 
associations [16-20].  Similarly, active patient outreach programs, designed to identify 
patients who miss scheduled visits and return them to care, have been associated with 
lower rates of loss to follow-up [21]. However, the joint impact of adherence support and 
active patient outreach on patient retention and survival has not been examined.  
This analysis use data from sites where three different sources of information (quarterly 
estimates of cumulative patient populations, 12-month ART cohorts, and patient-level 
data) on patient outcome are available to compare estimates of the impact of program-
level services designed to improve ART adherence and patient-retention in care after 
ART initiation: (1) overall facility-level estimates of rates of non-retention, loss to follow-
up and death, (2) estimates of non-retention risk 6 and 12 months after ART initiation, 
and (3) estimates of the rate of non-retention, loss to follow-up, and death from 
electronic patient-level databases.   
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Patients initiating ART care between January 2005 and June 2009 at one of 92 HIV 
care and treatment clinics in the National HIV programs of five sub-Saharan African 
countries (Kenya, Mozambique, Rwanda, South Africa, Tanzania) directly supported by 
PEPFAR via Columbia University’s International Center for AIDS Care and Treatment 
Programs (ICAP) that had electronic patient-level databases comprise the study 
population for this analysis.  Clinics with patients initiating ART between January 2005 
and June 2009 were included if the clinic (1) routinely reported aggregate data as 
required under the PEPFAR implementing agreement during this period, (2) completed 
at least one routine site assessment during this time, and (3) maintained an electronic 
patient-level database that was available for analysis.  Because the aggregate data is 
not directly derived from electronic patient-level databases in all situations, the analysis 
therefore had two somewhat independently derived estimates of the total number of 
patients included in the analysis (one from the aggregate indicator data and one from 
the patient-level database), with the aggregate database estimating 93,772 patients and 
the patient-level database estimating 92,651 patients initiating ART during the study 
period. 
Data sources  
This analysis uses three sources of data, two available at the aggregate level and one 
at the patient-level.  Figure 1 highlights key differences between these study 
populations. 
Overall facility-level population 
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ICAP is required to provide aggregate quarterly reports summarizing the patient 
population at sites it supports under PEPFAR’s Track 1.0 agreement [22].  These data 
are gathered by site staff with technical assistance and oversight by ICAP and focus on 
key “indicators of care” at each clinic, including the number of patients enrolled in care 
and initiating ART, disaggregated by sex and age, as well as information on cohorts of 
patients initiating ART.  These data are collected into a web-based database system. A 
standard operating procedure on indicator definitions and quality assurance is in place 
to help ensure consistency of reported indicators across sites and settings. 
ART cohort population  
A subset of the patients comprising the aggregate cumulative study population also had 
information on the proportion retained in care at six and 12 months after ART initiation.  
All but one of the 92 clinics in the study reported information on cohorts of patients 
initiating ART.  Cohorts are comprised of patients aged 6 years and above who initiated 
ART at a given site over a 3-month period. Information on cohorts includes the number 
of new ART patients in the cohort (cohort size), the number of patients retained at 6 and 
12 months after ART initiation, and the number of retained patients receiving ART 
medication during all months of follow-up.  Cohorts were included in this analysis if they 
reported retention at 6 and 12 months after ART initiation, and if baseline estimates of 
the proportion of patients initiating ART measured six and 12 months after ART initiation 
did not differ by more than 20%.  675 cohorts, comprising 53,095 patients, comprise the 
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All sites used in this analysis had an electronic patient-level database system that was 
available for analysis.  Data clerks at sites with electronic patient-level data directly input 
information from paper patient records into their database.  While each country has a 
distinct patient-level database, variables of interest from all country databases were 
combined into a single common-format database for use in this analysis.  
Outcome definitions 
Facility-level rates (overall non-retention, Loss to follow-up, death) 
Facility-level rates of non-retention, LTF, and death per 100 person-years on ART were 
calculated from aggregate information reported quarterly from each clinic on (1) the 
cumulative number of patients in care and on ART, (2) the cumulative number of 
patients lost to program through death, transfer, withdrawal, or loss to follow-up, and (3) 
the number of patients newly enrolled in care and on ART during each quarter.  For rate 
denominators, the total person-time in care and on ART as of the end of each quarter 
was calculated, assuming care discontinuations (due to death, transfer, withdrawal, or 
loss to follow-up) occurred at the midpoint of the quarter.  Total person-time on ART for 
patients at a given facility was calculated by summing up the person-time from each 
quarter since the site began reporting on HIV care and ART services.  Cumulative 
death, loss to follow-up, and overall non-retention rates were computed for each clinic 
by dividing the cumulative number reported dead, LTF, or non-retained (dead or LTF), 
respectively, by the total person-time. Rates are expressed per 100 person-years on 
ART, and are through June 2009. 
 
Retention at 6 and 12 months following ART initiation 
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For the subset of patients in the ART cohorts, retention at 6 and 12 months was 
calculated as the proportion of patients in each cohort of patients initiating ART during 
2004-2008 who remained alive and in care at the original site 6 and 12 months after 
ART initiation.  
Patient-level non-retention, LTF, and death rates 
Non-retention, LTF, and death rates were also estimated from the patient-level 
database.  Deaths, transfers, and withdrawals from care that were known to clinic staff 
were recorded in the electronic database, along with the date these events were 
recorded.  Patients were defined as loss to follow-up if they were not documented as 
deaths or transfers, and if they had not had a visit documented in the electronic 
database in the 6 months before database closure (June 2009) and were censored at 
15 days after their last visit date.  ART patients known to have transferred out of an HIV 
care and treatment facility, or those that withdrew from care, were censored at their 
transfer or withdrawal date.  Per-site LTF, death, and non-retention rates were then 
calculated as the number of LTF, death, or non-retained (death + LTF) divided by the 
person-years of observation for a given site as of June, 2009.  We expect the estimates 
of loss to follow-up to be higher in the patient-level analysis than in the aggregate 
analysis because loss to follow-up is directly inferred from visit dates in the patient-level 
analysis, while loss to follow-up is based on clinic registry information that requires data 
clerks to actively mark a patient as “lost” before they are included as lost to follow-up in 
the aggregate database. 
Clinic-level data on adherence support and active o utreach 
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Clinic-level data, capturing information on clinic characteristics and service 
availability came from routinely conducted structured site assessments 
completed by ICAP field staff.  Rounds of site assessment were conducted in 
June 2007, December 2007, and July 2008.  Test-retest agreement was recently 
assessed at 58 ICAP-supported clinics in seven countries, including the five 
included in this analysis, by comparing survey responses to those assessed via 
repeat survey administration by a supervisory team.  For the 31 questions that 
were assessed, agreement between the two methods was 83% overall, 79% for 
the adherence support questions, and 74% for the outreach questions. 
 
Adherence support and related services 
Adherence support services offered at HIV clinics can be categorized according to the 
level of interaction between the patient and staff, and according to the barrier to ART 
adherence they target.  Services are considered to be “directed support services” if they 
require interaction with site staff and focus on improving adherence to medication.  
These “directed support services” include the availability of one-on-one or group 
adherence counseling, on-site support groups for HIV+ patients, and peer educator 
programs.  Services are defined as “informational” if they provide materials to promote 
ART adherence but do not require interaction with clinic staff, and include the provision 
of written educational tools providing information on the importance of adherence or 
reminder tools (such as pill boxes or calendars).  “Pharmacy services” include those 
services intended to make it easier for patients to regularly obtain prescribed ART 
regimens and to track pharmacy pickups, and include the availability of a dedicated on-
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site ART pharmacist or routine review of medication pickup.  The availability of food 
rations for adults and/or children to promote ART adherence is in a separate category, 
as it targets a structural barrier to ART adherence by offering a tangible incentive to 
consistently return to clinic.  Each measured adherence support service (Table 3) was 
dichotomized according to its reported availability at the time of the survey.  In addition, 
three additional variables were created to examine breadth and scope of adherence 
support services.  First, the total number of adherence support services at a given clinic 
were summed (range: 0-7), and a dichotomous variable was created comparing clinics 
offering 3 or more services with those offering 2 or fewer services to compare clinics in 
the lowest quintile of the number of services offered with those in the upper four 
quintiles. Second, the number of “directed ART support services” (defined here as: one-
on-one or group counseling, peer educator programs, and on-site HIV+ support groups) 
at a clinic were summed to compare clinics offering 2 or all three directed services to 
those offering only one service.  Third, the frequency with which one-on-one or group 
adherence counseling services were offered (at least every 3 months vs. less often) 
was examined based on the cutpoints established in the site assessment. 
Active Outreach 
Clinics were considered as offering active patient outreach if they reported actively 
tracing patients who miss visits through telephone calls, letters, or home visits.  Clinics 
reporting active outreach were further classified as to whether outreach activities 
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Factors routinely collected (either from the quarterly form or the semiannual structured 
site assessment) thought to be plausibly associated with patient outcomes and the 
exposures of interest examined as potential confounders included clinic size 
(cumulative number of patients in care), clinic location (urban/rural), facility type 
(primary, secondary, tertiary), provider-to-patient ratio, year of program start, and 
calendar time of ART initiation (12-month retention outcome). 
Patient-level 
Patient-level factors plausibly associated with patient non-retention, LTF, or death 
collected from the electronic patient-level database include sex, age, year of ART 
initiation, and WHO stage and CD4 count at enrollment into care and ART initiation.  
Several of these variables (WHO stage and CD4 count at ART initiation) are 
hypothesized to be mediators of the relationship between facility-level adherence 
support and outreach services and patient non-retention, LTF, and death, since many of 
these services (such as peer educators and support groups) target patients in the pre-
ART phase and may consequently improve health at ART initiation.   
 
Statistical Analyses 
Three sets of analyses were performed to assess the association between adherence 
support and active outreach services and patient retention, LTF, and death, depending 
on the source of the data (aggregate data, 12-month cohort, and patient-level). 
Facility-level analyses 
Multivariate Poisson regression using generalized estimating equations was used to 
estimate non-retention, LTF, and death rate ratios comparing facilities offering a given 
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adherence support or outreach service to those not offering such a service across the 
92 clinics.  Both unadjusted and adjusted models were fit, with adjusted models 
controlling for factors considered a priori as potential confounders (urban/rural, facility 
type, and total number of patients enrolled at the site).  Next, a “full” model was 
constructed to assess the influence of each treatment adherence and active outreach 
service found to be associated an alpha level of 0.1 or below.  Finally, to assess 
whether the association of adherence support services with non-retention differed 
depending on whether an outreach program was also present, analyses were repeated, 
both stratifying by the presence or absence of an active patient outreach program and 
testing for additive-scale interaction by computing the Interaction Contrast Ratio (ICR) 
introduced by Rothman [23] and 95% confidence intervals according to methodology 
outlined by Hosmer and Lemeshow [24]. 
Retention at 6 and 12 months following ART initiation 
Program-level information from repeated site assessments was matched to cohorts 
according to the quarter of ART initiation for each cohort. The mean proportion not 
retained in ART initiation cohorts within a given clinic at 6 and 12 months were modeled 
using Poisson regression with repeated measures generalized estimating equations 
[25], to account for the correlation in the cohort proportion retained within sites over 
time.  The potential for additive-scale interaction between various adherence support 
programs and active outreach was investigated in a manner identical to that discussed 
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Cox Proportional Hazards models, accounting for within-clinic correlation, were used to 
construct hazard ratios comparing the rate non-retention, LTF, or death at clinics 
offering a given adherence support or outreach service to those not offering such a 
service.  Proportional hazards modeling, instead of competing risk approaches, were 
used for loss to follow-up because for this analysis we are interested in differences in 
the rates of achieving the outcomes of interest, as opposed to the probability (risk) of 
achieving them.  A more thorough explanation of the difference between a competing 
risk and censoring approaches is provided in Appendix 2.1.  Four models were 
constructed to assess the association between site-level adherence support and active 
outreach services with non-retention, LTF, and death.  The first model, the “crude” 
model, compared the hazard of non-retention, LTF, and death among patients at sites 
with differing adherence support and active outreach services, without adjusting for 
potential confounding variables at the patient- or clinic-levels.  A second model adjusted 
only for patient-level differences as potential confounding variables.  Since many of the 
adherence support and active outreach services are available to patients regardless of 
their ART status, patient-level characteristics measured after enrollment into care, such 
as CD4 count, weight, and WHO stage at ART initiation, could plausibly be 
consequences of exposure to the adherence support and active outreach services.  
Thus, to avoid over-adjustment for intermediate variables on a pathway between 
exposure to these services and non-retention, LTF, or death, only variables measured 
at enrollment were included as patient-level covariates.  These included CD4 and WHO 
stage at enrollment into care, age, sex, and weight at enrollment into care.  For the 
CD4, WHO stage, and weight at enrollment variables, missing values were included as 
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a separate category in analyses.  A third model adjusted only for potential site-level 
confounding variables used in the aggregate analyses.  The final model adjusted for 
both site- and patient-level factors.  Finally, to assess potential interaction between 
active outreach and adherence support activities, analyses were repeated, both 
stratifying by the presence or absence of an active patient outreach program and testing 
for additive-scale interaction following the methods described by Rothman [23] and 
Hosmer and Lemeshow [24].  
Results 
92 care and treatment sites, comprised of 93,772 patients initiating ART, were included 
in the overall facility-level analyses.  Six and twelve month aggregate cohort follow-up 
data were available for 675 cohorts from 91 of these sites, comprising 53,095 patients.  
Estimations from the patient-level databases were that 92,651 patients across the 92 
sites initiated ART during the same time period (Table 1). 
Half of the sites were secondary facilities, and the majority of patients in the study 
population (65%) initiated ART at secondary facilities.  Half of patients were seen in 
urban settings, although only 18% of the clinics were in urban settings.  59% of the 
study population was adult females, with a median age at ART initiation of 34.5 years 
(34 years for women, 39 years for men) (Table 1).  
The overall non-retention and loss to follow-up rates calculated using the facility-level 
population were lower than those calculated using patient-level data (NR Rateaggregate  =  
13.9/100 person-years on ART (PYA); NR Ratepatient-level = 16.0/100 PYA; LTF 
Rateaggregate = 9.8/100 PYA; LTF Ratepatient-level = 12.6/100 PYA).  In contrast, the death 
rates were very similar (Death Rate: 4.0/100 PYA (aggregate) vs. 3.4/100 PYA (patient-
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level)).  As discussed earlier, we expected loss to follow-up estimates to be higher in the 
patient-level analysis compared with the aggregate cumulative analysis.  In the ART 
cohort analysis, the overall non-retention proportion 12 months after ART initiation was 
25% (IQR: 14%-36%).  Using the patient-level database, mean non-retention, LTF, and 
death probabilities 12 months after ART initiation were estimated from Kaplan-Meier 
survival methods to be 21%, 17%, and 5%, respectively (data not shown).   
The distribution of adherence support and outreach services is given in Table 3.  One-
on-one or group adherence counseling services and pharmacy services promoting 
adherence (e.g., routine review of medication pickup) were offered in one form or 
another at nearly all sites, preventing analysis investigating differences between sites 
with and without these services.   
Non-retention 
Table 4a presents the results of crude and adjusted analyses for the three groups 
(overall facility-level, 12-month ART cohort, and patient-level). 
Non-retention: The number of different adherence support services provided by a given 
clinic was marginally associated with higher non-retention in the patient-level analyses 
(HRsite&patient-level adjusted = 1.16, 95% CI = 0.94-1.42), but was not associated with 
retention in either of the aggregate analyses.   
Directed adherence counseling or support services were associated with lower non-
retention at 12 months in the ART cohort analysis, but were not associated in the 
facility-level or patient-level analyses.  In the aggregate ART cohort analysis, clinics 
offering more than 1 directed service (one-on-one or group counseling, on-site support 
groups, and/or peer educator programs) had lower non-retention at 12 months after 
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ART initiation (RRadj = 0.84, 95% CI = 0.73-0.96).  Among specific directed counseling 
or support services, clinics offering on-site support groups for HIV+ patients (RRadj = 
0.77, 95% CI = 0.68-0.87) and peer educator programs (RRadj  =0.87, 95% CI = 0.76-
0.98) had lower non-retention. 
The provision of food support to promote ART adherence was associated with lower 
non-retention in the facility-level and ART cohort analyses, but not in the analysis using 
patient-level data.  In adjusted analysis, clinics offering food support had lower non-
retention rates (RRadj = 0.67, 95% CI = 0.44-1.03) and lower risk of non-retention 6 and 
12 months after ART initiation (RR6m,adj = 0.71, 95% CI = 0.55-0.92; RR12m,adj = 0.78, 
95% CI = 0.65-0.95).  In patient-level analyses, the hazard of non-retention was 
marginally lower at clinics offering food support after adjustment for facility-level 
covariates (HR = 0.84, 95% CI = 0.54-1.31), but this association was diminished after 
additional adjustment for patient-level factors (HRadj = 0.96, 95% CI = 0.66-1.32).   
Active patient outreach was associated with lower non-retention in the 6 and 12 month 
ART cohorts (RR6m,adj = 0.88, 95% CI = 0.66-0.97; RR12m,adj = 0.86, 95% CI = 0.75-
0.98), and in analyses using patient-level data (HRsite&patient-level adjusted = 0.88, 95% CI = 
0.78-0.99), but was not associated in the overall facility-level analyses (RRadj = 1.32, 
95% CI = 0.87-2.01). 
Loss to follow-up.  Similar-magnitude associations as those observed using non-
retention as the outcome of interest were seen for loss to follow-up in the facility-level 
and patient-level analyses (Table 4b).  Clinics offering food rations to promote ART 
adherence had marginally lower rates of loss to follow-up in the facility-level analysis 
(RRadj = 0.61, 95% CI = 0.33-1.14) but not in the patient-level analyses, while active 
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patient outreach was associated with lower loss to follow-up in the patient-level analysis 
(HRsite&patient-level adjusted = 0.82, 95% CI = 0.70-0.96) but not in the facility-level analysis 
(RRadj = 1.50, 95% CI = 0.84-2.67).  
Measured Death  Table 4c presents the results of the analyses using aggregate and 
patient-level data investigating the association between the availability of adherence 
support and outreach services and rates of measured death.  In both the facility-level 
and patient-level analyses, measured death rates were higher among those sites with 
more adherence support services.  Clinics offering more than two different adherence 
support services had 4.2 times the mortality rate (95% CI = 1.32-13.1) as clinics offering 
two or fewer services according in the facility-level analysis, while the association 
observed from the patient-level data was weaker (HRsite&patient-level adjusted = 1.31, 95% CI 
= 1.01-1.69).  Among specific adherence support services, clinics offering educational 
materials, reminder tools, and/or the availability of an ART pharmacist or routine 
medication pickup review had higher adjusted death rates in both facility-level and 
patient-level analyses than clinics not offering these services.  In contrast, clinics 
offering more than one directed counseling or support service had lower measured 
death rates in the facility-level (RRadj = 0.62, 95% CI = 0.47-0.81) but not the patient-
level analysis.  Among specific directed counseling or support services, clinics offering 
on-site HIV+ support groups had lower measured rates of death in the facility-level 
(RRadj = 0.79, 95% CI = 0.6-1.04) and in the patient-level analyses after adjusting for 
site-level covariates (HRsite-level adjusted = 0.78, 95% CI = 0.58-1.04), but not after 
additionally adjusting for patient-level covariates (HRsite&patient-level adjusted = 0.88, 95% CI = 
0.65-1.19).  Clinics offering food support to promote ART adherence had marginally 
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lower measures of death in both the facility-level analysis (RRadj = 0.76, 95% CI = 0.55-
1.04) and in the patient-level analysis after adjusting for site-level covariates (HRsite-level 
adjusted = 0.81, 95% CI = 0.60-1.1), but this association was diminished after adjusting for 
patient-level differences between sites (HRsite&patient-level adjusted =1.03, 95% CI = 0.81-
1.30).  Active patient outreach was not associated with measured death in any analysis.  
Interaction analyses  To investigate whether associations between specific adherence 
support services and patient outcome measures differed according to whether a given 
facility also offered active patient outreach services, we  tested for additive-scale 
interaction according to methods outlined in Rothman [23]and Hosmer and Lemeshow 
[24] (Figure 2).  Since active patient outreach was not found to be associated with non-
retention, loss to follow-up, or death in the facility-level analysis, this was only examined 
in the aggregate 12-month cohort and patient-level groups. 
12 month ART cohort 
Figure 2 presents the results of the interaction analysis using data from the six and 
twelve month cohort analyses.  All services except for food rations were tested for 
additive-scale interaction, because all clinics offering food rations also offered active 
outreach.  Among the services found to be associated with lower non-retention at six 
and 12 months (more than one directed counseling or support service, on-site support 
groups for HIV+ patients, and peer educators), the association between these services 
and reduced non-retention was similar regardless of whether a clinic also offered active 
patient outreach, suggesting no additional reduction in risk of non-retention from active 
patient outreach.  One-on-one or group adherence counseling remained associated with 
higher non-retention among sites both offering and not offering active outreach.  
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Additionally, the provision of educational materials to promote ART adherence, which 
was not associated with non-retention in the overall analysis, was associated with lower 
non-retention only among clinics also offering active patient outreach (RR6m = 0.78, 
95% CI = 0.62-1.00, ICR = 0.17, 95% CI = 0.00-0.33; RR12m = 0.88, 95% CI = 0.74-
1.05, ICR = 0.03, 95% CI  =-0.12-0.19).   
Patient-level analyses 
There was no evidence of additive-scale interaction between adherence support and 
active outreach for any of the outcomes (non-retention, loss to follow-up, or death) 
under investigation (data not shown). 
Discussion 
This analysis compared three approaches using existing service delivery data, each 
with some limitations, in testing the hypotheses that program-level services influence 
risk of non-retention, LTF, and death, and that this influence is modified by the 
availability of active patient outreach.  The approaches used are limited because they 
rely on routinely-collected data that is often incomplete, unvalidated, and, in the case of 
the facility-level and 12-month ART cohort analyses, only available at the aggregate-
level, and not the patient-level.  However, when similar conclusions are reached by 
these different types of data, it may strengthen inference that these observed 
associations are plausibly causal, whereas different conclusions reached by these 
different types of data point to possible limitations in their use. 
Areas of internal consistency 
Clinics offering food support to promote ART adherence were associated with reduced 
non-retention in the facility-level analysis, and with reduced non-retention 6 and 12 
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months after ART initiation in the aggregate cohort analysis.  In addition, a similar-
magnitude, but non-significant, association, between the availability of food support and 
lower non-retention was observed in analyses using patient-level data after adjustment 
for site-level covariates.  This association was diminished after further adjustment for 
patient-level differences.  Food support was also associated with reduced measured 
death in the aggregate analysis, with a similar-magnitude association in the patient-level 
analysis after adjustment for site-level covariates.  This association was again 
diminished after further adjustment for patient-level covariates.  The similarity in 
inference between these three types of analyses strengthens the likelihood that this 
association is plausibly causal.   
However, the observation of a diminished association after further adjustment for 
patient-level covariates warrants further discussion.  Patients attending clinics offering 
food support to promote ART adherence have higher average CD4 counts, and less 
advanced clinical stage at enrollment, than patients attending clinics not offering food 
support (data not shown).  Further, sites offering food support may also be more likely 
to offer a more comprehensive set of services than sites not offering food support.  
Adjusting for patient-level covariates may then be adjusting for differences in patient 
predictors of outcomes through pathways other than the offering of food support.  
Whether these patient-level differences are confounding the association, or mediating it, 
depends on whether another factor (such as overall comprehensiveness of care) is 
associated with both food support and better baseline patient-level measures, or 
whether food support services are responsible for improved patient-level measures 
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(such as by access to food support improving pre-art retention or initiating patients on 
ART earlier). 
Active patient outreach was associated with lower non-retention at 6 and 12 months 
after ART initiation in the cohort analysis, and with lower non-retention and LTF in 
analyses using patient-level data, but was not associated with non-retention in the 
overall facility-level analysis.  This is likely due to underestimation of loss to follow-up in 
the facility-level analysis.  Specifically, the data used to compute aggregate estimates of 
non-retention and LTF includes an indicator identifying the cumulative number of 
patients actively classified as lost to follow-up through a given reporting quarter.  
Patients are only considered to be LTF if they are identified as such in this indicator.  In 
contrast, the 12-month ART cohort data classified a patient as not retained in care if 
they did not have a recorded visit in the third quarter after ART initiation, and the 
patient-level data classify a patient as not retained if they did not have a recorded visit in 
the last 6 months.  This non-differential misclassification of patients will bias the results 
of the aggregate analysis toward the null.   
Non-intuitive associations between the availability of certain adherence support services 
and higher rates of measured death were found in both the aggregate and patient-level 
analyses.  Clinics offering more than 2 adherence support services, as well as clinics 
offering educational materials and reminder tools promoting ART adherence, had higher 
measured rates of death than clinics not offering these services.  The finding that 
educational materials and reminder tools were not associated with loss to follow-up 
weakens support for the theory that the higher observed death rates are in part due to 
more complete ascertainment of deaths among clinics offering educational materials or 
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reminder tools.  Alternatively, it is possible that clinics observing high death rates 
instituted adherence support services in efforts to intervene, leading to the observed 
finding.  Analyses examining changes in death rates after a given clinic initiates the 
provision of educational materials or reminder tools could test this theory, but limitations 
in our data prevented us from doing so. 
 Areas of internal inconsistency 
This analysis found several differences in the association between adherence support 
and outreach services and patient non-retention, LTF, and death when using different 
measures of non-retention, LTF, and death.  In analyses using non-retention as the 
outcome of interest (Table 4a), the availability of more than one directed adherence 
counseling or support service, as well as on-site support groups for HIV+ patients and 
peer educator programs were associated with lower non-retention 12 months after ART 
initiation in the aggregate cohort analysis, but were not associated with non-retention in 
the overall facility-level or patient-level analysis.  Differences between the aggregate 
cohort results and those from the patient-level data may be in part due to the 
heterogeneity of follow-up time among individual patients attending clinics.  In the cohort 
analysis, one estimate of non-retention is calculated for each cohort, which dampens 
within-cohort variability in retention probability.  In the patient-level analyses, the 
variability in non-retention probability between patients within the same cohort is taken 
into account, which may lead to greater similarity in non-retention rates between 
patients attending clinics offering a given support service and those not. 
The different findings when analyzing the same research question using different data 
sources from within the same population highlight the difficulty inherent in using 
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routinely-collected data to infer causal relationships between the availability of 
adherence support and outreach services on non-retention, loss to follow-up, and death.  
However, the similar findings of an association between active outreach and food 
rations to promote ART adherence and reduced non-retention and death provide 
support for the theory that these two services are having a positive impact.  It suggests 
that on-site support groups for HIV+ patients and food rations to promote ART are 
associated with lower ascertained death in both aggregate and patient-level analyses, 
and that active outreach is associated with reduced non-retention.  It also suggests that 
patient-level factors are important determinants of LTF, non-retention, and death (Table 
5).  This in turn strongly suggests that services geared toward initiating patients on ART 
at an earlier stage can improve patient outcomes.   
This investigation will expand the body of literature investigating the influence of 
program-level services on patient outcome.  Thus far, studies investigating factors 
associated with patient retention in care and survival in resource-limited settings have 
focused either on facility-level differences or, more frequently, patient-level 
characteristics.  Studies using routinely-collected data have found associations between 
the availability and type of active tracing programs and lower risk of loss to follow-up in 
resource-constrained settings [8, 21, 26], a result also observed in our analysis.  In 
addition, a study in Zambia using patient records to estimate loss to follow-up at 5 HIV 
care and treatment facilities before and after the introduction of community volunteer 
adherence support workers found that 12-month retention in care was substantially 
higher after the introduction of the service (85.4% vs. 100%) [19].   
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Higher risk of death has been associated with advanced immunodeficiency at ART 
initiation and male gender in a number of studies in resource-limited settings [3, 8, 27, 
28].  A recent study in Zambia found that 71% of the documented deaths among 
patients initiating ART occurred within 90 days of ART initiation, with mortality 
associated with low baseline CD4 count, baseline WHO stage III or IV, low baseline 
BMI, male gender, and poor attendance to scheduled ART pharmacy visits [29].  These 
factors have also been associated, with lower magnitude, with retention in HIV care, 
suggesting that patients lost to follow-up represent a heterogeneous population of 
unascertained deaths and healthy individuals not returning to care [11, 12]. 
This study has a number of important strengths.  First, it is the first study to combine 
routinely-collected aggregate and patient-level information in analyzing the association 
between adherence support and related services and patient non-retention, LTF, and 
death.  It was conducted across a diverse range of countries and care and treatment 
clinics.  Second, it used three different types of routinely collected data to address the 
same hypotheses, so that similar findings using the different data sources would 
strengthen the plausibility that these findings are not due to artifact.   
While the large number of sites and patients, and the clinical settings from which these 
data derive, provide beneficial evidence of factors associated with non-retention, LTF, 
and death at typical care and treatment sites, the fact that the data used are for clinical 
and program tracking purposes, and not designed with these specific research 
questions in mind, is an important limitation.  Although there are standard operating 
procedures and routine data quality assessments in place to improve the quality of data 
reported on a routine basis, resource limitations prevent this information from being 
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independently validated.  If errors resulting from the routine nature of the data are 
random, this will effectively reduce the study’s power to detect “true” associations.  
However, if these errors are related to the adherence support or active outreach 
services and the outcomes of interest, these can bias the results in unpredictable 
directions.  Thus, caution is warranted when interpreting these results. 
Conclusions  
This analysis provides evidence that clinics providing food support to promote ART 
adherence, and active patient outreach, are associated with a lower risk of non-
retention than those that do not across a wide range of HIV care and treatment settings 
in sub-Saharan Africa.  However, the fact that all clinics comprising the study population 
for this analysis had electronic patient-level databases may limit generalizability, as they 
may be a select group of clinics with more comprehensive services available.  A related 
study investigated the association between adherence support and outreach services 
on patient non-retention, loss to follow-up, and death at 349 ICAP-supported care and 
treatment facilities in 10 sub-Saharan African countries, using aggregate data only 
(Paper 1).   
Figures 3a-3c compare the associations observed in that larger study with the current 
one, and the Discussion section of this dissertation treats this comparison in more 
detail.  With non-retention and loss to follow-up as the outcomes of interest, the larger 
facility-level study found that facilities offering more than two adherence support 
services, provision of educational materials promoting adherence, one-on-one or group 
adherence counseling, reminder tools, or food support to promote ART adherence had 
lower non-retention and loss to follow-up rates than did facilities not offering these 
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services (Figures 3a-3b).  In the current analysis, only food support to promote ART 
adherence had similar-magnitude associations in both the larger 10-country and smaller 
5-country aggregate analyses, although these associations were diminished when using 
patient-level data.  In addition, active patient outreach, not associated with non-retention 
or loss to follow-up in the larger aggregate analysis, or in the current aggregate analysis 
of 92 facilities in 5 countries, was associated with lower non-retention and non-retention 
in analyses using patient-level data after adjustment for site- and patient-level 
covariates. 
Figure 3c compares the associations between adherence support and outreach 
services on death rates in the two studies.  In the larger 10-country aggregate analysis, 
facilities offering more than one directed adherence support service, on-site support 
groups for HIV+ patients, peer educators, reminder tools, or food rations to promote 
ART adherence had lower measured death rates than facilities not offering such 
services.  Similar-magnitude associations were observed in the smaller 5-country 
aggregate analysis for having more than one directed adherence support service, on-
site support groups for HIV+ patients, and food rations to promote ART adherence, with 
these associations diminishing after adjustment for patient-level covariates.   
Differences in the results of the aggregate analyses between the previous 10-country 
analysis and the current 5-country analysis that only included facilities with patient-level 
databases, suggests that the associations between adherence support and non-
retention, loss to follow-up, and death, may differ between facilities with and without 
electronic patient-level databases, and may differ between the subset of countries with 
electronic patient-level databases and those without.  It is likely that facilities with on-site 
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electronic databases may offer a more comprehensive set of services than facilities 
without these databases, and this may result in facilities with databases being more 
similar to each other with respect to services offered than are facilities without such 
databases.  This highlights a potential limitation of the analysis restricted to facilities 
with electronic patient-level data: they may not be representative of the overall 
relationship between adherence support and outreach services and patient non-
retention, loss to follow-up, and death.  However, the finding of similar associations 
between food support to promote ART adherence and lower rates of non-retention, loss 
to follow-up, and death in both the larger 10-country and smaller 5-country analyses 
suggests that this activity may have a more generalizable association.  However, the 
diminished association after adjustment for patient-level differences warrants caution in 
causal interpretation of this association. 
Using three types of routinely-collected data also points to areas of inconsistency in 
which causal inference should be cautioned.  In particular, the underascertainment of 
vital status due to loss to follow-up provides a barrier to causal inference in examining 
whether adherence support and outreach services impact patient survival on ART.  The 
availability of patient-level data can improve inference by adjusting for important 
predictors of loss to follow-up and death, while also improving the measurement of loss 
to follow-up as an outcome.  However, there remains the possibility that observed non-
intuitive associations between the availability of adherence support and related services 
and patient non-retention, LTF, and death are actually a consequence of reverse 
causality.  Namely, it is possible that clinics observing high levels of patient non-
retention instituted programs precisely in response to a non-retention problem, and that, 
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consequently, observed associations between these programs and increased death or 
non-retention have a different meaning altogether.  Before and after analyses restricting 
to clinics that changed their programs would be able to assess this, but currently our 
database does not contain a sufficient sample size of clinics to do this. 
The general tendency of adjustment for patient-level differences driving observed 
results toward the null is consistent both with the hypothesis that patient-level 
differences are confounding the observed association, with the hypothesis that these 
patient-level factors are in the causal pathway between exposure to the adherence 
support and related services and risk of non-retention, LTF, and death, and with the 
hypothesis that patient-level differences at baseline that are related to non-retention and 
death are themselves causes of a given site instituting a program to improve patient 
outcomes.  Future analyses could focus on sites known to have changed their 
availability of one or more services to assess whether this change resulted in 
improvement in patient outcomes.  In the absence of randomization, and without definite 
knowledge of the timing of the effect of the adherence and outreach services on 
changes in patient-level covariates, caution is warranted in assessing the influence of 
patient-level characteristics on the observed site-level associations between adherence 
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Table 1. Characteristics of the study population: F acility-level, 12-mohth ART cohort, and patient-lev el 
Overall facility-level 12-month ART cohort 
 
Patient-level characteristics 
N (%) sites 
 Cum N patients on 
ART (%)  
 median (q1-q3 
patients per site  
N (%) sites 
with cohorts N (%) cohorts 
 N (%) patients in 
cohorts  
median (q1-




patients per site 
N (%) patients on 
ART 
median (q1-q3)  
patients per site 
Total  
92 (100%) 93,772 (100%) 555 (180-1291)  91 (100%) 675 (100%) 53,095 (100%) 55 (24-102) 291 (87.5-876) 92,651 (100%) 528 (174-1268) 
Country  
                
Kenya 
21 (22.8%) 13,730 (14.6%) 183 (41-1254) 20 (22%) 108 (16%) 6,687 (12.6%) 65 (16-87) 89 (8-523) 13,519 (14.6%) 155 (28-1233) 
Mozambique 
24 (26.1%) 50,047 (53.4%) 1338 (835-3499) 24 (26.4%) 236 (35%) 29,885 (56.3%) 93 (49-188) 816 (466-2005) 48,873 (52.7%) 1214 (865-3284) 
Rwanda 
27 (29.3%) 15,284 (16.3%) 338 (173-736) 27 (29.7%) 166 (24.6%) 5,950 (11.2%) 27 (13-44) 116 (80-327) 17,991 (19.4%) 427 (186-756) 
South Africa 
3 (3.3%) 4,283 (4.6%) 1272 (1010-2001) 3 (3.3%) 31 (4.6%) 3,406 (6.4%) 92 (79-136) 1044 (904-1459) 3,719 (4%) 1111 (957-1651) 
Tanzania 
17 (18.5%) 10,428 (11.1%) 432 (129-698) 17 (18.7%) 134 (19.9%) 7,167 (13.5%) 41 (22-85) 243 (86-722) 8,549 (9.2%) 357 (134-767) 
Facility type  
                
Primary 
42 (45.7%) 20,032 (21.4%) 252 (77-577) 41 (45.1%) 214 (31.7%) 10,184 (19.2%) 22 (10-70) 91 (17-211) 19,992 (21.6%) 225 (77-608) 
Secondary 
46 (50%) 60,628 (64.7%) 911 (435-1619) 46 (50.6%) 421 (62.4%) 37,014 (69.7%) 66 (37-109) 523 (243-1080) 60,279 (65.1%) 871 (363-1553) 
Tertiary 
4 (4.3%) 13,112 (14%) 3499 (1801-4756) 4 (4.4%) 40 (5.9%) 5,897 (11.1%) 155 (82-220) 1702 (508-2441) 12,380 (13.4%) 3621 (2946-5753) 
Facility 
location  
                
Rural 
39 (42.4%) 13,600 (14.5%) 244 (77-458) 37 (40.7%) 206 (30.5%) 7,865 (14.8%) 30 (16-46) 99 (25-229) 14,024 (15.1%) 265 (77-505) 
Semi-urban 
35 (38%) 33,315 (35.5%) 698 (183-1554) 35 (38.5%) 271 (40.1%) 18,185 (34.3%) 61 (27-95) 335 (88-876) 30,421 (32.8%) 727 (167-1471) 
Urban 
18 (19.6%) 46,857 (50%) 2119 (1010-3902) 19 (20.9%) 198 (29.3%) 27,045 (50.9%) 92 (60-218) 986 (614-2419) 47,950 (51.8%) 2465 (1027-4243) 
Year of ART 
initiation 1 
                
2003 
3 (3.3%) 8,539 (9.1%) 1627 (971-5941)   --  --  --  261 (0.3%) n.a. 
2004 
16 (17.4%) 33,614 (35.8%) 1810 (1187-2959) 6 n.a. 8 (1.2%) 254 (0.5%) 21 (16-56) 26 (21-70) 2,304 (2.5%) n.a. 
2005 
23 (25%) 28,125 (30%) 885 (551-1307) 25 n.a. 40 (5.9%) 2,867 (5.4%) 44 (17-92) 66 (20-118) 8,759 (9.5%) n.a. 
2006 
20 (21.7%) 14,635 (15.6%) 354 (224-989) 46 n.a. 99 (14.7%) 8,293 (15.6%) 68 (34-89) 108 (69-233) 16,390 (17.7%) n.a. 
2007 
15 (16.3%) 5,023 (5.4%) 244 (154-435) 69 n.a. 191 (28.3%) 17,803 (33.5%) 66 (29-126) 121 (43-353) 25,789 (27.8%) n.a. 
2008 
14 (15.2%) 1,160 (1.2%) 42 (28-107) 86 n.a. 227 (33.6%) 16,310 (30.7%) 44 (19-104) 79 (27-317) 26,726 (28.8%) n.a. 
2009 
1 (1.1%) 2,676 (2.9%) . 72 n.a. 110 (16.3%) 7,569 (14.3%) 42 (18-95) 68 (21-156) 12,422 (13.4%)  




   
 




  N (%) Patients 
median(IQR) patients 
per site 
 Total 92,651 (100%) 528 (174-1268) 
 
Sex 
Pediatric* 6853 (7.4%) 42 (12-90) 
Adult Female 54989 (59.4%) 335.5 (98-753) 
Adult Male 30806 (33.2%) 170.5 (57-443.5) 
 
Age at ART 
initiation 
median (IQR) 34.5(28-42.2) 
0-15           6,802  (7.3%) 44 (13-90) 
15-30         22,900  (24.7%) 105 (37-313) 
30-45         45,549  (49.2%) 277 (81-675) 
45-60         15,435  (16.7%) 102 (30-206) 
> 60           1,914  (2.1%) 14 (5-27) 
 
CD4 count at 
enrollment into 
care 
median (IQR)  172 (82-285)  
missing         33,455  (36.1%) n.a. 
< 100         17,576  (19%) n.a. 
100-200         16,675  (18%) n.a. 
200-350         15,325  (16.5%) n.a. 
> 350           9,620  (10.4%) n.a. 
 
WHO stage at 
enrollment into 
care 
missing         22,162  (23.9%) 
I         11,862  (12.8%) n.a. 
II         16,241  (17.5%) n.a. 
III              33,007  (35.6%) n.a. 




CD4 count at 
ART initiation 
median (IQR) 159 (78-240) 
missing 28,443 (30.7%) n.a. 
< 100 20,095 (21.7%) n.a. 
100-200 21,344 (23%) n.a. 
200-350 17,586 (19%) n.a. 
> 350 5,183 (5.6%) n.a. 
 
   
WHO stage at 
ART initiation 
missing 51,290 (55.4%) n.a. 
I 5,293 (5.7%) n.a. 
II 8,781 (9.5%) n.a. 
III 20,153 (21.8%) n.a. 
IV 7,134 (7.7%) n.a. 
100 
 
   
 
Table 3.  Distribution of adherence support and act ive outreach services  
  
N (%) Facilities  N (%) 12-month ART 
cohorts 
 N(%) patients 
Total 92 (100%) 
             
675  (100%) 
         




Total number of 
adherence support 
services provided 
< three 11 (12%) 
 
82 (12%) 
         
10,095  (11%) 
three or more 81 (88%) 
 
593 (88%) 
         
82,556  (89%) 
  
Availability of educational 
pamphlets, etc 
no 31 (34%) 
             
198  (29%) 
         
27,755  (30%) 
yes 61 (66%) 
             
477  (71%) 
         
64,896  (70%) 
   




0 5 (5%) 
             
165  (24%) 
         
17,692  (19%) 
1 22 (24%) 
             
184  (27%) 
         
29,732  (32%) 
2 24 (26%) 
             
172  (25%) 
         
26,971  (29%) 
3 41 (45%) 
             
154  (23%) 
         
18,256  (20%) 
   
one-on-one or group 
adherence counseling 
services 
no 5 (5%) 
             
353  (52%) 
         
54,173  (58%) 
yes 87 (95%) 
             
322  (48%) 
         
38,478  (42%) 
   
Frequency of counseling 
services among sites 
providing them 
< every 3 
months 10 (11%) 
               
38  (12%) 
           
8,122  (21%) 
> every 3 
months 77 (89%) 
             
284  (88%) 
         
30,356  (79%) 
   
on-site support group for 
HIV+ patients 
no 36 (39%) 
             
294  (44%) 
         
30,642  (33%) 
yes 56 (61%) 
             
381  (56%) 
         
62,009  (67%) 
   
peer educator program no 42 (46%) 
             
388  (57%) 
         
54,696  (59%) 
yes 50 (54%) 
             
287  (43%) 
         
37,955  (41%) 





Availability of reminder 
tools (e.g., clocks, 
calendars, pill boxes) 
no 22 (24%) 
                   
120  (18%) 
             
15,773  (17%) 
yes 70 (76%) 
                    
555  (82%) 
              
76,878  (83%) 
 




  Dedicated pharmacist, 
team pharmacist, or 
routine  medication pickup 
review 
no 14 (15%) 
                       
56  (8%) 
                 
3,727  (4%) 
yes 78 (85%) 
                    
619  (92%) 
              
88,924  (96%) 





Food rations provided to 
adults or children 
no 65 (71%) 
                   
587  (87%) 
             
86,376  (93%) 
yes 27 (29%) 
                       
88  (13%) 
                 
6,275  (7%) 
Outreach Services 





Active patient outreach 
no 31 (34%) 
                   
239  (35%) 
             
30,238  (33%) 
yes 61 (66%) 
                    
436  (65%) 
              
62,413  (67%) 





Target population among 
sites w/ active outreach 
ART patients
only 14 (23%) 
                   
102  (24%) 
             
22,194  (36%) 
All Patients 47 (77%) 
                    
321  (76%) 
              
38,644  (64%) 
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Table 4a.  Rate ratios (Facility-level and Patient- level) and risk ratios (12-month ART cohort) for no n-retention by availability of adherence support an d active outreach service   
Facility-level analysis: N = 92 sites  12-month ART cohort analysis   Non-retention rate ratio 1 Non-retention risk ratio 2 
 
6 months 12 months 
 Adherence support services  Crude RR (95% CI) 
Adjusted3 RR (95% 
CI) 
Crude RR (95% CI) Adjusted
4 RR (95% 
CI) 
Crude RR (95% CI) Adjusted
4 RR (95% 
CI) Total number of adherence 
support services offered 
>2 vs. < 2 0.91 (0.44-1.86) 1.05 (0.5-2.2)  0.92 (0.73-1.17) 0.9 (0.67-1.2) 1.1 (0.94-1.28) 0.99 (0.83-1.18)  
Availability of educational 
pamphlets, etc 
yes vs. no 1.13 (0.85-1.49) 0.99 (0.72-1.34)  1.01 (0.8-1.27) 1.02 (0.82-1.27) 1.01 (0.85-1.2) 1.03 (0.88-1.21)  
Number of separate directed 
counseling services available 
2 vs. 1 1.28 (0.86-1.91) 0.86 (0.53-1.38)  0.89 (0.73-1.09) 0.89 (0.74-1.08) 0.87 (0.73-1.03) 0.84 (0.73-0.97)  
3 vs. 1 1.2 (0.85-1.71) 0.81 (0.53-1.22)  1.07 (0.79-1.45) 0.93 (0.67-1.28) 1.04 (0.82-1.3) 0.82 (0.67-1.01)  
more than 1 vs. 1 1.23 (0.89-1.71) 0.82 (0.55-1.22)  0.96 (0.78-1.17) 0.91 (0.74-1.11) 0.93 (0.79-1.1) 0.84 (0.73-0.96)  
one-on-one or group adherence 
counseling services 
yes vs. no 0.89 (0.43-1.86) 1.04 (0.49-2.22)  1.17 (0.98-1.39) 1.91 (1.57-2.32) 1.26 (1.12-1.4) 1.46 (1.27-1.68)  
Frequency of counseling services 
among sites providing them 
> every 3 vs. < 
every 3 months 
1.9 (1.35-2.66) 1.67 (1.16-2.4)  0.74 (0.48-1.13) 0.75 (0.5-1.13) 0.93 (0.73-1.17) 0.93 (0.75-1.15)  
on-site support group for HIV+ 
patients 
yes vs. no 1.27 (0.95-1.69) 1 (0.7-1.43)  0.87 (0.68-1.1) 0.82 (0.66-1.01) 0.86 (0.72-1.04) 0.77 (0.68-0.87)  
peer educator program yes vs. no 0.99 (0.76-1.29) 0.81 (0.62-1.07)  0.94 (0.75-1.18) 0.9 (0.74-1.1) 0.93 (0.79-1.1) 0.87 (0.76-0.98)  
Availability of reminder tools  yes vs. no 1.15 (0.8-1.66) 1.29 (0.9-1.85)  1.08 (0.84-1.38) 1.11 (0.84-1.47) 1.02 (0.79-1.3) 1.06 (0.83-1.34)  
Routine medication pickup 
review/dedicated pharmacist 
yes vs. no 0.88 (0.46-1.67) 1 (0.52-1.93)  1.12 (0.88-1.43) 1.21 (0.94-1.57) 1.13 (0.94-1.36) 1.17 (0.94-1.47)  
Food rations provided to promote 
ART adherence 
yes vs. no 0.81 (0.55-1.2) 0.67 (0.44-1.03)  0.82 (0.64-1.04) 0.71 (0.55-0.92) 0.92 (0.77-1.11) 0.78 (0.65-0.95)  
Outreach Services                
Active patient outreach yes vs. no 1.58 (1.11-2.25) 1.32 (0.87-2.01)  0.85 (0.69-1.04) 0.8 (0.66-0.97) 0.92 (0.78-1.08) 0.86 (0.75-0.98)  
Target population among sites w/ 
active outreach 
all patients  vs 
ART patients only 









Table 4a (continued).  Rate ratios (Facility-level and Patient-level) and risk ratios (12-month ART co hort) for non-retention  by availability of adherence support and active ou treach service 
  Patient-level analysis 5: N = 93,772 patients  
Adherence support services   
Crude HR (95% CI) 
site-level Adjusted6 
HR (95% CI) 
patient-level 
Adjusted7 HR (95% 
CI) 





Total number of adherence support services offered >2 vs. < 2 1.32 (1.06-1.65) 1.09 (0.85-1.39) 1.12 (0.92-1.36) 1.16 (0.94-1.42) 
Availability of educational pamphlets, etc yes vs. no 1.06 (0.89-1.26) 1.05 (0.88-1.24) 1.07 (0.95-1.21) 1.08 (0.95-1.22) 
Number of separate directed counseling services available 2 vs. 1 1.14 (0.94-1.38) 1.04 (0.91-1.19) 1.07 (0.94-1.21) 1.07 (0.95-1.21) 
3 vs. 1 1.2 (0.93-1.54) 1.03 (0.75-1.4) 1.06 (0.86-1.3) 1.06 (0.83-1.35) 
more than 1 vs. 1 1.16 (0.96-1.4) 1.04 (0.88-1.22) 1.06 (0.93-1.22) 1.07 (0.93-1.23) 
one-on-one or group adherence counseling services yes vs. no 1.3 (1.19-1.43) 1.67 (1.43-1.96) 1.54 (1.4-1.7) 1.52 (1.36-1.71) 
Frequency of counseling services among sites providing them > every 3 months vs. < every 3 months 0.91 (0.63-1.3) 1.01 (0.74-1.38) 1 (0.76-1.31) 1.02 (0.81-1.28) 
on-site support group for HIV+ patients yes vs. no 0.95 (0.77-1.18) 0.95 (0.77-1.17) 1 (0.86-1.17) 1.01 (0.86-1.19) 
peer educator program yes vs. no 1.15 (0.95-1.39) 1.11 (0.91-1.35) 1.1 (0.95-1.26) 1.1 (0.93-1.31) 
Availability of reminder tools (e.g., clocks, calendars, pill boxes) yes vs. no 1.26 (1-1.58) 1.13 (0.93-1.36) 1.14 (0.96-1.34) 1.15 (0.99-1.32) 
Routine medication pickup review/dedicated pharmacist yes vs. no 1.34 (1.04-1.74) 1.13 (0.88-1.44) 1.13 (0.92-1.39) 1.16 (0.97-1.38) 
Food rations provided to promote ART adherence yes vs. no 0.83 (0.53-1.29) 0.84 (0.54-1.31) 0.94 (0.67-1.34) 0.93 (0.66-1.32) 
Outreach Services   
Active patient outreach yes vs. no 0.89 (0.73-1.08) 0.83 (0.72-0.96) 0.9 (0.79-1.02) 0.88 (0.78-0.99) 
Target population among sites w/ active outreach all patients  vs ART patients only 0.96 (0.7-1.31) 1.26 (0.98-1.63) 1.27 (1.04-1.55) 1.28 (1.05-1.56) 
1. Facility-level non-retention rates estimated as the cumulative number of patients at a site lost to follow-up, withdrawn, or reported dead, over the total person-years observed on ART at that site 
2. 6 and 12 month ART cohort risk ratios estimated as the proportion of patients retained and on ART 6 and 12 months after ART initiation 
3. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year facility began providing ART care, and cumulative number of patients seen in care 
4. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year cohort initiated ART care, and cumulative number of patients seen in care 
5. Patient-level non-retention rate ratios estimated from proportional hazards models 
6. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year patient initiated ART care, and cumulative number of patients seen in care 
7. Adjusted for CD4 count at enrollment, WHO stage at enrollment, Weight at enrollment, age, and sex 
8. Adjusted for facility- and patient-level covariates listed in notes 6 and 7 
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Table 4b.  Rate ratios for loss to follow-up by adherence support and active outreach service av ailability 
    Facility-level analysis: N = 92 sites   Patient-level analysis: N = 93,772 patients 
LTF rate ratio 1 LTF rate ratio 2 
Adherence support services   
Crude RR (95% CI) 
Adjusted3 RR (95% 
CI)   Crude HR (95% CI) 
site-level Adjusted4 
HR (95% CI) 
patient-level 
Adjusted5 HR (95% 
CI) 
site and patient-level 
Adjusted6 HR (95% 
CI) 
Total number of adherence support 
services offered 
>2 vs. < 2 
0.7 (0.31-1.54) 0.76 (0.32-1.81) 1.51 (1.12-2.05) 1.08 (0.79-1.46) 1.09 (0.86-1.38) 1.12 (0.86-1.46) 
Availability of educational pamphlets, etc yes vs. no 0.92 (0.65-1.29) 0.83 (0.56-1.24) 1.07 (0.87-1.32) 1.01 (0.81-1.25) 1.04 (0.9-1.21) 1.03 (0.87-1.23) 
Number of separate directed counseling 
services available 
2 vs. 1 1.35 (0.82-2.2) 1.07 (0.55-2.08) 1.18 (0.88-1.56) 1.06 (0.9-1.25) 1.09 (0.93-1.27) 1.1 (0.94-1.27) 
3 vs. 1 1.18 (0.76-1.83) 0.92 (0.52-1.63) 1.22 (0.89-1.68) 1.07 (0.75-1.51) 1.08 (0.83-1.4) 1.1 (0.82-1.48) 
more than 1 vs. 1 1.23 (0.82-1.86) 0.95 (0.54-1.66) 1.19 (0.9-1.57) 1.06 (0.88-1.28) 1.08 (0.92-1.28) 1.1 (0.93-1.3) 
one-on-one or group adherence 
counseling services 
yes vs. no 
0.65 (0.3-1.45) 0.72 (0.3-1.73) 1.4 (1.24-1.58) 1.8 (1.49-2.19) 1.67 (1.49-1.88) 1.65 (1.41-1.92) 
Frequency of counseling services among 
sites providing them 
> every 3 months 
vs. < every 3 
months 1.77 (1.15-2.72) 1.71 (1.05-2.76) 0.82 (0.55-1.22) 0.95 (0.69-1.32) 0.94 (0.68-1.3) 0.98 (0.76-1.27) 
on-site support group for HIV+ patients yes vs. no 1.3 (0.9-1.87) 1.12 (0.69-1.82) 1.03 (0.8-1.33) 1.02 (0.76-1.36) 1.05 (0.84-1.32) 1.07 (0.84-1.38) 
peer educator program yes vs. no 0.87 (0.63-1.22) 0.75 (0.53-1.07) 1.2 (0.94-1.53) 1.18 (0.94-1.49) 1.14 (0.96-1.36) 1.18 (0.96-1.45) 
Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) 
yes vs. no 
1.16 (0.74-1.83) 1.3 (0.81-2.09) 1.33 (1-1.76) 1.08 (0.87-1.35) 1.09 (0.91-1.3) 1.09 (0.91-1.29) 
Dedicated pharmacist, team pharmacist, 
or routine  medication pickup review 
yes vs. no 
0.68 (0.33-1.38) 0.71 (0.32-1.55) 1.56 (1.23-1.98) 1.11 (0.85-1.46) 1.1 (0.88-1.38) 1.12 (0.9-1.39) 
Food rations provided to promote ART 
adherence 
yes vs. no 
0.66 (0.39-1.11) 0.61 (0.33-1.14) 0.79 (0.45-1.4) 0.87 (0.52-1.46) 0.96 (0.62-1.49) 0.94 (0.61-1.44) 
Outreach Services  
Active patient outreach yes vs. no 1.66 (1.05-2.61) 1.5 (0.84-2.67) 0.87 (0.69-1.1) 0.79 (0.66-0.95) 0.83 (0.71-0.97) 0.82 (0.7-0.96) 
Target population among sites w/ active 
outreach 
all patients  vs 
ART patients only 0.92 (0.63-1.35) 1.14 (0.66-1.95)   0.83 (0.57-1.22) 1.22 (0.95-1.57) 1.27 (1.03-1.56) 1.25 (1.02-1.52) 
 
1. Facility-level loss to follow-up rates estimated as the cumulative number of patients at a site lost to follow-up, over the total person-years observed on ART at that site 
2. Patient-level loss to follow-up rate ratios estimated from proportional hazards models 
3. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year facility began providing ART care, and cumulative number of patients seen in care 
4. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year patient initiated ART, and cumulative number of patients seen in care 
5. Adjusted for CD4 count at enrollment, WHO stage at enrollment, Weight at enrollment, age, and sex 
6. Adjusted for facility- and patient-level covariates listed in notes 4 and 5 
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Table 4c.  Rate ratios for ascertained death by adh erence support and active outreach service availabi lity 
    Facility-level analysis: N = 92 sites   Patient-level analysis: N = 93,772 patients 
Outcome = ascertained death rate ratio 1 Outcome = ascertained death rate ratio
2 
Adherence support services   
Crude RR (95% CI) 
Adjusted3 RR (95% 
CI)   Crude HR (95% CI) 
site-level Adjusted4 
HR (95% CI) 
patient-level 
Adjusted5 HR (95% 
CI) 
site and patient-level 
Adjusted6 HR (95% 
CI) 
Total number of adherence support 
services offered 
>2 vs. < 2 
3.21 (0.75-13.72) 4.16 (1.32-13.1) 0.88 (0.58-1.34) 1.16 (0.88-1.54) 1.17 (0.87-1.57) 1.31 (1.01-1.69) 
Availability of educational pamphlets, etc yes vs. no 2 (1.45-2.75) 1.59 (1.2-2.11) 1.04 (0.78-1.38) 1.18 (0.95-1.47) 1.17 (0.92-1.49) 1.25 (1.01-1.53) 
Number of separate directed counseling 
services available 
2 vs. 1 1.13 (0.73-1.75) 0.55 (0.39-0.77) 1 (0.65-1.54) 0.99 (0.68-1.44) 1.04 (0.74-1.46) 1 (0.72-1.4) 
3 vs. 1 1.27 (0.88-1.83) 0.64 (0.49-0.85) 1.1 (0.68-1.78) 0.94 (0.6-1.46) 1.07 (0.73-1.58) 0.99 (0.68-1.46) 
more than 1 vs. 
1 1.22 (0.86-1.73) 0.62 (0.47-0.81) 1.03 (0.67-1.59) 0.97 (0.67-1.43) 1.05 (0.75-1.47) 1 (0.72-1.4) 
one-on-one or group adherence 
counseling services 
yes vs. no 
6.06 (0.8-45.94) 7.76 (1.63-37.06) 1 (0.8-1.25) 1.32 (1.03-1.67) 1.21 (0.92-1.59) 1.2 (0.92-1.56) 
Frequency of counseling services among 
sites providing them 
> every 3 
months vs. < 
every 3 months 2.28 (1.57-3.31) 1.56 (1.14-2.12) 1.58 (0.99-2.53) 1.42 (0.91-2.2) 1.39 (0.97-2) 1.4 (1.03-1.9) 
on-site support group for HIV+ patients yes vs. no 1.2 (0.87-1.66) 0.79 (0.6-1.04) 0.73 (0.55-0.95) 0.78 (0.58-1.04) 0.87 (0.65-1.17) 0.88 (0.65-1.19) 
peer educator program yes vs. no 1.34 (1-1.81) 0.99 (0.78-1.26) 0.98 (0.69-1.39) 0.92 (0.65-1.3) 0.99 (0.74-1.31) 0.91 (0.66-1.24) 
Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) 
yes vs. no 
1.14 (0.76-1.7) 1.27 (0.93-1.74) 1.04 (0.72-1.5) 1.25 (0.97-1.6) 1.24 (0.95-1.6) 1.33 (1.09-1.62) 
Dedicated pharmacist, team pharmacist, 
or routine  medication pickup review yes vs. no 
2.75 (0.82-9.25) 3.66 (1.45-9.24) 0.88 (0.56-1.4) 1.13 (0.79-1.62) 1.19 (0.84-1.69) 1.25 (0.93-1.67) 
Food rations provided to promote ART 
adherence 
yes vs. no 
1.23 (0.84-1.81) 0.76 (0.55-1.04) 0.96 (0.72-1.28) 0.81 (0.6-1.1) 1 (0.8-1.25) 1.03 (0.81-1.3) 
Outreach Services  
Active patient outreach yes vs. no 1.41 (0.95-2.08) 1.05 (0.75-1.46) 0.94 (0.7-1.27) 0.97 (0.75-1.26) 1.15 (0.91-1.45) 1.15 (0.9-1.46) 
Target population among sites w/ active 
outreach 
all patients  vs 
ART patients 
only 1.34 (1.01-1.78) 1.08 (0.78-1.47)   1.71 (0.95-3.09) 1.69 (1.03-2.77) 1.5 (0.98-2.3) 1.62 (1.07-2.46) 
1. Facility-level death rates estimated as the cumulative number of patients at a site ascertained to be dead, over the total person-years observed on ART at that site 
2. Patient-level death rate ratios estimated from proportional hazards models 
3. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year facility began providing ART care, and cumulative number of patients seen in care 
4. Adjusted for facility type (primary, secondary, or tertiary), urban/rural, year patient initiated ART, and cumulative number of patients seen in care 
5. Adjusted for CD4 count at enrollment, WHO stage at enrollment, Weight at enrollment, age, and sex 
6. Adjusted for facility- and patient-level covariates listed in notes 4 and 5 
7. Patient-level analyses account for within-facility similarity using generalized estimating equations 
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Table 5: Patient -level factors associated with non -retention, l oss to follow -up, and measured death  
 
Rate Ratios and 95% CI 
Variable Class N (%) 
 
Non-retention   LTF   Death 
Age at enrollment 
< 15  6401 (8%)  
 
 0.89 (0.84-0.94) 0.81 (0.76-0.87) 1.15 (1.04-1.27) 
15-30  19761 (24.8%)  
 
 1.32 (1.28-1.36) 1.43 (1.38-1.48) 0.95 (0.89-1.03) 
30-45  38766 (48.7%)  
 
1.0 (ref)     
45-60  13036 (16.4%)  
 
  0.98 (0.94-1.02) 0.92 (0.88-0.96) 1.21 (1.12-1.3) 
> 60  1614 (2%)  
 
 1.21 (1.11-1.33) 1.04 (0.93-1.16) 1.81 (1.55-2.11) 
 
 
CD4 count (cells/uL) at 
enrollment 
missing  27300 (34.3%)  
 
  1.58 (1.51-1.65) 1.52 (1.44-1.59) 1.89 (1.7-2.09) 
< 50  8433 (10.6%)  
 
  1.97 (1.87-2.08) 1.67 (1.57-1.77) 3.39 (3.03-3.79) 
50 -100  7115 (8.9%)  
 
  1.45 (1.37-1.53) 1.32 (1.23-1.41) 2.05 (1.81-2.33) 
100-150  7136 (9%)  
 
  1.26 (1.19-1.34) 1.2 (1.12-1.28) 1.52 (1.33-1.74) 
150-200  7327 (9.2%)  
 
  1.13 (1.06-1.20) 1.13 (1.06-1.21) 1.13 (0.98-1.31) 
200-350  9662 (12.1%)  
 
  1.04 (0.98-1.10) 1.04 (0.98-1.11) 1.03 (0.89-1.18) 
> 350  12605 (15.8%)  
 
1.0 (ref)     
 
 
WHO stage at enrollment 
missing  16619 (20.9%)  
 
1.84 (1.75-1.94) 1.83 (1.73-1.94) 1.9 (1.66-2.16) 
1  10595 (13.3%)  
 
1.0 (ref)     
2  14252 (17.9%)  
 
1.00 (0.94-1.06) 0.92 (0.86-0.98) 1.47 (1.28-1.69) 
3  28789 (36.2%)  
 
1.46 (0.94-1.54) 1.3 (1.23-1.37) 2.38 (2.11-2.69) 
4  9323 (11.7%)  
 
2.55 (2.42-2.69) 2.08 (1.96-2.21) 5.26 (4.63-5.98) 
 
 
Weight (kg) at enrollment 
missing  19586 (24.6%)  
 
1.29 (1.25-1.33) 1.34 (1.3-1.39) 1.09 (1.01-1.18) 
< 25  4585 (5.8%)  
 
1.05 (0.99-1.12) 0.93 (0.87-1.01) 1.5 (1.33-1.69) 
25-50  19529 (24.5%)  
 
1.57 (1.52-1.62) 1.45 (1.39-1.5) 2.07 (1.93-2.21) 
50-100  35743 (44.9%)  
 
1.0 (ref)     
> 100  135 (0.2%)  
 
0.60 (0.39-0.93) 0.65 (0.41-1.03) 0.44 (0.14-1.38) 
  
Sex Female  50300 (63.2%)  
 
1.0 (ref)     
Male  29278 (36.8%)  
 
  1.30 (1.27-1.34)   1.22 (1.19-1.26)  1.64 (1.55-1.73) 
  
Year of enrollment 
2003  19669 (24.7%)  
 
0.43 (0.37-0.50) 0.43 (0.37-0.51) 0.44 (0.31-0.63) 
2004  6882 (8.6%)  
 
0.53 (0.49-0.57) 0.54 (0.49-0.58) 0.51 (0.43-0.61) 
2005  604 (0.8%)  
 
0.61 (0.58-0.63) 0.55 (0.52-0.58) 0.85 (0.77-0.93) 
2006  2704 (3.4%)  
 
0.69 (0.66-0.72) 0.62 (0.6-0.65) 0.97 (0.89-1.06) 
2007  10119 (12.7%)  
 
0.84 (0.81-0.87) 0.82 (0.79-0.85) 0.92 (0.85-1) 
2008  16542 (20.8%)  
 
1.0 (ref)     
2009  23058 (29%)  
 
0.83 (0.78-0.88)   0.76 (0.7-0.81)   1.16 (1.02-1.32) 
Rate ratios presented obtained from proportional hazards modeling accounting for within-facility similarity using generalized estimating equations.  




   
 




12-month ART cohort Patient-level 
can estimate non-retention 
proportion x x 
ability to separate out non-retention 
into LTF and death x x 
includes all patients at clinics in 
study population x 
can estimate non-retention within 6 
months or 1 year after ART 
initiation x x 
sensitive to changes in non-
retention rate over time at a given 
clinic x x 
can adjust for clinic-level predictors 
of non-retention x x x 
can adjust for patient-level 
predictors of non-retention     x 
Notes: Risk ratios and 95% CIs presented are from the 12 month ART cohort analysis, adjusting for the 
 
Figure 2. Six and twelve month non- retention risk ratios stratified by the presence or  absence of active patient outreach
NR 6 months after 
ART initiation 
NR 12 months after 
ART initiation 
 
same site-level factors described in Table 4
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Abstract 
Background: High rates of loss to follow-up among patients who initiated ART at HIV care and 
treatment clinics in sub-Saharan Africa complicate examinations of the potential impact of program-
level services on patient survival.  Patients lost to follow-up have, by definition, unknown vital status, 
and routine methods of survival analysis assume that individuals lost to follow-up have the same 
probability of death as those retained in care, conditioned on predictors of death.  This assumption is 
unrealistic where loss to follow-up is substantial and is itself an important predictor of death.  Previous 
analyses have suggested that loss to follow-up biases measures of individual-level determinants of 
survival, but whether and how it may bias measures of program-level determinants of survival is 
unknown.   We conducted a sensitivity analysis to adjust estimated mortality rates under differing 
assumptions concerning the likelihood of death among patients lost to follow-up, to assess whether 
changes in the estimated survival risk impacted relative comparisons of the mortality rates between 
patients at clinics offering different ART adherence support and active outreach services. 
 Methods:  The study population included 50,379 patients initiating ART between January 2008 and 
December 2009 at one of 102 HIV care and treatment clinics in 4 countries (Kenya, Mozambique, 
Rwanda, Tanzania) with patient-level data available for analysis to investigate whether specific 
adherence support and active outreach services were associated with measures of non-retention, 
loss to follow-up, and death.  Data on adherence support and outreach services were obtained from 
annual structured site assessments.  We then compared the results from these assessments with 5 
sensitivity analyses, using multiple imputation and inverse probability weighting techniques, making 
different assumptions about the probability of death among patients lost to follow-up. Proportional 
Hazards models were used to assess the association between adherence support and outreach 
services on death rates un the baseline and sensitivity analyses.    
Results:  One-year non-retention, loss to follow-up, and mortality risk in this population was 4%, 17%, 
and 21%, respectively.  Naive analyses comparing rates of non-retention, loss to follow-up and death 
between clinics offering various adherence support and active outreach services found that clinics 
offering on-site support groups for HIV+ patients, food rations to promote ART adherence, or active 
patient outreach had lower rates of non-retention than patients at clinics not offering these services, 
while patients at clinics offering food rations or ART counseling services had lower rates of 
ascertained deaths.  In the sensitivity analysis active patient outreach became associated with 
reduced death, and food rations to support ART adherence remained associated with death.  Other 
adherence support services were associated with reduced death in some, but not all, sensitivity 
analyses.   
Conclusions: Adherence support and outreach services, strongly associated with loss to follow-up, 
also became associated with mortality after imputing the likely death probability among patients lost 
to follow-up. Findings were robust under a variety of assumptions, suggesting that loss to follow-up is 










Access to antiretroviral therapy in resource-limited settings has increased exponentially in the last five 
years [1].  Consequently, attention has shifted from scale-up efforts at initiating patients in care to 
longer-term efforts to optimize patient outcomes in care.  Care and treatment facilities offer a range of 
services intended to improve patient retention in care and on ART, and, ultimately, to improve 
survival, but the relative effectiveness of different services on these outcomes are not known.  Patient 
survival after ART initiation is the ultimate outcome of interest when examining how HIV care and 
treatment facilities are performing.  Unfortunately, direct comparisons of patient survival after ART 
initiation are complicated by substantial loss to follow-up, since patients lost to follow-up by definition 
have unknown vital status.     
Patients lost to follow-up can be categorized into three groups based on their actual (but 
unascertained) status with respect to survival and maintenance of care: (1) transferred and continuing 
care at another facility, (2) dead (including deaths from both HIV and non-HIV causes), and (3) out of 
care (withdrawal).  The distribution of these three groups is likely context-dependent, but most studies 
investigating mortality among ART patients lost to follow-up from HIV care and treatment clinics in 
resource-limited settings have found higher mortality rates among patients lost to follow-up compared 
to the rates found among those not lost [2].  One study tracing a sample of patients lost to follow-up 
from a clinic in Uganda estimated that up to 59% of patients lost to follow-up had attended a different 
clinic for HIV treatment in the last 3 months (unascertained transfers), while 25% were unascertained 
deaths [3].  Other studies focusing on the proportion of unascertained deaths among patients lost to 
follow-up ([3-13]; reviewed in [2]) estimate that 20-60% of LTF patients who could be traced had died.   
Underestimation of mortality due to lost to follow-up does not necessarily imply that relative 
comparisons of mortality between facilities offering different services will be biased.  Studies 
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investigating predictors of mortality among patients lost to follow-up have found, not surprisingly, that 
patients with pre-loss indicators of poor health and older age had higher risk of mortality than 
healthier patients [3, 4, 9].  However, relative comparisons of mortality between different exposure 
groups will be biased by loss to follow-up only if the effect of these characteristics on mortality differs 
between patients lost to follow-up and those not lost.  A recent study by Geng et al [12] suggests that 
male gender may be spuriously associated with mortality at an HIV clinic in Uganda if mortality 
among patients lost to follow-up is not taken into account, while an increasing risk of mortality with 
increasing age may be masked.  Healthier male patients were more likely to be lost, creating a 
selection bias where the males remaining in care were sicker, and at greater risk of death, than the 
female population initiating treatment.  Similarly, younger patients who were not lost were at higher 
risk of death than younger patients lost to follow-up, biasing comparisons of mortality by age.  We 
expect that differences in the mortality rate among patients retained in care and lost to follow-up may 
also impact relations between program-level service availability and mortality.  The extent to which 
this bias exists is unknown and the focus of this paper. 
In settings where sampling of those lost to ascertain the true outcome is not possible, other 
approaches can be used to adjust mortality estimates based on missing vital status information due to 
loss to follow-up.  One approach assumes patients lost to follow-up have the same probability of 
death as those retained in care, conditioned on measured predictors of death among patients whose 
vital status is known.  A second approach allows for the relationship between these predictors and 
mortality to differ between patients retained and those lost to follow-up, with predictors of loss to 
follow-up obtained either from a sampling approach or through use of externally-derived assumptions 
about predictors of death among patients lost to follow-up.  This paper examines the extent to which 
estimates of the effectiveness of adherence support and active outreach services on improving 
patient survival are influenced by loss to follow-up.  
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Methods  
Study Population  
Patients 5 years old and above initiating ART between January 1, 2008 and December 31, 2009 at 
one of 102 HIV care and treatment facilities in 4 sub-Saharan African countries (Kenya (N = 25 
facilities, 7,147 patients), Mozambique (N =27 facilities, 29,745 patients), Rwanda (N = 31 facilities, 
7,325 patients), and Tanzania (N = 21 facilities, 6,162 patients)) comprise the study population.  
Electronic patient-level databases from each site were anonymized, key variables transformed into a 
common format, and combined into a single database comprising all sites from these four countries.  
Facility Services 
Availability of services targeting ART adherence and retention in care was estimated from an 
annual structured site assessment, completed by facility staff.  Two site assessments were 
completed during the time frame of the study.  Patients initiating ART between January and 
December 2008 were assigned facility-level services based on responses to the first of these 
assessments (completed in June-August of 2008), while patients initiating ART between 
January and December 2009 were assigned facility-level services based on responses to the 
second assessment (completed in June-August of 2009). 
Specific facility-level services targeting ART adherence and retention in care examined in this 
analysis include “directed” services, involving direct consultation with health professionals or 
support groups (one-on-one or group adherence counseling, peer educator programs, and on-
site support groups for HIV+ patients),  routine review of ART pharmacy medication pickup, 
food support services to promote ART adherence, and active outreach services that track 
patients missing scheduled visits to ascertain vital status and return lapsed patients to care.  
Outcomes 
The primary outcome in this analysis survival one year after ART initiation.  Time from ART initiation 
until documented death or transfer was calculated as the difference between their ART initiation date 
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and their date of reported death or transfer in the database.  Patients not documented as dead or 
transferred who have not had a recorded visit in the 6 months before the database close date (June 
30, 2010) were classified as lost to follow-up, and their date of LTF was taken as 15 days after their 
last recorded visit.  For all analyses, the measure of association is the hazard rate ratio, comparing 
the rate of death between sites offering a given service and those not offering such a service. 
Analytic Methods 
To test the hypothesis that ART patients attending facilities offering specific adherence support and 
outreach services had lower rates of death than ART patients attending facilities not offering these 
services, we used Cox Proportional Hazards models, accounting for within-facility correlation, to 
estimate the measured death rate ratio between facilities with and without such services.  We first 
tested this hypothesis using a naïve approach, assuming that patients lost to follow-up were missing 
at random and censoring them at their calculated loss to follow-up date.  Next, we imputed survival 
probabilities among patients lost to follow-up in a series of sensitivity analyses (described in detail 
below).  Finally, we compared the results of the naïve analyses with the sensitivity analyses to assess 
the degree to which measures of association were biased by loss to follow-up. 
Baseline (“naïve”) analyses 
Associations between adherence support and outreach services and measured rates of loss to follow-
up, death, and non-retention were first estimated using Cox Proportional Hazards models, accounting 
for within-clinic correlation.  A model using death as the outcome of interest was used as the baseline 
model against which the sensitivity analyses were compared.  The model using loss to follow-up as 
the outcome of interest was used to examine factors associated with loss to follow-up, which then 
served to construct key populations used in the sensitivity analyses described below.  Finally, a 
model using non-retention (loss to follow-up + death) as an outcome was used to provide an estimate 
of the relationship between adherence support and outreach services assuming that loss to follow-up 
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and death are both undesirable outcomes.  For all three outcomes, the first model, the “crude” model, 
compared the hazard of non-retention, LTF, and death among patients at sites with differing 
adherence support and active outreach services, without adjusting for potential confounding 
variables.  A second model adjusted for patient-level differences as potential confounding variables, 
including age, sex, weight at enrollment, CD4 count and WHO stage at enrollment, and status of 
tuberculosis treatment before ART initiation.  Missing values were included as a separate category in 
analyses.  A third model additionally adjusted for potential site-level confounding variables (facility 
type (primary, secondary, or tertiary), location (urban, semi-urban, or rural), and facility size 
(cumulative number of patients seen at the clinic)) 
Sensitivity analyses  
The naïve analyses assume that those lost to follow-up are missing completely at random (in the 
crude analysis) or missing at random (adjusted analyses) conditioned on covariates in the analysis.  
However, these assumptions are unrealistic.  To assess whether relaxation of these assumptions 
impacts our conclusions about the impact of program services on patient survival, three approaches 
were used to estimate the mortality rate among patients lost to follow-up, and ultimately to assess 
whether adjustment of the overall mortality rate based on different assumptions influences observed 
relationships between the availability of adherence support and outreach services and mortality rates.   
Approach #1: Multiple Imputation 
The first approach assumes that any differences in the death rate between those lost and those 
retained is due to a differential distribution of known causes of death between those lost  and those 
not lost.  This is equivalent to a missing at random assumption. For this analysis, we assume that 
predictors of mortality are the same among patients lost to follow-up and those retained in care.  
Under this approach, we constructed three models.  First, a parsimonious model, using a patient’s 
last available CD4 count as the only predictor of mortality was constructed.  Second, a model was 
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constructed controlling for last known CD4 count, and other patient-level factors, including age, sex, 
and TB infection status, as predictors of mortality.  Third, model that controlled only for program-level 
factors was constructed using country, facility location (urban, peri-urban, or rural), and facility type 
(primary, secondary, or tertiary) as predictors of mortality.  For all analyses under this approach we 
first calculated the probability of death within one year of ART initiation among patients not lost to 
follow-up, stratified by one of the three sets of predictor variables described above.  These 
probabilities were then assigned to patients lost to follow-up according to their strata of predictor 
variables, and a random sample of N*(P(Death|strata)) lost to follow-up patients were re-assigned as 
dead, where N is the number of patients LTF in a given strata, and (P|Death|strata)) is the probability 
of death among patients not LTF in that same strata.  The entire imputation process was repeated 50 
times to create 50 sample populations for analysis to achieve greater than 99.5% efficiency [14].   
Proportional Hazards regression was then performed on these 50 sample populations to obtain 50 
effect estimates and 50 standard errors of the association between a given adherence support or 
outreach service and patient survival.  Finally, a multiply-imputed Hazard Ratio, which is the average 
hazard ratio across all 50 imputations, and 95% CI was obtained for each facility-level adherence 
service exposure category according to formulas given by Rubin [14]: 
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The variables have the following definitions: 
 bk = parameter estimate obtained from iteration k 
  = average parameter estimate 
 M = number of iterations 
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Approach #2: Inverse probability of treatment and c ensoring weights 
The second approach also assumes that predictors of survival are the same among patients lost and 
retained in care, but uses a different approach allowing for simultaneous adjustment for confounding 
and selection bias due to loss to follow-up.  For this analysis, we use both patient-level and facility-
level predictors of exposure and loss to follow-up to estimate the probability of loss to follow-up, and 
the probability of death, given a patient’s exposure and covariate stratum.  This inverse probability 
weighting approach [15, 16] calculates two weights: one to adjust for potential confounding, and one 
to adjust for selection bias due to loss to follow-up.  This approach creates a pseudopopulation where 
exposure (in this case the availability of adherence support or outreach services) is independent of 
measured confounders and produces effect estimates for a population where no loss to follow-up 
occurred by creating a pseudopopulation where patients not lost to follow-up are weighted by the 
inverse of the probability of not being lost to follow-up for a patients exposure status and strata of 
measured confounders [16].  The hazard ratios and 95% confidence intervals obtained from this 
approach represent the effect of the exposure of interest on mortality rates assuming (1) correct 
model specification (i.e., the proportional hazards assumption is correct), (2) no unmeasured 
confounding, and (3) the mortality rate among patients lost to follow-up is equal to the mortality rate 
among patients not lost to follow-up, conditioned on exposure and covariate history.  For this 
analysis, patient-level (age, sex, CD4 count and WHO stage at enrollment, tuberculosis treatment 
status before ART initiation) and clinic-level (facility type (primary, secondary tertiary), facility location 
(urban, semi-urban, rural), and facility size (the cumulative number of patients seen in care at a given 
facility)) were included. 
Approach #3: Externally derived estimates of mortal ity among patients lost to follow-up 
Both the multiple imputation and inverse probability weighting approaches described above assume 
that patients lost to follow-up are missing at random within each stratum, meaning that conditioned on 
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potentially confounding variables the probability of death does not differ between patients lost to 
follow-up and those not lost.  Recent studies that have used sampling approaches to estimate the 
probability of death among patients lost to follow-up, and factors associated with mortality among this 
group, suggest that mortality is higher among patients lost to follow-up, and that predictors of 
mortality differ in their relationship between patients lost to follow-up and those retained [3-5, 8, 12].  
To assess the sensitivity of our estimates of the association between availability of adherence support 
and outreach services and mortality rates under situations where the relationship between predictors 
of mortality differs between patients lost to follow-up and those retained, we used parameters 
obtained from a recent study by Fox et al [4] that traced patients lost to follow-up and examined 
factors associated with mortality among this group to correct for mortality estimates in our study 
population.  This study was chosen because factors it identified as associated with mortality among 
those lost to follow-up (CD4, tuberculosis diagnosis, age at ART initiation) were those that we could 
measure from information in our routine patient-level database. 
For this analysis, estimates of the probability of death among patients lost to follow-up, conditioned on 
last known measures of CD4, pre-loss tuberculosis diagnosis, and age were extracted from the Fox 
et al study [4] and applied to our population.  In particular we made the following assumptions: 
• Overall probability of death among LTF: 37% 
• HR over 40 vs under 40 yrs of age = 1.67 
• HR for last CD4 count < 100 vs. > 200:  = 3.38 
• HR for last CD4 count  100-200 vs. > 200:  = 1.8 
• HR for diagnosis of TB (yes vs no) = 1.29 
 
Patients missing pre-loss CD4 measures (~18%) were assumed to have a probability of death equal 
to the average probability of death for the entire subsample within strata of other known measures 
(tuberculosis diagnosis and age).  Random samples of N*P(Death|strata) lost to follow-up patients 
are re-assigned dead in a manner identical to that used for the multiple imputation analyses, and 
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statistical analyses were performed using proportional hazards regression in an identical approach to 
that described above.  
 
For the multiple imputation and externally derived sensitivity analyses, three regression models were 
tested: an unadjusted model, a model adjusting for site-level differences between facilities --(facility 
type (primary, secondary tertiary), location characteristics (urban, semi-urban, rural), and the 
cumulative number of patients seen in care at a given facility (log-transformed and modeled as a 
linear variable) --  and a model adjusting for both site- and patient-level differences --patient 
covariates: sex, age at ART initiation, CD4 count at enrollment, WHO stage at enrollment, TB status 
before ART initiation, and weight at enrollment.  For all analyses, repeated-measures techniques 
were used to cluster patients according to site. 
For the inverse probability weighting sensitivity analyses, potential confounding was adjusted for in 
the weighting process so the models presented are conditional unadjusted models [17]. 
In total, 6 models (a non-imputation analysis, three internally-derived multiple imputation analyses, 
one inverse probability weighting analysis, and one externally-derived multiple imputation analysis) 
were constructed and examined. 
Results 
Table 1 presents characteristics of the 102 clinics (in 4 countries) comprising the study population for 
this analysis.  The majority of facilities were primary health centers (47%) or secondary facilities such 
as district hospitals (46%), and they were distributed between large urban areas ( 32%), peri-urban 
areas (either population growth areas or business centers serving a large, mostly rural population 
(26%), and rural areas (42%).  All facilities reported offering at least one adherence support service, 
and nearly all reported offering at least one adherence counseling service (either one-on-one or 
group adherence counseling services, peer educators, or on-site support groups for HIV+ patients).  
There was heterogeneity in the proportion offering specific services, ranging from 35% offering food 
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support for ART adherence to 86% offering dedicated on-site pharmacists and/or routine review of 
medication pickup.   
Table 2 presents characteristics of the patient population (N = 50,379 patients).   63% of the patients 
were female, with the majority older than 25 years of age.  A substantial proportion of patients 
initiated ART without a recorded CD4 count (34%) or WHO stage (21%). 
Cumulatively, of the 50,379 patients initiating ART in this population between January 2008 and 
December 2009, 1,961 (4%) were ascertained deaths and 8,669 (17%) were LTF.  Using Kaplan-
Meier estimates, the risk of ascertained mortality 1 year after ART initiation was 4.5%, and the risk of 
being lost to follow-up was 18.6%.  Table 3 shows how the different sensitivity analyses changed the 
Kaplan-Meier estimates of loss to follow-up and death proportions in the population.  The internally-
derived estimates of the death probability increased in all sensitivity analyses, but this increase was 
relatively modest (0.16%-1.7% absolute increase).  Estimates obtained assuming those lost to follow-
up had higher risk of death than those retained in care increased the overall death rate substantially 
(by 6.9%).   
Baseline (no imputation) analysis 
Table 4 presents the baseline (no imputation) results of the analyses estimating the association 
between adherence support and outreach services on non-retention, loss to follow-up, and death.  
For the outcome of death, all patients lost to follow-up are censored at their date of loss, resulting in 
the assumption that, conditioned on exposure and covariates in the model, patients lost to follow-up 
have the same probability of death as those retained.  Using non-retention as an outcome of interest 
can be viewed as a “worst case” analysis in which patients lost to follow-up and ascertained to be 
dead are grouped together as an undesirable outcome (i.e., all patients LTF are assumed to have 
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Directed adherence counseling and support services 
In crude analyses, clinics offering multiple adherence counseling and support services had lower 
rates of 1-year non-retention and loss to follow-up than did clinics offering only one such service.   
This association persisted after adjustment for site-level covariates, but diminished after further 
adjustment for patient-level differences.  After adjustment for site-level differences, facilities offering 
all three adherence counseling and support services (one-on-one or group adherence counseling, 
peer educators, and on-site support groups for HIV+ patients) had 0.79 times the rate of loss to 
follow-up compared to patients offering only one such service (95% CI: 0.69-0.99); after additional 
adjustment for patient-level differences this association diminished (HR = 0.88, 95% CI: 0.71-1.09).  
Among specific directed counseling or support services, only the availability of on-site support groups 
for HIV+ patients was associated with lower non-retention or LTF (HR for non-retention after adjusting 
for site-level factors: 0.72, 95% CI: 0.51-1.0; after additional adjustment for patient-level factors: HR = 
0.79, 95% CI: 0.58-1.06).   
Clinics offering one-on-one or group adherence counseling were associated with lower one-year 
mortality after both site-and patient-level adjustment (HR = 0.58, 95% CI: 0.34-0.98).  Neither the 
availability of more than one directed counseling or support service nor the availability of on-site 
support groups for HIV+ patients, which were associated with reduced non-retention and loss to 
follow-up, were associated with 1-year survival in this baseline analysis. 
Routine review of ART pharmacy pickup 
Routine review of medication pickup was not associated with non-retention, loss to follow-up, or death 
in this analysis. 
Food support for ART adherence  
The availability of food support to promote ART adherence was associated with lower non-retention, 
LTF, and death.   After adjustment for site-level covariates, the HRs for non-retention (HR = 0.65, 
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95% CI: 0.46-0.93), LTF (HR = 0.65, 95% CI: 0.42-0.99), and death (HR = 0.67, 95% CI: 0.53-0.85) 
were similar, but the HR for death was more diminished after additional adjustment for patient-level 
covariates (HRnon-retention = 0.74, 95% CI: 0.54-1.01; HRLTF = 0.72, 95% CI: 0.49-1.07; HRdeath = 0.85, 
95% CI: 0.68-1.06). 
Active patient outreach 
The availability of an active patient outreach program to track patients missing scheduled visits was 
associated with lower non-retention and LTF, but not death, in the baseline analysis.  The 
associations with non-retention and LTF persisted after adjustment for site- and patient-level 
covariates (HRnon-retention = 0.68, 95% CI: 0.51-0.90; HRLTF = 0.63, 95% CI: 0.46-0.87), while active 
patient outreach was not associated with death after adjustment for site-and patient-level covariates 
(HRdeath = 0.98, 95% CI: 0.75-1.28). 
Based on the results from the non-imputation analysis, we would conclude that food support to 
promote ART adherence and the availability of one-on-one or group adherence counseling services 
are associated with lower mortality, with the remaining adherence support services examined not 
associated with mortality.  Further, we would conclude that food rations to promote ART adherence 
and active outreach are associated with lower loss to follow-up and non-retention.  
Sensitivity analyses 
To test the hypothesis that differences in mortality between patients lost to follow-up and those 
retained in care are biasing the observed results in the naïve analyses, we conducted a series of 
sensitivity analyses.  Table 3 presents the changes in the estimated death rates under the different 
assumptions of the sensitivity analyses.  The estimated one-year death risk ranged from 4.5% (no 
imputation) to 11.4% (imputation based on an assumed increased risk of death among patients lost to 
follow-up).  Figure 1 presents the results of the sensitivity analyses examining the degree to which 
various imputations of death probability among patients lost to follow-up influences these results.  
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Figure 1a presents the crude (unadjusted for covariates) analysis, Figure 1b presents the analysis 
adjusted for site-level covariates (facility type, location (urban,semi-urban,rural), and the cumulative 
number of patients seen in care at a given facility).  Figure 1c presents the analyses adjusted for both 
site and patient-level (sex, age at enrollment, CD4 and WHO stage at enrollment, enrollment weight, 
and tuberculosis status).  The inverse probability-weighted sensitivity analysis (sensitivity analysis #4) 
is included only in the Figure 1c because it adjusts for potential site- and patient-level confounding in 
its calculation of weights.  The six models are as follows: 
Baseline (naïve) : Identical to the results in Table 2, corresponding to the results we would obtain if 
we did not impute death probabilities among those lost to follow-up. 
Internally-derived sensitivity analyses  
Sensitivity analysis #1 : A parsimonious model using multiple imputation techniques after assuming 
that patients lost to follow-up have the same death probability as those not lost to follow-up within 
strata of last known CD4 count. 
Sensitivity analysis #2 : A parsimonious model using multiple imputation techniques to adjust the 
mortality rate assuming that patients lost to follow-up have the same death probability as those not 
lost to follow-up within strata of last known CD4 count, WHO stage at enrollment, sex, age, and 
tuberculosis status. 
Sensitivity analysis #3 : Similar to sensitivity analysis #1 and #2, but adjusting for country, clinic type 
(primary, secondary, tertiary), location (urban, semi-urban, rural), and the cumulative number of 
patients seen in care. 
Sensitivity analysis #4:  Uses inverse probability-weighting techniques to simultaneously adjust for 
potential confounding variables at both the clinic- and patient-level (combines the adjustments in 
analyses #2 and #3). 
Externally-derived sensitivity analyses:   
Sensitivity analysis #5: Uses information from Fox et all and assumes that patients lost to follow-up 




Figure 1a presents comparisons of the mortality rate ratios in models not adjusting for covariates.  
The availability of one-on-one or group adherence counseling services, associated with lower 
mortality in the baseline (no imputation analysis), remained associated in all imputation analyses 
(sensitivity analyses #1-#4) with very similar-magnitude associations.  In addition, the availability of 
food rations to promote ART adherence and active patient outreach, not associated with mortality in 
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the crude baseline analysis, was associated after imputation of death among patients lost to follow-
up.  The associations between food rations and active outreach and reduced death became stronger 
in magnitude after imputation of death among patients lost to follow-up using the externally-derived 
risks of death (sensitivity analysis #5).  Analyses imputing death probability among patients lost to 
follow-up using externally-derived estimates also resulted in an observed association between the 
availability of more than one directed counseling or support service and reduce rate of death (HR = 
0.76, 95% CI = 0.61-0.95) that was not present in the non-imputation analyses and when death 
probabilities were imputed based on the death probabilities among patients not lost to follow-up.  
Finally, the availability of routine review of ART medication pickup was associated with increased 
death rate in the sensitivity analysis imputing death rates based on strata of patient-level covariates 
(sensitivity analysis #2), but not in the other sensitivity analyses.   
Site-level adjusted analyses  
Figure 1b presents comparisons of the mortality rate ratios in models adjusting for site-level 
covariates only.  The same sensitivity analyses presented in Figure 1a are presented here.   There 
were few differences in the death rate ratio estimates between the baseline (no-imputation) and 
sensitivity analyses, with the following exceptions.  First, the availability of routine review of ART 
medication pickup was associated with increased death rate in the sensitivity analysis imputing death 
rates based on strata of patient-level covariates (sensitivity analysis #2), but not in the other 
sensitivity analyses. Second, while active outreach was not associated with death rate in the non-
imputation analysis, it was associated with a lower death in all sensitivity analyses, with the strongest-
magnitude association found in the imputation using externally-derived estimates of the death 
probability among patients lost to follow-up (sensitivity analysis #5).  
Site- and patient-level adjusted analyses   
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Figure 1c presents comparisons of the mortality rate ratios in models adjusting for both site- and 
patient-level covariates.  In these analyses, an additional sensitivity analysis is presented, using 
inverse probability weights to adjust for both potential confounding and selection bias (sensitivity 
analysis #4).  The graph shows that the first four sensitivity analyses resulted in very little change to 
the hazard ratios of 1-year death estimated from the baseline analyses, with a few exceptions.  First, 
the availability of any directed counseling or support service, which was not associated with survival 
in baseline analyses, became marginally associated with higher death rates in sensitivity analysis #2 
(assuming the distribution of death among those LTF is the same as that among those not LTF within 
strata of sex, last known CD4 count, age, and TB treatment status before ART initiation) and 
sensitivity analysis #5  (using an external estimate of the death proportion among those LTF (37%), 
with risks associated with age, TB treatment status, and last known CD4 count).  After adjustment for 
site- and patient-level covariates, the HR of death shifted from 1.06 (95% CI: 0.78-1.44) in the 
baseline analysis to 1.23 (95% CI: 0.94-1.60) in Sensitivity analysis #2, to 1.28 (95% CI: 1.01-1.63) in 
sensitivity analysis #5. 
Second, after adjustment for site- and patient-level covariates, facilities offering active patient 
outreach were unassociated with hazard of death in the baseline analysis (HRdeath = 0.98, 95% CI: 
0.75-1.28) but significantly associated with a lower hazard of death in those sensitivity analyses after 
adjustment for site-level covariates, and in sensitivity analysis #5 after adjustment for site- and 
patient-level covariates (HRdeath = 0.74, 95% CI: 0.59-0.93). 
Discussion 
This analysis focuses on an assessment of whether estimations of rates of survival among patients 
lost to follow-up, both from internally-derived and externally-derived populations, influences 
assessments of the association between program-level services and hazard of death.  We found that, 
with two exceptions, the sensitivity analyses did not markedly impact our estimation of the association 
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between the availability of program services and mortality rate.  However, the two situations where 
sensitivity analyses did impact results may serve to highlight both potential drawbacks, and benefits, 
of this approach. 
The sensitivity analysis produced different inference for the association between the availability of any 
directed adherence counseling or support service and a lower risk of death.  In the baseline analysis, 
there was no evidence of an association, while in the sensitivity analysis using an external distribution 
of death among patient LTF there was an association observed between the availability of any 
directed adherence counseling or support service and a higher hazard of death (HR= 1.28, 95% CI = 
1.01-1.63 after adjustment for site-and patient-level covariates).  Looking at Table 1, we see that only 
2 facilities in this study reported not offering any of these services.  Thus, the small sample from 
which this group is drawn limits our confidence in the validity of this conclusion, especially since 
adjustment for site-level characteristics is relatively meaningless when there are only two sites in this 
exposure group. 
The most substantial difference between baseline results and sensitivity analyses comes from the 
association between active patient outreach and 1-year survival since ART initiation, going from no 
evidence of an association in the baseline analysis (HRdeath = 0.98, 95% CI: 0.75-1.28) to evidence of 
an association between active outreach and lower risk of death in nearly all sensitivity analyses, with 
the strongest evidence in the sensitivity analysis assuming that patients lost to follow-up had a 
substantially higher death rate than patients not lost (sensitivity analysis 5).  The results from Table 4 
show that among the adherence support and outreach services examined, only active patient 
outreach was associated with lower loss to follow-up in this study population after adjustment for site- 
and patient-level factors.  Patients lost to follow-up consist of unascertained deaths, unascertained 
transfers, and those truly “lost” from care who are no longer engaged.  Facilities with programs in 
place to track patients missing visits are likely also increasing the proportion of actual deaths that are 
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ascertained, thereby increasing their measured death rate even if the program is not impacting the 
actual death rate.  This may result in a scenario where, even if an active outreach program reduces 
the actual death rate, the fact that it is concurrently increasing the measured death rate may result in 
an inability to detect the true impact on the actual death rate.  The sensitivity analyses artificially 
create parity in death rate ascertainment between facilities by assuming an underlying distribution of 
actual death among patients lost to follow-up, and allow us to investigate the impact of program 
services on actual death rate under different assumptions about the distribution of death among 
patients lost to follow-up.  The extent to which these assumptions are reasonable determines the 
confidence we have in any individual sensitivity analysis. 
The aim of these sensitivity analyses is not to establish a single “true” estimate of a given association, 
but rather to provide a range from plausible assumptions about the distribution of death among 
patients LTF.  Sampling approaches, where a representative sample of patients lost to follow-up are 
tracked and their vital status ascertained, can help improve the assumptions needed for these 
sensitivity analyses.  The results for non-retention in Table 4 provide the most conservative 
assumption of the death rate among patients LTF, effectively (if non-retention is taken as a proxy 
measure for death) assuming that all patients LTF are in actuality unascertained death.  Sensitivity 
analysis #5, which increases the overall death rate from 4% to 12% by assuming that 37% of the 
patients LTF are in actuality death, allows us to investigate a situation in which being LTF is an 
independent cause of death, something the other analyses (including the baseline analysis) do not. 
The fact that two adherence support and retention-promoting services: food support to promote ART 
adherence and active patient outreach, remain associated with reduced death across the  vast 
majority of these sensitivity analyses, incorporating both patient- and site-level factors, strengthens 
the evidence that these two services act to improve patient survival. 
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This analysis has a number of strengths.  First, it uses routinely-collected information from a large 
population in clinical, as opposed to research settings or centers of excellence.  It it likely that this 
population, across four countries and both urban and rural settings, is in many ways typical of HIV 
care patients and clinics in other areas of sub-Saharan Africa.  Second, the sensitivity analysis allows 
us to examine potential ways in which our lack of complete outcome ascertainment affects our ability 
to make inference about the ways in which program-level services are improving patient survival.  
Previous analyses estimating death rates among patients lost to follow-up have focused on its impact 
on patient survival (e.g, [4, 7-9, 13, 18]), or focused on patient-level factors associated with death 
among patients lost to follow-up (e.g., [3, 7, 9, 11, 12, 19]).  This analysis builds on those by using the 
information learned about patient characteristics associated with loss to follow-up to assess whether 
differences in these characteristics between facilities offering various types of adherence support and 
retention services can influence our ability to assess whether program-level services are associated 
with patient survival.  Thus, even though loss to follow-up may result in a substantial overestimate of 
patient survival, this overestimate will only influence relative comparisons between survival among 
facilities with and without various adherence support services if the degree of overestimation also 
differs by these facility-level services.   
Conclusion 
This analysis suggests that some associations between adherence support and outreach services 
and patient survival are masked by loss to follow-up.  The results of the sensitivity analyses provide 
strong evidence that food support services promote ART adherence and active patient outreach 
improve 1-year survival among ART patients at facilities in 4 countries in sub-Saharan Africa.  
Outcome imputation for the purposes of sensitivity analysis provides an effective means of assessing 
the impact of known biases on relative measures of association.  Loss to follow-up creates problems 
in our attempts to assess whether facility-level services are improving patient survival, especially 
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when the relationship between these factors and mortality risk differs between patients loss to follow-
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Table 1.  Facility -level characteristics of the study 
population 
Number (%) of sites Number (%) of patients 
Total   102 100%   50,379 100% 
Country 
Kenya 25 24.5% 
 
7,147 14.2% 
Mozambique 27 26.5% 
 
29,745 59% 
Rwanda 31 30.4% 
 
7,325 14.5% 
Tanzania 19 18.6% 
 
6,162 12.2% 
       
Facility type* 
Primary 48 47.1% 
 
15,753 31.3% 
Secondary 47 46.1% 
 
29,719 59% 
Tertiary 7 6.9% 
 
4,265 8.5% 
       
Facility location 
Urban 33 32.4% 
 
25,389 50.4% 
semi-urban 26 25.5% 
 
16,194 32.1% 
rural 43 42.2% 
 
8,796 17.5% 
Adherence support and outreach services  
Adherence Counseling 
yes 100 98% 
 
         
49,363  
98% 
no 2 2% 
 
           
1,016  
2% 
On-site support groups for HIV+ patients 
yes 80 78.4% 
 
         
39,253  
77.9% 
no 22 21.6% 
 




yes 84 82.4% 
 
         
36,851  
73.1% 
no 18 17.6% 
 
         
13,528  
26.9% 
Routine  medication pickup review/dedicated 
pharmacist 
yes 77 75.5% 
 
         
37,028  
73.5% 
no 25 24.5% 
 
         
13,351  
26.5% 
Food support to promote ART adherence 
yes 36 35.3% 
 
         
10,622  
21.1% 
no 66 64.7%  
         
39,757  78.9% 
Active Outreach 
  
yes 86 84.3% 
 
         
40,584  
80.6% 
no 16 15.7%   







Dissertation Paper #3   
 
Table 2. Patient-level characteristics of the study  population 
    N % 
Sex Female 31,944 63.4% 
Male 18,434 36.6% 
Age at ART initiaton 
5-15 years 1,991 4% 
15-25 years 5,384 10.7% 
25-40 years 26,722 53% 
40-60 years 15,047 29.9% 
> 60 years 1,235 2.5% 
Weight at ART initiation 
(kg) 
< 40 kg 25,441 50.5% 
40-50 kg 7,343 14.6% 
50-60 kg 10,554 20.9% 
60-70 kg 5,085 10.1% 
> 70 kg 1,956 3.9% 
CD4 at enrollment into 
care (cells/uL) 
missing 17,347 34.4% 
< 50 4,870 9.7% 
50-100 3,972 7.9% 
100-200 8,226 16.3% 
200-350 9,427 18.7% 
> 350 6,537 13% 
WHO stage at 
enrollment into care 
missing 10,679 21.2% 
I 8,212 16.3% 
II 9,565 19% 
III 17,092 33.9% 
IV 4,831 9.6% 
On tuberculosis 
treatment before ART 
initiation 
no 47,284 93.9% 
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Table 3. Comparison of estimated 1 -year mortality under different sensitivity analysis  
assumptions 
Model Ascertained death risk LTF risk 
Baseline (no sensitivity analysis) 4.46% 18.60% 
Multiple imputation analyses 
Model 1: CD4 count 5.99% 17.29% 
Model 2: CD4 count, WHO stage, age, weight, sex, tb 6.16% 17.14% 
Model 3:  site-level 5.43% 17.80% 
Inverse probability weighting analyses 
Model 4: site and patient-level 4.62%1 *2 
External weights 
Model 5: probabilities based on Fox et al 11.39% 12.21% 
1 inverse probability weighted probabilities of death calculated without adjustment for exposure or covariates 
2 Inverse probability weighting creates a pseudopopulation in which there is no loss to follow-up 
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Table 4a.  Baseline (no imputation) analysis: rate ratios of 1-year non-retention by adherence support  or outreach service 
 
Non-retention after 1 year on ART 
 
Crude1 site adjusted2 
patient- and site 
adjusted3 
Variable   HR 95% CI HR 95% CI HR 95% CI 
Availability of directed 
Counseling or support 
yes vs. no 1.39 (1.13-1.71) 1.3 (1.02-1.66) 1.25 (1.05-1.5) 
2 vs 1 0.9 (0.58-1.39) 0.95 (0.63-1.44) 1.08 (0.74-1.58) 
3 vs 1 0.72 (0.59-0.87) 0.79 (0.62-0.99) 0.88 (0.71-1.09) 
more than 1 vs. 1 0.77 (0.62-0.95) 0.84 (0.64-1.11) 0.95 (0.73-1.23) 
one-on-one or group adherence 
counseling services 
yes vs. no 0.82 (0.51-1.32) 0.88 (0.61-1.28) 0.85 (0.61-1.17) 
Frequency of counseling among 
sites providing service 
> every 3 months vs. < every 3 months 1.05 (0.72-1.51) 1.11 (0.79-1.55) 1.09 (0.82-1.46) 
on-site support group for HIV+ 
patients 
yes vs. no 0.69 (0.47-1.02) 0.72 (0.51-1) 0.79 (0.58-1.06) 
peer educator program yes vs. no 0.93 (0.74-1.18) 1 (0.73-1.35) 1.02 (0.78-1.35) 
Routine  medication pickup 
review/dedicated pharmacist 
yes vs. no 1.11 (0.69-1.77) 1.14 (0.71-1.83) 1.06 (0.70-1.61) 
Food rations provided to adults 
or children 
yes vs. no 0.6 (0.44-0.83) 0.65 (0.46-0.93) 0.74 (0.54-1.01) 
Outreach Services         
Active patient outreach yes vs. no 0.6 (0.41-0.89) 0.63 (0.46-0.86) 0.68 (0.51-0.9) 
Target population among sites 
w/ active outreach 
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Table 4b: Baseline (no imputation) analysis: rate r atios of 1-year loss to follow-up by adherence supp ort or outreach service 
Loss to Follow-up after 1 year on ART 
Crude1 site adjusted2 
patient- and site 
adjusted3 
Variable   HR 95% CI HR 95% CI HR 95% CI 
Availability of directed 
Counseling or support 
yes vs. no 1.62 (1.29-2.04) 1.44 (1.07-1.93) 1.33 (1.06-1.67) 
2 vs 1 0.87 (0.52-1.47) 0.93 (0.57-1.53) 1.04 (0.66-1.63) 
3 vs 1 0.69 (0.55-0.87) 0.77 (0.57-1.03) 0.85 (0.65-1.11) 
more than 1 vs. 1 0.74 (0.57-0.96) 0.82 (0.59-1.15) 0.92 (0.67-1.26) 
one-on-one or group adherence 
counseling services yes vs. no 0.9 (0.53-1.53) 0.99 (0.67-1.47) 0.95 (0.7-1.28) 
Frequency of counseling 
services among sites providing 
them 
> every 3 months vs. < every 3 
months 1.03 (0.67-1.58) 1.13 (0.76-1.69) 1.13 (0.8-1.6) 
on-site support group for HIV+ 
patients yes vs. no 0.68 (0.42-1.11) 0.7 (0.46-1.06) 0.76 (0.53-1.1) 
peer educator program yes vs. no 0.92 (0.69-1.21) 0.99 (0.69-1.43) 1.01 (0.73-1.41) 
Availability of reminder tools 
(e.g., clocks, calendars, pill 
boxes) yes vs. no 1.36 (0.97-1.92) 1.34 (0.95-1.91) 1.26 (0.94-1.7) 
Routine  medication pickup 
review/ dedicated pharmacist yes vs. no 1.11 (0.62-1.99) 1.16 (0.65-2.05) 1.08 (0.65-1.79) 
Food rations provided to adults 
or children yes vs. no 0.55 (0.37-0.83) 0.65 (0.42-0.99) 0.72 (0.49-1.07) 
Outreach Services 
Active patient outreach yes vs. no 0.56 (0.36-0.89) 0.59 (0.41-0.85) 0.63 (0.46-0.87) 
Target population among sites w/ 
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Table 4c: Baseline (no imputation) analysis: rate r atios of 1-year hazard of death by adherence suppor t or outreach service 
Death after 1 year on ART 
Crude1 site adjusted2 
patient- and site 
adjusted3 
 Variable   HR 95% CI HR 95% CI HR 95% CI 
Availability of directed Counseling 
or support 
yes vs. no 0.84 (0.64-1.09) 0.98 (0.7-1.37) 1.06 (0.78-1.44) 
2 vs 1 1.03 (0.63-1.69) 1.12 (0.72-1.74) 1.39 (0.94-2.06) 
3 vs 1 0.85 (0.55-1.32) 0.9 (0.62-1.29) 1.09 (0.79-1.5) 
more than 1 vs. 1 0.9 (0.59-1.38) 0.96 (0.67-1.36) 1.17 (0.86-1.6) 
one-on-one or group adherence 
counseling services yes vs. no 0.57 (0.39-0.83) 0.57 (0.36-0.89) 0.58 (0.34-0.98) 
Frequency of counseling services 
among sites providing them 
> every 3 months vs. < every 3 
months 1.14 (0.72-1.81) 0.93 (0.6-1.45) 0.88 (0.59-1.32) 
on-site support group for HIV+ 
patients yes vs. no 0.76 (0.53-1.07) 0.8 (0.55-1.17) 0.91 (0.65-1.29) 
peer educator program yes vs. no 1.03 (0.77-1.37) 1.04 (0.82-1.31) 1.13 (0.93-1.36) 
Routine  medication pickup 
review/ dedicated pharmacist yes vs. no 1.08 (0.78-1.49) 1.05 (0.78-1.42) 0.96 (0.72-1.29) 
Food rations provided to adults or 
children yes vs. no 0.86 (0.66-1.13) 0.67 (0.53-0.85) 0.85 (0.68-1.06) 
Outreach Services 
Active patient outreach yes vs. no 0.87 (0.62-1.23) 0.86 (0.64-1.15) 0.98 (0.75-1.28) 
Target population among sites w/ 
active outreach all patients  vs ART patients only 1.33 (0.94-1.89) 1.03 (0.74-1.43) 1.04 (0.78-1.38) 
1. Rate ratios obtained from proportional hazards modeling accounting for within-site similarity using generalized estimating equations 
2. Site-level covariates include: facility type (primary, secondary, tertiary), location (urban, semi-urban, rural), and the cumulative number of patients seen in care at a given clinic 





Figure1a. Comparison of the association between adh erence sup
Crude analysis (no adjustment for covariates) 
  
 







Figure1b. Comparison of the association between adh erence support and outreach services and 
Site-level adjusted analysis (no adjustment for pat ient- level covariates)
  
 








Figure1c. Comparison of the association between adh erence support and outreach services and
Site-level adjusted analysis (adjustment for site- and  patient
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Notes: 
The red circles correspond to the Rate Ratio of mortality 1 year after ART initiation, with 95% Confidence Intervals presented as the 
range 
Baseline analysis: no adjustment for mortality among patients loss to follow-up modeled 
Sensitivity #1: Multiple imputation assigning probability of mortality among patients lost to follow-up as equal to the probability of 
mortality among patients not lost to follow-up within strata of last CD4 count. 
 
Sensitivity #2: Multiple imputation assigning probability of mortality among patients lost to follow-up as equal to the probability of 
mortality among patients not lost to follow-up within strata of last CD4 count, WHO stage at enrollment, sex, age, and Tuberculosis 
status. 
 
Sensitivity #3: Multiple imputation assigning probability of mortality among patients lost to follow-up as equal to the probability of 
mortality among patients not lost to follow-up within strata of country, facility type (primary, secondary, tertiary), facility location (urban, 
semi-urban, rural) 
 
Sensitivity #4: Inverse-probability weighted estimate of the Hazard ratio of mortality under conditions in which nobody is lost to follow-
up.  Probability of exposure weights estimated within strata of site- and patient-level potential confounding  variables, and probability of 
not being lost to follow-up weights estimated using same set of covariates.   
 
Sensitivity #5: Multiple imputation assigning probability of mortality among patients lost to follow-up according to estimates obtained 









As the scale-up of antiretroviral therapy in sub-Saharan Africa reaches maturity, 
program evaluation research is shifting from identifying means of scaling up services as 
rapidly as possible to investigating the outcomes of patients receiving these services.  
This dissertation was motivated by a simple question: do programmatic services 
intended to improve patient adherence to ART medication and long-term retention in 
care improve survival and retention in care? However, due to the vastness and 
heterogeneity of HIV service scale-up in the region, and limitations in the type and 
quality of information collected in this setting, a methodologic question became central 
to evaluating this simple programmatic one.  Namely, if programmatic services are 
influencing patient survival and retention in care, will routinely-collected data be able to 
reliably identify this association? 
Specification of causal hypothesis 
The initial motivation for this work came from a series of papers demonstrating levels of 
adherence to antiretroviral therapy in resource-limited settings similar to, or greater 
than, those observed in research-rich settings among patients successfully retained in 
care [1-13], with heterogeneous but generally high rates of loss to follow-up among ART 
patients in resource-limited settings [14, 15].   A review of the literature on adherence to 
ART and retention in care in resource-limited settings, included in the proposal for this 
dissertation (available on request), focused on individual-level, program-level, and 
146 
 
Dissertation: Discussion   
 
structural determinants of non-adherence to ART, non-retention after ART initiation, and 
survival.  From this review the following conclusions were drawn: 
1. Barriers to ART adherence include individual-level, facility-level, and structural 
factors 
a. Qualitative studies in resource-rich and resource-poor settings have 
identified forgetfulness, change in life circumstances/routine, and lack of 
belief in drug effectiveness as reasons for non-adherence [12, 16-21] 
b. In addition to those factors listed above, studies in resource-limited 
settings have identified more facility-level and structural barriers to 
adherence, including waiting time, transportation or other opportunity 
costs, fear of hunger without sufficient food supply, and stigma [12, 20] 
c. Very few studies in resource-limited settings have investigated whether 
services designed to improve adherence are actually doing so.  The 
studies that have found that adherence counseling and support services 
improve adherence [22, 23] 
2. Barriers to long-term retention in care among ART patients 
a. Low CD4 count at ART initiation was associated with increased probability 
of early loss to follow-up after ART initiation in a large multi-center study 
[14], suggesting that loss to follow-up is in part comprised of 
unascertained deaths. 
b. Facilities actively tracking patients missing scheduled visits had lower 
rates of loss to follow-up than facilities not actively tracking patients in a 
study from the same multi-center consortium [24]. 
c. There has been almost no published research evaluating the impact of 
program-level services on patient retention in care in resource-limited 
settings 
3. The relationship between loss to follow-up and mortality 
a. An early study investigating the vital status of patients lost to follow-up, 
discussed in the proposal to this dissertation found a high proportion of 
patients lost were unascertained deaths [25].  Papers published since I 
wrote the proposal have reached similar conclusions [26-33]. 
b. Loss to follow-up complicates our ability to assess program-level factors 
associated with patient survival because  a substantial proportion of 
patients loss to follow-up are unascertained deaths, leading to the finding 
that facilities with less loss to follow-up will have higher ascertained deaths 
even if the “true” amount of death is the same.  
4. Research is needed evaluating facility-level fac tors influencing patient 
retention in care and survival, especially in resou rce-limited settings. 
147 
 
Dissertation: Discussion   
 
The literature review conducted for my dissertation proposal was then used to create a 
causal theory hypothesizing what facility-level factors may influence patient retention 
and survival, the relationship between ascertained death, actual (ascertained plus 
unascertained) death, and loss to follow-up, and what other predictors of retention in 
care and survival, at both the facility-level and the patient-level, may bias associations 
between facility-level services and non-retention, loss to follow-up, and death.  Figure 1 
presents this causal theory in the form of a Directed Acyclic Graph (DAG) [34]. 
Key to understanding the complexity involved in identifying factors associated with 
patient survival is the relationship between non-retention, loss to follow-up, and 
ascertained death.  In Figure 1, non-retention is defined as patients not returning to 
clinic for a regular appointment without a known transfer to another clinic.  There are 
two reasons why a patient would not return to clinic.  Either they died between their last 
attended visit and their next scheduled visit (represented by the line from NRD) or 
they were lost to follow-up (represented by the line from NRLTF), defined in this DAG 
as missing scheduled appointments and not known to have died or transferred.  
However, not all patients who died are ascertained as dead by the facility.  This creates 
the situation where some deaths are ascertained (the line DD*), while others become 
lost to follow-up (D  LTF).  A further complication is that loss to follow-up reduces the 
proportion of “true” deaths (D) that are ascertained by the facility to have died (D*), 
because loss to follow-up causes reduced death ascertainment (LTFD*). 
Adherence support services are hypothesized to improve patient survival (Eadherence 
NRD) by improving adherence to ART medication.  In addition, adherence support 
services are hypothesized to reduce loss to follow-up through incentivizing return visits 
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(e.g., offering food support), education on the importance of long-term adherence, and 
reducing stigma through peer support groups and counseling (EadherenceNRLTF).  
Active patient outreach is hypothesized reduce non-retention by identifying patients 
missing scheduled visits and returning them to care, which in turn is hypothesized to 
improve patient survival. 
Variables G and A represent covariates at the facility-level (G) and patient-level (A) that 
are hypothesized to be causes of patient non-retention, loss to follow-up, and death that 
are also associated with our exposures of interest.  In the facility-level analyses 
conducted in Papers 1 and 2, we do not have information at the patient-level do adjust 
for the potential impact of patient-level causes of non-retention, loss to follow-up and 
death.  The patient-level analysis conducted in Paper 2 can adjust for patient-level 
differences, but the hypothesized relationship between G and U complicates control of 
both patient-level and facility-level predictors of non-retention.  Specifically, we 
hypothesize that a set of facility-level services and characteristics (such as program 
size, overall comprehensiveness of care, location, etc.) influence non-retention 
independently of their adherence support and outreach service availability.  We also 
hypothesize that patient-level characteristics, such as baseline immunologic and 
demographic measures, influence non-retention.   
Papers 1 and 2 focus on assessing whether adherence support and outreach services, 
independently and/or synergistically, influence patient non-retention, loss to follow-up, 
or ascertained death as hypothesized in Figure 1.  Paper 3 conducts a sensitivity 
analysis by estimating the strength of the causal relationship between actual death and 
loss to follow-up under a range of plausible scenarios. 
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Figure 1.  Causal Diagram of the relationship betwe en adherence support service 





Eoutreach = availability of an active outreach program to track ART patients missing 
scheduled visits and return them to care or ascertain outcome status (dead, transferred 
to another facility) 
Eadherence = availability of one of the tested facility-level services designed to improve 
patient adherence to ART.  For simplicity of the DAG, only one generic example service 
is given 
NR = patient non-retention in care, defined in this DAG as patients missing a clinic visit. 
LTF = patient loss to follow-up.  One component of non-retention, defined as patients 
without a clinic visit in 6 months who are not known to have died or transferred to 
another facility. 
D = Patient death.  This is comprised of patients known to have died, and those who 
have died but whose death is unascertained. 
D* = ascertained death.  This is a patient’s vital status as documented by a given clinic. 
G = a set of program-level variables associated with both the exposures and outcomes 
of interest (e.g., clinic size, location, availability of other program services) 
U = a set of patient-level variables associated with the outcomes of interest that are also 
associated (through G) with the program-level exposures of interest. 
A = a proxy measure for the set of patient-level variables (e.g., CD4 count and WHO 
stage at ART initiation, age, sex, tuberculosis status) based on information that is 
available in the data source. 
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Methodological questions: can imperfect data be use d to test this hypothesis?  
Once the causal model was specified, I undertook to identify what sources of data were 
available to test this model.  Since the primary research questions underlying this 
dissertation are questions of effectiveness (do program-level services improve patient 
retention in service delivery settings in sub-Saharan Africa), as opposed to questions of 
efficacy, I believe it is important to test these questions in “real world” settings.  Further, 
since the exposures of interest occur at the facility-level, it was necessary to ensure 
inclusion of sufficient numbers of facilities, with sufficient heterogeneity in program 
services availability, in order to be able to test these hypotheses in a statistically 
meaningful manner.  This lead to the prioritization of data sources from HIV care and 
treatment clinics, as opposed to data sources from trials or other research settings.  
This allowed the investigation of the association between facility-level services and non-
retention, loss to follow-up, and death in a very large and diverse population.  However, 
the information available from this large population is limited in the amount of 
information collected and often available only in aggregate.   
To best utilize available data while identifying how different measures of similar 
constructs may influence inference about the relationship between program-level 
service availability and non-retention, loss to follow-up, and death, three different 
measures of these outcomes were estimated and compared against one another.  Each 
estimation has strengths and weaknesses, and Paper 2 discusses these at some 
length.  Briefly, overall rates of non-retention, loss to follow-up, and ascertained death 
can be derived from aggregate data sources that are routinely available from care and 
treatment facilities in sub-Saharan Africa.  These estimates are approximately 
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equivalent to rates calculated from patient-level data sources under a “rolling entry” 
scenario where patients are allowed entry into the study population during the duration 
of the observation period, and all patients are censored at the end of the observation 
period (see Appendix 3).  The strength of this measure is its ubiquity, while it suffers 
from an inability to assess rates of non-retention, loss to follow-up, or death through a 
given time interval after ART initiation.  In addition, the proportion of patients initiating 
ART in a given reporting quarter who are retained and on ART for 6 and 12 months 
after ART initiation is routinely available from care and treatment clinics in sub-Saharan 
Africa, but suffers from an inability to segment non-retention into loss to follow-up and 
ascertained death.  Finally, patient-level data provides the most versatile source for rate 
estimations, since it can estimate both cumulative rates and endpoint-specific rates 
(such as the rate through 1 year after ART initiation), but suffers from lack of 
generalizability because most care and treatment facilities do not have electronic 
patient-level databases, and those that do may be materially different from those that do 
not.   
This dissertation compares associations between facility-level services and these 
different measures of non-retention, loss to follow-up, and death, in order to assess 
which services are associated under all measures of the outcome, and to investigate 
potential reasons for different inference drawn from use of different outcome measures. 
Key Findings 
The first paper in this dissertation presents an ecologic analysis of over 232,000 
patients at 349 HIV care and treatment facilities in10 countries initiating ART between 
January 2004 and December 2008 using two ecologic measures of the outcome of 
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interest: (1) overall non-retention, loss to follow-up and death rates and (2) 6- and 12- 
month non-retention proportions among cohorts of patients initiating ART within the 
same reporting quarter.  In this analysis, after adjustment for program-level covariates, 
facilities offering three or more adherence support services, written educational 
materials promoting ART adherence, one-on-one or group adherence counseling 
sessions, reminder tools, and food rations to promote ART adherence were associated 
with reduced non-retention and loss to follow-up, while facilities offering on-site support 
groups for HIV+ patients, peer educators, provision of reminder tools, and food rations 
to promote ART adherence were associated with reduced death rates.  In sub-analyses 
investigating six- and 12-month retention after ART initiation, facilities offering three or 
more separate adherence support services, routine review of medication pickup and/or 
dedicated ART pharmacists, and active patient outreach to trace patients missing visits 
had lower non-retention.  Taken together, this analysis provides evidence that program-
level services found efficacious in experimental settings are also effective in operational 
settings. 
The second paper refines the non-retention, loss to follow-up, and death rate estimates 
by (1) comparing estimates obtained from aggregate vs. patient-level databases and (3) 
additionally allowing for adjustment for patient-level predictors of loss to follow-up and 
death.  This analysis focuses on a subset of 92 HIV care and treatment facilities in 5 
countries that also have electronic patient-level databases, containing 92,561 ART 
patients.  A key finding, examined in more detail in Appendix 3, is that estimates of 
death rates were similar in the aggregate and patient-level analyses, while loss to 
follow-up rates were higher in analyses using the patient level database.  In multivariate 
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analyses, clinics offering active patient outreach had lower rates of non-retention in both 
the ART cohort analysis and the patient-level analysis, and clinics offering food rations 
to promote ART adherence were associated with a lower risk of ascertained death in 
both the facility-level and patient-level analyses, but this association was diminished 
after adjustment for patient-level covariates.  In contrast, various adherence counseling 
or support services were associated with lower non-retention in the ART cohort 
analyses but not in the patient-level data analyses. 
Comparing the results of the similar analyses conducted in Paper 1 and Paper 2 (as 
discussed in the conclusion to Paper 2) highlights a common epidemiologic problem: 
limitations to generalizability.  Namely, the study population investigated in Paper 2 is a 
subset of the population investigated in Paper 1, but the associations between various 
program-level services and non-retention, loss to follow-up, and death rates differ 
between the two populations in many cases even when using the same statistical 
models (see Figures 3a-3c in Paper 2).  If facilities having electronic patient-level 
databases were a true random sample of all of the facilities comprising the study 
population for the Paper 1 analysis, we would expect similar-magnitude associations 
between facility-level services and rates of non-retention, loss to follow-up, and death 
across the two studies. 
Tables D1a-D1c of this discussion compare the percentage difference in estimates of 
the rate ratios for non-retention, loss to follow-up, and death obtained in adjusted 
analyses in Papers 1 and 2.  Of the facility-level services tested, only three (the 
availability of 2 vs. 1 separate directed counseling services, on-site support groups for 
HIV+ patients, and food support to promote ART adherence) had similar-magnitude 
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associations across both study populations, while other facility-level associations were 
substantially divergent.  The findings of similar-magnitude associations in these two 
overlapping populations for these facility-level services increases our confidence that 
these associations are plausibly causal because it reduces the likelihood that 
uncontrolled confounding is responsible for the results.  For example, it may be 
plausible to hypothesize that the association between food support and reduced non-
retention is really due to the fact that facilities that offer more comprehensive services 
are more likely both to offer food support and to have less non-retention.  In order for 
this hypothesis to explain the results from Paper 1 and Paper 2, the effect of 
comprehensiveness of services on non-retention and the availability of food support 
would have to be similar among the overall population analyzed in Paper 1 as in the 
sub-population of clinics in 5 countries with electronic patient-level databases analyzed 
in Paper 2.  However, if this were the case, we would also expect the associations 
between other facility-level services and non-retention, loss to follow-up, and death 
rates to be similar between the two populations if we assume that comprehensive clinics 
are also more likely to offer these other services.  Since we have found similar 
associations in the two analyses for specific facility-level services but not others, the 
“comprehensiveness of care” hypothesis introduced above would have to be further 
specified to suggest that “comprehensive” facilities are those that offer food support, 
more than one directed counseling service, and on-site support groups for HIV+ 
patients, regardless of whether they offer other services. 
The findings of associations between several adherence support and outreach services 
and rates of non-retention, loss to follow-up, and death in the overall population in 
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Paper1 but not in the population in Paper 2 is consistent with the theory that these 
services influence patient outcomes in specified, but unknown, circumstances that do 
not exist at the clinics in which patient-level databases exist.  More thorough 
examination of specific characteristics of the facilities with and without electronic 
databases, in order to better understand the reasons for these discrepant findings, is a 
potentially fruitful next step to this research. 
Another finding from the analyses presented in Paper 2 is that adjustment for patient-
level predictors of non-retention, loss to follow-up, and death diminishes the observed 
associations between facility-level services and non-retention, loss to follow-up, and 
death rates.  Whether adjustment for patient-level covariates is appropriate depends on 
whether these factors are potentially influenced by exposure to the facility-level 
characteristics under consideration.  For example, facilities that offer on-site support 
groups for HIV+ patients are likely to offer these groups for patients both in pre-ART 
care and after ART initiation.  If these services improve patient retention in the pre-ART 
phase, a potential consequence would be initiating patients on ART earlier in disease 
progression.  Since the patient-level covariates were based on measures taken at ART 
initiation, it is possible that these measures could be influenced by exposure to on-site 
support groups for HIV+ patients during their pre-ART phase, such that adjusting for 
their ART initiation CD4 measure is in fact adjusting for a consequence of exposure, 
leading to a bias of effect estimates toward the null.  Because we do not have complete 
information on the timing of exposure compared to the timing of the measures used as 
“baseline” measures for all patient-level covariates (excepting age and sex), it is 
conceptually difficult to disentangle the potential confounding and mediating impact of 
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certain patient-level measures.  It is for this reason that both are presented in Paper 2, 
to allow the reader to reach her own conclusions about the appropriateness of 
adjustment. 
Finally, Paper 3 attempts to investigate the problem of loss to follow-up in limiting our 
ability to infer influences on patient survival.  Loss to follow-up is a mixture of patients 
who have transferred to other clinics but whose transfer is not known to their initiating 
clinic, patients who have died but whose death is not known to their clinic, and patients 
who have withdrawn from care.  Loss to follow-up results in underestimates of death 
incidence because we are missing vital status on those patients who are lost, and 
because some proportion of them are unascertained death.  In analyses investigating 
whether facility-level services improve patient survival, loss to follow-up is additionally 
problematic because services that reduce loss to follow-up are likely to improve death 
ascertainment, such that even if these services do nothing to change the actual death 
rate, they will increase the ascertained death rate. 
Traditional methods of accounting for loss to follow-up treat these patients as 
“censored” observations, allowing them to contribute person-time to rate denominators 
up until the time of their loss.  Implicit in these methods is the assumption that the 
reasons for loss to follow-up are non-informative with respect to death likelihood, 
meaning that, conditioned on covariates, patients who are lost are assumed to have the 
same likelihood of death as those not lost. 
The key finding from this sensitivity analysis is that different assumptions concerning the 
death probability among patients loss to follow-up impact our estimations of the impact 
of program-level services on patient survival.  Adherence support and outreach 
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services, strongly associated with loss to follow-up, also became associated with 
mortality after imputing the likely death probability among patients lost to follow-up. 
Findings were robust under a variety of assumptions, suggesting that loss to follow-up is 
masking real associations between adherence support and active outreach programs 
and reduced death. 
Limitations in using facility-level measures of adh erence support and outreach 
service availability  
This dissertation has focused on investigating whether the existence of specific facility-
level services targeting adherence and retention, as measured by a standardized site 
assessment tool, influence measures of non-retention, loss to follow-up, and death.  It is 
important to recognize the limitations inherent in assigning exposures in this manner.  
First, facilities are dichotomized according to whether or not they reported the 
availability of a given service.  No information is available that would allow further 
categorization based on the overall quality of the service being offered or the number or 
proportion of patients utilizing the service.  While our choice to dichotomize exposure 
was governed in part by data limitations, it is analogous to the “intention to treat” 
principle common in randomized clinical trials: every patient who attended a given 
facility was assumed to be exposed to the facility-level service reported, regardless of 
whether or not they partook in this service.  On the patient-level, this creates 
misclassification of “true” exposure for patients who attended a facility offering a service 
that they did not participate in in the same sense that an intent-to-treat analysis creates 
misclassification of “true” exposure for patients assigned to an active treatment who did 
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not comply, but does not impact our interpretation of the facility-level effect of having a 
service available on patient outcomes. 
Second, the fact that exposures were classified through questionnaire by in-country 
staff leaves open the possibility of misclassification.  For example, the facility-level 
characteristic most consistently associated with reduced non-retention, loss to follow-
up, and ascertained death in this dissertation was based on results to the following 
question: 
 
Facilities responding to option # 1 or #3 were considered to provide food support to 
promote ART adherence, while those responding to any other option, were considered 
not to have such a service.  It is possible that some facilities responded to options #1 or 
#3 when the food support service they offered was not specifically designed for ART 
adherence, but unlikely that a facility would report offering this type of service when it 
did not offer any food support service.  This highlights the fact that the measures we are 
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using of facility-level services should be interpreted broadly, but does not diminish the 
associations observed. 
Implications and future research 
This dissertation is among the first to assess the potential influence of program-level 
services on patient retention in care and survival in resource-limited settings.  Taken 
together, it provides evidence that program-level services can impact non-retention, loss 
to follow-up and death rates in this context.  Keeping in mind the limitations of routinely-
collected observational data, it provides evidence that this data can be used, with 
appropriate caution, to inform program evaluation.  This will add to the small but 
accumulating body of literature in both resource-rich and resource-poor settings 
suggesting that adherence support and outreach services improve patient retention and 
survival [24, 35]. 
Future research can build on this dissertation by addressing some of its limitations.  
First, more complete sources of information on facility- and patient-level predictors of 
loss to follow-up and death are needed to reduce the likelihood that observed 
associations are due to unmeasured confounding.  Second, the influence of loss to 
follow-up on measures of survival would be much better understood with more studies 
sampling patients lost to follow-up to ascertain reasons for their loss as well as vital 
status.  Finally, more specific measures of the quality of services offered would allow us 
to better quantify exactly what aspects of adherence support and outreach services 
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Table D1a.  Comparison between Paper 1 and Paper2: Covariate-adjusted estimates of the overall non-ret ention rate ratio 
    Paper 1 (N = 349 clinics)   Paper 2 (N = 92 clinics)   
% difference 
in Rate Ratio 
  
Adherence Support Service   
N 
yes/no RR 95% CI 
N 
yes/no RR 95% CI   
Total number of adherence support 
services offered >2 vs. < 2 292/57 0.59 (0.35-1.0)  81/11 1.05 (0.5-2.2)  78%   
Availability of educational pamphlets, etc yes vs. no 199/150 0.73 (0.63-0.85) 
 




Number of separate directed counseling 
services available 
2 vs. 1 97/115 0.91 (0.72-1.14)  24/22 0.86 (0.53-1.38)  5%   
3 vs. 1 113/115 0.98 (0.82-1.18) 
 




one-on-one or group adherence 
counseling services yes vs. no 308/41 0.62 (0.42-0.92)  87/5 1.04 (0.49-2.22)  68%   
Frequency of counseling services among 
sites providing them 
> every 3 months vs. 
< every 3 months 
276/32 1.14 (0.88-1.49) 
 




on-site support group for HIV+ patients 
all patients  vs ART 
patients only 190/159 1.03 (0.87-1.22)  56/36 1 (0.7-1.43)  3%   
peer educator program yes vs. no 150/199 0.99 (0.86-1.14) 
 




Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) yes vs. no 245/104 0.79 (0.64-0.97)  70/22 1.29 (0.9-1.85)  63%   
Dedicated pharmacist, team pharmacist, 
or routine  medication pickup review 
yes vs. no 278/71 0.71 (0.48-1.05) 
 




Food rations provided to promote ART 
adherence yes vs. no 60/289 0.72 (0.58-0.9)  27/65 0.67 (0.44-1.03)  7%   
Outreach Services              
Active patient outreach yes vs. no 185/164 1.00 (0.85-1.18) 
 




Target population among sites w/ active 
outreach 
all patients  vs ART 









Table D1b.  Comparison between Paper 1 and Paper2: Covariate-adjusted estimates of the overall loss to  follow-up rate ratio 





Adherence Support Service   
N 
yes/no RR 95% CI 
N 
yes/no RR 95% CI  
Total number of adherence support 
services offered >2 vs. < 2 292/57 0.48 (0.25-0.92)  81/11 0.76 (0.32-1.81)  58%  
Availability of educational pamphlets, etc yes vs. no 199/150 0.63 (0.52-0.77)  61/31 0.83 (0.56-1.24)  32%  
Number of separate directed counseling 
services available 
2 vs. 1 97/115 1.01 (0.74-1.38)  24/22 1.07 (0.55-2.08)  6%  
3 vs. 1 113/115 1.16 (0.9-1.49) 
 




one-on-one or group adherence 
counseling services yes vs. no 308/41 0.55 (0.33-0.89)  87/5 0.72 (0.3-1.73)  31%  
Frequency of counseling services among 
sites providing them 
> every 3 months vs. 
< every 3 months 
276/32 1.20 (0.84-1.7) 
 




on-site support group for HIV+ patients yes vs. no 190/159 1.20 (0.95-1.52)  56/36 1.12 (0.69-1.82)  7%  
peer educator program yes vs. no 150/199 1.08 (0.89-1.32)  50/42 0.75 (0.53-1.07)  31%  
Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) 
yes vs. no 245/104 0.77 (0.58-1.02) 
 




Dedicated pharmacist, team pharmacist, 
or routine  medication pickup review yes vs. no 278/71 0.60 (0.36-1)  78/14 0.71 (0.32-1.55)  18%  
Food rations provided to promote ART 
adherence 
yes vs. no 60/289 0.65 (0.47-0.88) 
 




Outreach Services             
Active patient outreach yes vs. no 185/164 1.05 (0.84-1.32)  61/31 1.5 (0.84-2.67)  43%  
Target population among sites w/ active 
outreach 
all patients  vs ART 
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Table D1c.  Comparison between Paper 1 and Paper2: Covariate-adjusted estimates of the overall ascerta ined death rate ratio 
    Paper 1 (N = 349 clinics)   Paper 2 (N = 92 clinics)   
% difference 
in Rate Ratio 
 
Adherence Support Service   
N 
yes/no RR 95% CI 
N 
yes/no RR 95% CI  
Total number of adherence support 
services offered >2 vs. < 2 292/57 0.94 (0.55-1.61)  81/11 4.16 (1.32-13.1)  343%  
Availability of educational pamphlets, etc yes vs. no 199/150 0.98 (0.85-1.13) 
 




Number of separate directed counseling 
services available 
2 vs. 1 97/115 0.77 (0.63-0.93)  24/22 0.55 (0.39-0.77)  29%  
3 vs. 1 113/115 0.75 (0.64-0.87)  41/22 0.64 (0.49-0.85)  15%  
one-on-one or group adherence 
counseling services 
yes vs. no 308/41 0.82 (0.55-1.21) 
 




Frequency of counseling services among 
sites providing them 
> every 3 months vs. 
< every 3 months 276/32 1.05 (0.82-1.33)  77/10 1.56 (1.14-2.12)  49%  
on-site support group for HIV+ patients yes vs. no 190/159 0.81 (0.7-0.93)  56/36 0.79 (0.6-1.04)  2%  
peer educator program yes vs. no 150/199 0.84 (0.74-0.96) 
 




Availability of reminder tools (e.g., clocks, 
calendars, pill boxes) yes vs. no 245/104 0.81 (0.66-0.98)  70/22 1.27 (0.93-1.74)  57%  
Dedicated pharmacist, team pharmacist, 
or routine  medication pickup review 
yes vs. no 278/71 0.95 (0.66-1.37) 
 




Food rations provided to promote ART 
adherence yes vs. no 60/289 0.83 (0.69-1)  27/65 0.76 (0.55-1.04)  8%  
Outreach Services             
Active patient outreach yes vs. no 185/164 0.91 (0.79-1.06) 
 




Target population among sites w/ active 
outreach 
all patients  vs ART 
patients only 136/45 0.86 (0.7-1.06)   47/14 1.08 (0.78-1.47)   26%  
Rate ratios presented are for facility-level analys es adjusting for facility type (primary, secondary, tertiary), location (urban, semi-urban, rural), and the cumulative number of 
patients seen in care at a given clinic 
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Appendix 1.1: Program-level factors associated with  retention in care and 
receiving ART for 6 out of 6, or 12 out of 12 month s 
 
Introduction:  
To test whether adherence support services improve patient retention in part by 
improving adherence to ART medication, a secondary analysis used the proportion of 
patients receiving ART medication for 6 out of 6, or 12 out of 12 months, as the 
outcome of interest.  This outcome combines retention and ART adherence.  Analyses 
follow the same structure outlined for the 6 and 12 month ART cohorts in Paper 1.  





Table A1.1.  Association between adherence support and outreach services and the proportion of patient s 
retained and receiving ART for 6 or 12 months 
Non-adherence* Risk Ratio through 6 
months 1 
 Non-adherence* Risk Ratio through 
12 months 2 
    
    N (yes/no) Crude   RR (95% CI) 
Adjusted3 RR 
(95% CI) 




Adherence support services 
  
 
Total number of adherence 
support services provided 
> 2 vs < 2 1016/81 0.83 (0.64-1.07) 0.81 (0.69-0.95)  0.88 (0.66-1.17) 0.87 (0.66-1.15) 
Availability of educational 
pamphlets, etc 
yes vs. no 773/315 0.89 (0.74-1.07) 0.87 (0.74-1.02)  0.93 (0.8-1.08) 0.93 (0.8-1.08) 
Availability of directed 
Counseling or support 
yes vs. no 935/162 1.04 (0.8-1.36) 1.07 (0.86-1.32)  1.1 (0.81-1.51) 1.10 (0.85-1.41) 
Number of directed counseling or 
support services 
2 vs 1 311/327 0.95 (0.73-1.23) 1.04 (0.85-1.26)  0.96 (0.78-1.19) 1.00 (0.84-1.18) 
3 vs 1 297/327 1.07 (0.81-1.42) 1.06 (0.87-1.28)  1.13 (0.9-1.43) 1.09 (0.91-1.3) 
one-on-one or group adherence 
counseling services 
yes vs. no 685/403 1.2 (1.06-1.36) 1.10 (0.98-1.24)  1.36 (1.19-1.54) 1.25 (1.1-1.42) 
Frequency of counseling services 
among sites providing them 
> every 3 months vs 
< every 3 months 
612/73 1.38 (0.77-2.47) 1.07 (0.68-1.7)  1.06 (0.68-1.65) 0.90 (0.63-1.28) 
on-site support group for HIV+ 
patients 
yes vs. no 679/409 0.95 (0.76-1.2) 1.01 (0.84-1.22)  0.94 (0.75-1.16) 0.95 (0.8-1.13) 
peer educator program yes vs. no 476/612 1.01 (0.81-1.26) 1.03 (0.88-1.22)  1.05 (0.86-1.28) 1.04 (0.89-1.21) 
Availability of reminder tools 
(e.g., clocks, calendars, pill 
boxes) 
yes vs. no 978/110 1.23 (0.78-1.94) 1.15 (0.78-1.7)  1.2 (0.88-1.63) 1.14 (0.87-1.5) 
Routine  medication pickup 
review, dedicated or team 
pharmacist 
yes vs. no 1027/61 0.83 (0.62-1.1) 0.80 (0.68-0.94)  0.85 (0.59-1.2) 0.80 (0.59-1.08) 
Food rations provided to adults 
or children 
yes vs. no 178/919 0.85 (0.65-1.11) 0.81 (0.64-1.02)  0.95 (0.76-1.19) 0.93 (0.76-1.13) 
Outreach Services             
Active patient outreach yes vs. no 725/363 0.84 (0.73-0.97) 0.91 (0.79-1.05)  0.83 (0.71-0.96) 0.89 (0.76-1.03) 
Target population among sites w/ 
active outreach 
All patients vs. ART 
only 
525/178 1.31 (0.97-1.76) 1.18 (0.91-1.53)   1.14 (0.89-1.46) 1.03 (0.82-1.31) 
* Non-Adherence defined as either not being retained in care or not receiving medication for all months 
1,2.  Cohort non-adherence to care and ART estimates as the proportion of patients receiving ART for 6 out of 6 (or 12 out of 12 months) among those initiating ART in a given 3-month cohort 
3.  Adjusted for facility type (primary, secondary, or tertiary), urban/rural, cohort start year, and cumulative number of patients seen in care  




Appendix 1.2: Results of additive-scale interaction  analysis (Paper 1) 
Introduction:  
This appendix presents the numeric results that are displayed in Figures 2a-2c of Paper 
1, and that test for additive-scale interaction between active outreach and adherence 





Table A1.2a.  Results of additive-scale interaction  analyses: Overall Non-retention, loss to follow-up , and death rate ratios  
  Adherence only Outreach only 






Ratio LCL UCL 
Rate 
Ratio LCL UCL 
Rate 
Ratio LCL UCL ICR LCL UCL 
Non-retention 
three or more vs. fewer adherence 
services 0.56 0.33 0.97 0.52 0.04 6.34 0.58 0.34 0.99 0.49 -0.81 1.80 
educational materials provision 0.83 0.62 1.11 1.10 0.85 1.44 0.77 0.60 1.00 
-
0.16 -0.50 0.18 
one-on-one/group adherence 
counseling 0.55 0.36 0.83 0.37 0.07 1.91 0.58 0.39 0.86 0.67 0.06 1.28 
reminder tool provision 0.64 0.40 1.02 0.79 0.48 1.29 0.65 0.42 1.02 0.23 -0.17 0.63 
dedicated pharmacist or routine 
review of medication pickup 0.70 0.42 1.17 0.99 0.46 2.12 0.71 0.43 1.18 0.02 -0.74 0.78 
food rations to promote adherence 0.66 0.32 1.38 1.04 0.88 1.24 0.75 0.58 0.97 0.05 -0.49 0.58 
Loss to follow-up 
three or more vs. fewer adherence 
services 0.44 0.22 0.86 0.46 0.02 13.84 0.48 0.24 0.94 0.58 -1.00 2.15 
educational materials provision 0.72 0.49 1.06 1.16 0.83 1.63 0.70 0.50 0.98 
-
0.18 -0.62 0.26 
one-on-one/group adherence 
counseling 0.43 0.26 0.73 0.13 0.005 3.69 0.50 0.31 0.82 0.94 0.49 1.38 
reminder tool provision 0.60 0.31 1.14 0.79 0.40 1.56 0.64 0.35 1.20 0.26 -0.27 0.79 
dedicated pharmacist or routine 
review of medication pickup 0.63 0.32 1.24 1.25 0.47 3.33 0.68 0.35 1.32 
-
0.21 -1.42 1.00 
food rations to promote adherence 0.46 0.15 1.40 1.09 0.87 1.37 0.71 0.50 1.02 0.16 -0.43 0.75 
Ascertained 
death 
more than 1 vs 1 directed 
counseling or support service 0.93 0.72 1.20 1.48 1.13 1.94 0.84 0.70 1.00 
-
0.58 -1.02 -0.13 
one-on-one/group adherence 
counseling 0.88 0.57 1.36 1.10 0.368 3.30 0.81 0.53 1.24 
-
0.17 -1.40 1.05 
support groups for HIV+ patients 0.94 0.73 1.22 1.21 0.95 1.56 0.86 0.72 1.02 
-
0.30 -0.67 0.08 
peer educators 1.00 0.72 1.38 1.08 0.89 1.31 0.86 0.73 1.01 
-
0.22 -0.59 0.16 
reminder tool provision 0.72 0.48 1.06 0.80 0.52 1.22 0.66 0.45 0.97 0.15 -0.22 0.52 
food rations to promote adherence 1.19 0.67 2.10 0.97 0.83 1.13 0.79 0.64 0.98 
-





Table A1.2b.  Results of additive-scale interaction  analyses: 6 and 12 month non-retention risk ratios  
ART cohort 
analysis  Adherence only Outreach only 






Ratio LCL UCL 
Risk 
Ratio LCL UCL 
Risk 
Ratio LCL UCL ICR LCL UCL 
Non-retention 
through 6 months 
three or more vs. fewer adherence 
services 0.91 0.77 1.08 0.96 0.72 1.28 0.78 0.65 0.94 -0.09 -0.49 0.30 
support groups for HIV+ patients 0.73 0.55 0.96 0.62 0.49 0.78 0.78 0.64 0.95 0.43 0.28 0.58 
dedicated pharmacist or routine 




three or more vs. fewer adherence 
services 0.87 0.73 1.04 0.76 0.53 1.09 0.74 0.61 0.89 0.11 -0.18 0.39 
support groups for HIV+ patients 0.79 0.63 0.99 0.68 0.55 0.84 0.78 0.66 0.91 0.30 0.17 0.44 
dedicated pharmacist or routine 
review of medication pickup 1.01 0.76 1.34 1.10 0.75 1.60 0.84 0.63 1.12 -0.27 -0.70 0.17 
1.  Overall non-retention rates estimated as the cumulative number of patients at a site lost to follow-up, withdrawn, or reported dead, over the total 
person-years observed on ART at that site 
2.  Overall loss to follow-up rates estimated as the cumulative number of patients not returning to clinic for > 6 months since last visit, with no known 
status, over the total person-years observed on ART at that site 
3.  Overall death rates estimated as the cumulative number of patients reported dead, over the total person-years observed on ART at that site 
4. Overall analyses adjusted  for facility type (primary, secondary, or tertiary), urban/rural, year facility began providing ART care, and cumulative 
number of patients seen in care  
5.  Cohort non-retention % estimated as 100 - (number of patients on ART through 6 months/number starting cohort at baseline) 
6.  Cohort non-retention % estimated as 100 - (number of patients on ART through 12 months/number starting cohort at baseline) 




Appendix 2.1: Comparing competing risk and censorin g methodologies with loss 
to follow-up as the outcome of interest. 
 
Introduction:   
Recent analyses investigating the incidence of loss to follow-up have treated death as a 
competing risk (e.g., [1-4]), with authors suggesting that traditional time-to-event 
analyses, such as Kaplan-Meier and Proportional Hazards modeling, overestimate 
incidence of loss to follow-up in the presence of substantial death.  Kaplan-Meier and 
proportional hazards models censor patients who obtain an outcome that prevents 
ascertainment of the outcome of interest (e.g., loss to follow-up).  For example, when 
modeling death as an outcome of interest in a population where there is loss to follow-
up, Kaplan-Meier methods will allow a patient who is lost to follow-up to contribute 
person-time until they are lost, after which they are censored.  Kaplan-Meier methods 
can be used to estimate the cumulative incidence of death in the presence of loss to 
follow-up.  However, the implicit assumption in using this approach is that, conditioned 
on covariates, the incidence of death among patients lost to follow-up is the same as 
the incidence of death among patients not lost to follow-up (e.g., patients lost to follow-
up are missing at random). 
Estimating the incidence of loss to follow-up in the presence of death represents a 
different scenario, because patients known to have died by definition cannot be lost to 
follow-up.  Under this scenario, death is a competing risk for loss to follow-up because it 
precludes loss to follow-up from occurring.  Various investigators (e.g., [1-5]) have 
correctly pointed out that estimates of the cumulative incidence function using Kaplan-
Meier methods (or of using the hazard ratio from proportional hazards modeling as an 




in the presence of death as a competing risk because it assumes that patients who died 
have the same probability of loss to follow-up as those who have not died.  Fine and 
Gray [5] introduced a method of calculating proportional hazards in the presence of 
competing risk. 
This dissertation does not present proportional hazards models using the competing risk 
approach, instead calculating proportional hazards using Cox Proportional Hazards 
models.  The reasons for this have to do with the interpretation of the proportional 
hazards ratios obtained from the two methodologies.  Under the Cox Proportional 
Hazards model, incidence rates of loss to follow-up are estimated, allowing persons to 
contribute person-time until they either achieve the endpoint of interest, achieve a 
different endpoint (such as death or transfer) that precludes them from achieving the 
endpoint of interest, or until the end of the follow-up time.  If this measure is interpreted 
as a ratio of rates, rather than as an approximation of a ratio of cumulative incidence, 
then it is the appropriate measure to use.  Specifically, if our research question of 
interest is how quickly an average person in a cohort under investigation is followed 
before becoming lost to follow-up, then a rate-based measure appropriately measures 
this question.  On the other hand, if our research question of interest is in the risk of 
becoming lost to follow-up within a given time frame, rather than how quickly these 
events occur, then the competing risk measure gives a better approximation of this 
question. 
This dissertation is primarily interested in questions of rate, for several reasons.  First, in 
paper 2, where loss to follow-up is estimated using both aggregate and patient-level 




interpretable as an estimation of patient-level risk.  Thus, patient-level estimates of rate 
are the appropriate comparison measure.  Second, because the programmatic goal is to 
achieve life-long retention on ART, and because patients will ultimately either become 
lost to follow-up or die, the question of interest focuses on whether we can take steps to 
increase the amount of time it takes for this to happen.  This question is a question of 
rate. 
 
To examine whether treating death as a competing risk in patient-level analyses 
investigating the association between program-level factors and loss to follow-up, the 
analyses presented in Table 4b were performed treating death as a competing risk.  
These analyses were performed in R using the computational packages cmprsk 
developed by Fine and Gray.  The rate ratio estimations presented in Table 4b were 
virtually unchanged when assessing using a competing risk framework (average change 
in point estimate < 1%; data not shown).  The reason for this is because competing risk 
analysis differs from proportional hazards analysis based on (1) the prevalence of the 
competing risk and (2) the average amount of time a person who obtains the competing 
risk is followed.  If competing risks are of the same order of magnitude AND they 
disproportionately occur after very little follow-up time, estimates will diverge.  In our 
study, the amount of loss to follow-up is substantially higher than the amount of death, 
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Appendix 3: Further explanation of the aggregate no n-retention, loss to follow-up, 
and death rates. 
Papers 1 and 2 estimate facility-level non-retention, loss to follow-up, and death rates 
by calculating the cumulative number of events occurring at a given clinic, and dividing 
by the cumulative person-time observed at that clinic.  This appendix further examines 
this rate measure, and compares it to incidence rate estimates obtained with patient-
level data.  It shows that the overall rate estimates obtained from aggregate data are 
approximately equivalent to patient-level rate estimates under a “rolling entry” scenario, 
where patients are entered into the study population throughout the observation period, 
and followed until the end of the observation period, with no minimum follow-up time 
requirement.  The overall rate measure differs from endpoint-specific incidence rate 
estimates (e.g., death rate through one year after ART initiation) because it cannot 
estimate average follow-up duration on the patient-level.  The extent to which facility-
level and patient-level rate measures differ is a function of the distribution of new vs. 
existing patients in the population, the average time of follow-up until reaching an event, 
and the minimum follow-up time required for inclusion in the study population. 
 
Methods  
First, a sample population was created for heuristic purposes to explain the process of 
deriving aggregate estimates of person-time and rates of loss to follow-up and death 
from patient-level data (Table 1).  For this sample, the following assumptions were 
made: 
• All patients were enrolled in 2005 




• Patients who died were assumed to do so 90 days after ART initiation 
• Patients who were lost to follow-up were assumed to be lost 180 days 
after ART initiation 
• Patients who transferred were assumed to transfer 30 days after ART 
initiation 
From this patient-level study population, quarterly aggregate estimates similar to those 
used in Papers 1 and 2 were derived as follows.  First, all patients are assigned an ART 
initiation quarter based on their ART start date (orange section in Table 1).  Next, 
patients are assigned a quarterly “status” (dead, transferred, lost to follow-up, active) 
based on their reported last visit date, reported status, and status date (blue section in 
Table 1).  For each quarter, patients are “currently on ART at the beginning of the 
quarter” if (1) they initiated ART before the quarter onset and (2) they have not been 
identified as lost to follow-up, transferred, or dead by the beginning of the quarter 
(purple section in Table 1).  For the aggregate estimates, quarter-specific person time 
was then calculated as follows: 
PTqi = Current*3months + New*1.5 months – Events * 1.5 months 
PT = ∑PTqi 
 
Patient-level estimates of person-time are calculated by taking the time from ART 
initiation to either the end of the reporting time (December 31, 2005) or the date of an 
event. 
In the example given in Table 1, nearly identical estimates of person-time and rates of 
death and loss to follow-up are obtained assuming a “rolling entry” scenario where 
patients are entered into the study population over the duration of the observation time, 
with no minimum amount of follow-up time required, with observation ending on 
December 31, 2005 (Table 1, grey columns).  This occurs because patients initiating 




quarter, so assuming patients initiating ART in a given quarter, or achieving an event 
during a quarter, do so at the midpoint is a reasonable assumption. 
However, it is common practice in patient-level analyses to estimate rates of loss to 
follow-up or death through a given amount of time after ART initiation (e.g., 1 year after 
ART initiation, black column in Table 1).  In this scenario, patients are followed up for a 
minimum amount of time until they reach the endpoint of interest, are censored, or 
achieve the outcome of interest.  Rates derived from patient-level data will diverge from 
those derived from aggregate data in certain situations where patients are followed for a 
set amount of time (say, 1 year after ART initiation) and patient-level estimates of loss 
to follow-up and death rates through one year of ART treatment are estimated. 
Table 2 presents the three different estimates of loss to follow-up and death rates 
(patient-level rolling entry, patient-level one-year follow-up, aggregate) and shows that 
in this example, the patient-level rolling and aggregate estimates are nearly identical, 
while the rolling-entry estimates are larger than the one-year patient-level estimates for 
both loss to follow-up and death.  This is to be expected because, in the one-year 
follow-up scenario, patients who initiate ART later on in 2005 are followed past the 
aggregate observation closing date (December 2005), increasing the denominator 
without equivalent increase in the numerator because events are relatively rare. 
To estimate the potential differences in our study population, the study population from 
the Paper 2 patient-level analysis was used to generate aggregate estimates of loss to 
follow-up, and death rates in the same manner described in Table 1 of this appendix.  
Briefly, 92,561 patients initiating ART between January 2005 and June 2009 were 




beginning of each quarter, the number of patients newly initiating ART during the 
quarter, and the number of “events” during each quarter (death, transfer, loss to follow-
up) were tallied from the patient-level data to create an aggregate data set.  Patient-
level estimates of loss to follow-up and death rates were obtained for a “rolling entry 
scenario” equivalent to the grey cells in Table 1 of this appendix, and for one-year 
follow-up (equivalent to the black cells in Table 1).  Table 3 presents these results. 
Similar to the simulation study presented in Tables 1 and 2, the aggregate and patient-
level data provide similar estimates of the overall loss to follow-up and death rates 
under a “rolling entry” scenario that does not specify a minimum follow-up period or 
duration of follow-up time.  However, the estimation of one-year loss to follow-up and 
death rates from the patient-level data are higher in our study population.  The reason 
for this is because most events (loss to follow-up or death) occur within the first year 
after ART initiation.  Restricting follow-up to one year after ART initiation results in lower 
person-time of observation (less than 50% of the overall person-time occurs in the first 
year after ART initiation in our population) without a concurrent decrease in the number 
of events (73% of the events occur in the first year after ART initiation). 
This analysis shows that overall rates of loss to follow-up and death are lower than one-
year estimates of loss to follow-up and death obtained from patient-level follow-up under 
the scenario experienced on our patient population.  This is to be expected since the 
rate of loss to follow-up and death are not constant over time after ART initiation.  It is 
therefore improper to interpret aggregate estimates of loss to follow-up and death as 




follow-up period.  However, aggregate estimates are approximately equivalent to the 










Table A4.1.  Example calculations: obtaining aggreg ate person-time from patient-level data 
  Patient-level person-time Aggregate person-time 






























1 1/1/2005 D 4/1/2005 90 90 1 0 0 0 0 1 0 0 0 1 0 0 1.5 1.5 0 0 91.3 
2 2/15/2005   319 365 1 0 0 0 0 1 1 1 0 0 0 0 1.5 3 3 3 319.6 
3 3/31/2005 LTF 9/27/2005 180 180 1 0 0 0 0 1 1 0 0 0 1 0 1.5 3 1.5 0 182.6 
4 4/1/2005   274 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
5 4/5/2005   270 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
6 4/8/2005   267 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
7 4/12/2005   263 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
8 5/1/2005   244 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
9 6/5/2005 T 7/5/2005 30 30 0 1 0 0 0 0 1 0 0 0 1 0 0 1.5 1.5 0 91.3 
10 6/22/2005 LTF 12/19/2005 180 180 0 1 0 0 0 0 1 1 0 0 0 1 0 1.5 3 1.5 182.6 
11 6/30/2005   184 365 0 1 0 0 0 0 1 1 0 0 0 0 0 1.5 3 3 228.3 
12 7/5/2005   179 365 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1.5 3 137.0 
13 7/15/2005   169 365 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1.5 3 137.0 
14 8/5/2005   148 365 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1.5 3 137.0 
15 8/30/2005   123 365 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1.5 3 137.0 
16 9/30/2005   92 365 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1.5 3 137.0 
17 10/15/2005   77 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
18 10/31/2005 LTF 4/29/2006 61 180 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
19 11/5/2005   56 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
20 11/30/2005   31 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
21 12/1/2005 T 12/31/2005 30 30 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0.0 
22 12/5/2005   26 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
23 12/10/2005   21 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 
24 12/15/2005   16 365 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1.5 45.7 








Table A4.2: Comparison between patient-level and ag gregate estimates of LTF and Death rates, sample da ta from 
Table A4.1  
N LTF N Dead 
Person-
time 
LTF Rate (per 100 
person-months) 
Death Rate (per 
100 person-
months) 
Patient-level, rolling 2 1 3,336.00  1.82          0.91  
Patient-level, 1 year 
follow-up 3 2 7350.00  1.24        0.83  
Aggregate   2 1    3,287.25    1.85            0.93  
 
Table A4.3: Comparison between patient-level and ag gregate estimates of LTF and Death rates, patient-l evel 
population from Paper 2 
N LTF N Dead 
Person-
time 
LTF Rate (per 100 
person-months) 




         
19,481           5,284  150,309         12.96              3.5  
Patient-level, 1 year 
follow-up 
        
14,085           3,910  
       
71,410         19.72              5.5  
Aggregate 
             
19,481           5,284  
    
143,767          13.55                3.7  
*”rolling” estimates refers to the scenario where individuals initiate ART throughout the study period, with no exclusion 
restrictions on minimum follow-up time 
** 1 year follow-up estimates the rate 1 year after ART initiation 
 
 
 
 
 
